
<html lang="en"     class="pb-page"  data-request-id="fdb10390-2734-4155-ac25-ebb3b1c551d2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b00506;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment" /></meta><meta name="dc.Creator" content="Jeffrey&#xA;J.  Jackson" /></meta><meta name="dc.Creator" content="John M.  Ketcham" /></meta><meta name="dc.Creator" content="Ashkaan  Younai" /></meta><meta name="dc.Creator" content="Betty  Abraham" /></meta><meta name="dc.Creator" content="Berenger  Biannic" /></meta><meta name="dc.Creator" content="Hilary P.  Beck" /></meta><meta name="dc.Creator" content="Minna H. T.  Bui" /></meta><meta name="dc.Creator" content="David  Chian" /></meta><meta name="dc.Creator" content="Gene  Cutler" /></meta><meta name="dc.Creator" content="Raymond  Diokno" /></meta><meta name="dc.Creator" content="Dennis X.  Hu" /></meta><meta name="dc.Creator" content="Scott  Jacobson" /></meta><meta name="dc.Creator" content="Emily  Karbarz" /></meta><meta name="dc.Creator" content="Paul D.  Kassner" /></meta><meta name="dc.Creator" content="Lisa  Marshall" /></meta><meta name="dc.Creator" content="Jenny  McKinnell" /></meta><meta name="dc.Creator" content="Cesar  Meleza" /></meta><meta name="dc.Creator" content="Abood  Okal" /></meta><meta name="dc.Creator" content="Deepa  Pookot" /></meta><meta name="dc.Creator" content="Maureen K.  Reilly" /></meta><meta name="dc.Creator" content="Omar  Robles" /></meta><meta name="dc.Creator" content="Hunter P.  Shunatona" /></meta><meta name="dc.Creator" content="Oezcan  Talay" /></meta><meta name="dc.Creator" content="James R.  Walker" /></meta><meta name="dc.Creator" content="Angela  Wadsworth" /></meta><meta name="dc.Creator" content="David J.  Wustrow" /></meta><meta name="dc.Creator" content="Mikhail  Zibinsky" /></meta><meta name="dc.Description" content="Recruitment of suppressive CD4+ FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-o..." /></meta><meta name="Description" content="Recruitment of suppressive CD4+ FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-o..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 17, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00506" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00506" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00506" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00506" /></link>
        
    
    

<title>Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00506" /></meta><meta property="og:title" content="Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0016.jpeg" /></meta><meta property="og:description" content="Recruitment of suppressive CD4+ FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents. Human Treg express CCR4 and can be recruited to the TME through the CC chemokine ligands CCL17 and CCL22. In some cancers, Treg accumulation correlates with poor patient prognosis. Preclinical data suggests that preventing the recruitment of Treg and increasing the population of activated effector T cells (Teff) in the TME can potentiate antitumor immune responses. We  developed a novel series of potent, orally bioavailable small molecule antagonists of CCR4. From this series, several compounds exhibited high potency in distinct functional assays in addition to good in vitro and in vivo ADME properties. The design, synthesis, and SAR of this series and confirmation of its in vivo activity are reported." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00506"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00506">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00506&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00506&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00506&amp;href=/doi/10.1021/acs.jmedchem.9b00506" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6190-6213</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00428" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00519" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T<sub>reg</sub> Trafficking into the Tumor Microenvironment</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jeffrey J. Jackson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey J. Jackson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey%0AJ.++Jackson">Jeffrey J. Jackson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7219-5279" title="Orcid link">http://orcid.org/0000-0002-7219-5279</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John M. Ketcham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John M. Ketcham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+M.++Ketcham">John M. Ketcham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ashkaan Younai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ashkaan Younai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ashkaan++Younai">Ashkaan Younai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Betty Abraham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Betty Abraham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Betty++Abraham">Betty Abraham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Berenger Biannic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Berenger Biannic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Berenger++Biannic">Berenger Biannic</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hilary P. Beck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hilary P. Beck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hilary+P.++Beck">Hilary P. Beck</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minna H. T. Bui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minna H. T. Bui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minna+H.+T.++Bui">Minna H. T. Bui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Chian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Chian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Chian">David Chian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gene Cutler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gene Cutler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gene++Cutler">Gene Cutler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raymond Diokno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raymond Diokno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raymond++Diokno">Raymond Diokno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dennis X. Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dennis X. Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dennis+X.++Hu">Dennis X. Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Jacobson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Jacobson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Jacobson">Scott Jacobson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emily Karbarz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emily Karbarz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emily++Karbarz">Emily Karbarz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul D. Kassner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul D. Kassner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+D.++Kassner">Paul D. Kassner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisa Marshall</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa Marshall</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Marshall">Lisa Marshall</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jenny McKinnell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jenny McKinnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jenny++McKinnell">Jenny McKinnell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cesar Meleza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cesar Meleza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cesar++Meleza">Cesar Meleza</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Abood Okal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Abood Okal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Abood++Okal">Abood Okal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Deepa Pookot</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deepa Pookot</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deepa++Pookot">Deepa Pookot</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maureen K. Reilly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maureen K. Reilly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maureen+K.++Reilly">Maureen K. Reilly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Omar Robles</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Omar Robles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Omar++Robles">Omar Robles</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hunter P. Shunatona</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hunter P. Shunatona</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hunter+P.++Shunatona">Hunter P. Shunatona</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Oezcan Talay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Oezcan Talay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Oezcan++Talay">Oezcan Talay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James R. Walker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James R. Walker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Walker">James R. Walker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Angela Wadsworth</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angela Wadsworth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Wadsworth">Angela Wadsworth</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David J. Wustrow</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David J. Wustrow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong><a href="/cdn-cgi/l/email-protection#640013111710160b1324160514104a070b09"><span class="__cf_email__" data-cfemail="b8dccfcdcbcccad7cff8cad9c8cc96dbd7d5">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+J.++Wustrow">David J. Wustrow</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Mikhail Zibinsky</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mikhail Zibinsky</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong><a href="/cdn-cgi/l/email-protection#482532212a21263b2331083a29383c662b2725"><span class="__cf_email__" data-cfemail="fc9186959e95928f9785bc8e9d8c88d29f9391">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mikhail++Zibinsky">Mikhail Zibinsky</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00506&amp;href=/doi/10.1021%2Facs.jmedchem.9b00506" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6190–6213</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 17, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 March 2019</li><li><span class="item_label"><b>Published</b> online</span>17 June 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00506" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00506</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6190%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJeffrey%250AJ.%2BJackson%252C%2BJohn%2BM.%2BKetcham%252C%2BAshkaan%2BYounai%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D13%26contentID%3Dacs.jmedchem.9b00506%26title%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSelective%2BCCR4%2BAntagonist%2BThat%2BInhibits%2BTreg%2BTrafficking%2Binto%2Bthe%2BTumor%2BMicroenvironment%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6213%26publicationDate%3DJuly%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00506"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2226</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00506" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jeffrey\nJ.&quot;,&quot;last_name&quot;:&quot;Jackson&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;M. Ketcham&quot;},{&quot;first_name&quot;:&quot;Ashkaan&quot;,&quot;last_name&quot;:&quot;Younai&quot;},{&quot;first_name&quot;:&quot;Betty&quot;,&quot;last_name&quot;:&quot;Abraham&quot;},{&quot;first_name&quot;:&quot;Berenger&quot;,&quot;last_name&quot;:&quot;Biannic&quot;},{&quot;first_name&quot;:&quot;Hilary&quot;,&quot;last_name&quot;:&quot;P. Beck&quot;},{&quot;first_name&quot;:&quot;Minna&quot;,&quot;last_name&quot;:&quot;H. T. Bui&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Chian&quot;},{&quot;first_name&quot;:&quot;Gene&quot;,&quot;last_name&quot;:&quot;Cutler&quot;},{&quot;first_name&quot;:&quot;Raymond&quot;,&quot;last_name&quot;:&quot;Diokno&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;X. Hu&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Jacobson&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;Karbarz&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;D. Kassner&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Marshall&quot;},{&quot;first_name&quot;:&quot;Jenny&quot;,&quot;last_name&quot;:&quot;McKinnell&quot;},{&quot;first_name&quot;:&quot;Cesar&quot;,&quot;last_name&quot;:&quot;Meleza&quot;},{&quot;first_name&quot;:&quot;Abood&quot;,&quot;last_name&quot;:&quot;Okal&quot;},{&quot;first_name&quot;:&quot;Deepa&quot;,&quot;last_name&quot;:&quot;Pookot&quot;},{&quot;first_name&quot;:&quot;Maureen&quot;,&quot;last_name&quot;:&quot;K. Reilly&quot;},{&quot;first_name&quot;:&quot;Omar&quot;,&quot;last_name&quot;:&quot;Robles&quot;},{&quot;first_name&quot;:&quot;Hunter&quot;,&quot;last_name&quot;:&quot;P. Shunatona&quot;},{&quot;first_name&quot;:&quot;Oezcan&quot;,&quot;last_name&quot;:&quot;Talay&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Walker&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Wadsworth&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;J. Wustrow&quot;},{&quot;first_name&quot;:&quot;Mikhail&quot;,&quot;last_name&quot;:&quot;Zibinsky&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;6190-6213&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00506&quot;},&quot;abstract&quot;:&quot;Recruitment of suppressive CD4+ FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents. Human Treg express CCR4 and can be recruited to the TME through the CC chemokine ligands CCL17 and CCL22. In some cancers, Treg accumulation correlates with poor patient prognosis. Preclinical data suggests that preventing the recruitment of Treg and increasing the population of activated effector T cells (Teff) in the TME can potentiate antitumor immune responses. We developed a novel series of potent, orally bioavailable small molecule antagonists of CCR4. From this series, several compounds exhibited high potency in distinct functional assays in addition to good in vitro and in vivo ADME properties. The design, synthesis, and SAR of this series and confirmation of its in vivo activity are reported.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00506&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00506" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00506&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00506" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00506&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00506" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00506&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00506&amp;href=/doi/10.1021/acs.jmedchem.9b00506" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00506" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00506" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00506%26sid%3Dliteratum%253Aachs%26pmid%3D31259550%26genre%3Darticle%26aulast%3DJackson%26date%3D2019%26atitle%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSelective%2BCCR4%2BAntagonist%2BThat%2BInhibits%2BTreg%2BTrafficking%2Binto%2Bthe%2BTumor%2BMicroenvironment%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D13%26spage%3D6190%26epage%3D6213%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/jmcmar.2019.62.issue-13/20190711/jmcmar.2019.62.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Recruitment of suppressive CD4<sup>+</sup> FOXP3<sup>+</sup> regulatory T cells (T<sub>reg</sub>) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents. Human T<sub>reg</sub> express CCR4 and can be recruited to the TME through the CC chemokine ligands CCL17 and CCL22. In some cancers, T<sub>reg</sub> accumulation correlates with poor patient prognosis. Preclinical data suggests that preventing the recruitment of T<sub>reg</sub> and increasing the population of activated effector T cells (T<sub>eff</sub>) in the TME can potentiate antitumor immune responses. We  developed a novel series of potent, orally bioavailable small molecule antagonists of CCR4. From this series, several compounds exhibited high potency in distinct functional assays in addition to good in vitro and in vivo ADME properties. The design, synthesis, and SAR of this series and confirmation of its in vivo activity are reported.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25266" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25266" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">CC chemokine receptor 4 (CCR4) is a seven-transmembrane G protein-coupled receptor (GPCR) that is known to play a dominant role in the recruitment of highly immunosuppressive CD4<sup>+</sup>, CD25<sup>+</sup>, and FOXP3<sup>+</sup> regulatory T cells (T<sub>reg</sub>) into the tumor microenvironment (TME).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Within the TME, dendritic cells and macrophages produce the cognate ligands for CCR4, CCL17, and CCL22.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> This chemokine gradient attracts T<sub>reg</sub> into the TME,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> where they accumulate and suppress the function of CD8<sup>+</sup> effector T cells (T<sub>eff</sub>), which would otherwise act to fight the tumor.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Several studies have shown that accumulation of T<sub>reg</sub> in the TME and increased levels of CCL22 can lead to poor patient prognosis.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11">(7−11)</a> Thus, the antagonism of CCR4 leading to the inhibition of this T<sub>reg</sub> trafficking pathway makes CCR4 an attractive target for the development of an immuno-oncology (IO) therapy.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">The CCR4 receptor also plays a role in the recruitment of T helper type 2 cell (Th2) subsets for autoimmune disorders such as asthma, allergic rhinitis, and atopic dermatitis.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> To probe the role of CCR4 receptor antagonists in inflammatory disorders, several attempts have been made to design potent small molecule antagonists of CCR4,<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> leading to two series differing in their proposed binding mode.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20">(17−20)</a> Class I antagonists have been shown to bind to an extracellular portion of the GPCR (<b>1</b>–<b>3</b>,<a onclick="showRef(event, 'ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24">(21−24)</a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), while Class II antagonists (<b>4</b>–<b>6</b>,<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) bind intracellularly.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In general, Class I antagonists contain a heteroaromatic ring with a lipophilic arene and a side chain containing a basic amine. Class II antagonists tend to be sulfonamides that are flanked by a heteroaromatic ring and a more lipophilic arene.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative CCR4 Antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The most prominent of these antagonists is a Class II antagonist GSK2239633 (<b>6</b>), developed by GlaxoSmithKline.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Mentioning asthma as a possible therapeutic indication, GSK2239633 was evaluated in a Phase I clinical trial in healthy volunteers that ended in 2011.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In this study, the compound suffered low target engagement and low exposure in the blood which prevented further development. AstraZeneca has also reported two Class II antagonists from their CCR4 program, identified as preclinical candidates AZD-2098 and AZD-1678 (<b>4</b> and <b>5</b>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> While AZD-2098 was licensed to Cancer Research UK as a potential therapy for kidney cancer in 2013,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> no further development of this compound has been disclosed.</div><div class="NLM_p">More recently, a CCR4-targeted cell-depleting monoclonal antibody, mogamulizumab (KY-0761, Kyowa Hakko Kirin Co., Ltd.), has received approval from the FDA to treat patients with two subtypes of relapsed cutaneous T-cell lymphoma (CTCL).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> However, treatment has shown a risk of serious side effects such as dermatologic toxicity, autoimmune issues, and complications from stem cell treatment prior to mogamulizumab administration.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">While targeting CCR4 via an antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism has shown clinical efficacy, the mechanism of action is much different compared to targeting CCR4 with a small molecule antagonist. Depletion of T<sub>reg</sub> that serve other essential functions could cause a severe autoimmune reaction leading to further complications.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> However, simply inhibiting T<sub>reg</sub> trafficking into the TME via a small molecule antagonist may lead to tumor killing without affecting other vital immune cell functions.</div><div class="NLM_p last">To this end, we  designed novel CCR4 antagonists and evaluated their ability to inhibit T<sub>reg</sub> migration into the tumor microenvironment. Herein, we highlight the SAR of a series of novel CCR4 antagonists that demonstrate best-in-class potency and pharmacokinetic properties.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63238" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63238" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure–Activity Relationships</h3><div class="NLM_p">Upon reviewing the literature of known Class I antagonists, a pharmacophore map was built to aide in the design of a new class of CCR4 antagonists (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In general, these antagonists are comprised of a heteroarene core structure with a side chain containing a basic nitrogen on the left-hand portion and a lipophilic arene on the northern end. The lipophilic arene and basic amine side chain are attached to the core via a 1,3-relationship.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pharmacophore map of Class I CCR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To assess potency of the compounds, they were first put into a calcium flux assay. Calcium flux is a robust, high-throughput functional assay that we utilized to rapidly triage compounds for in vitro cellular migration mediated by chemokine receptors.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> On the basis of this pharmacophore model, a series of amides closely related to <b>8</b> was made which was found to inhibit calcium flux in the double-digit nanomolar range; however, these compounds suffered from low bioavailability in rats (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Upon surveying several different cores, a novel pyrazolopyrazine, compound <b>9</b>, was discovered that was within 5-fold potency of the parent compound <b>8</b> as a racemic mixture. Additionally, this core increased the bioavailability in rats by more than 3-fold. To broaden the SAR of these antagonists, various piperidinyl-containing side chains were appended onto the left-hand side of the molecule. Replacing the amide side chain with a piperidinyl-piperidine gave <b>10</b>, which resulted in a 10-fold shift in potency. To create more conformational restriction about the 4-piperidinyl-piperidine side chain, a methyl group was installed in the 3 position of the piperidine to afford <b>11</b>. Fortunately, incorporation of the 3′-methyl-1,4′-bipiperidine was equipotent to the amide linkage found in compound to <b>9</b>. From this result we began focusing our early-stage efforts on evaluating the SAR of these substituted piperidinyl-piperidine side chains.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Discovery of a pyrazolopyrazine core and 3′-methyl-1,4′-bipiperidine side chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Substitution on the C3 position of the pyrazolopyrazine core was carefully examined while leaving the left-hand 3′-methyl-1,4′-bipiperidine intact. Replacing the C3–H substituent in <b>11</b> with more polar functional groups to give amide <b>12</b> and nitrile <b>13</b> resulted in compounds that were equipotent but also suffered from extremely high hepatic clearance and low AUC<sub>∞</sub> when dosed IV in rats, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Installation of the more lipophilic Me (<b>14</b>) and CF<sub>3</sub> (<b>15</b>) groups dramatically improved the IV clearance in rats; however, the C3-CF<sub>3</sub> was 8-fold less potent. Consequently, our SAR focused on developing new side chains to append onto the C3-methyl pyrazolopyrazine core.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Evaluation of the C3 Position of the Pyrazolopyrazine Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0010.gif" alt="" id="gr4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">Ca<sup>2+</sup> flux IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">rat IV CL (mL/min/kg)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">rat IV AUC<sub>∞</sub> (h·ng/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">238</td><td class="colsep0 rowsep0" align="char" char=".">121.7</td><td class="colsep0 rowsep0" align="left">68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">228</td><td class="colsep0 rowsep0" align="char" char=".">101.7</td><td class="colsep0 rowsep0" align="left">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">251</td><td class="colsep0 rowsep0" align="char" char=".">101.7</td><td class="colsep0 rowsep0" align="left">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">126</td><td class="colsep0 rowsep0" align="char" char=".">38.3</td><td class="colsep0 rowsep0" align="left">217</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">837</td><td class="colsep0 rowsep0" align="char" char=".">56.7</td><td class="colsep0 rowsep0" align="left">148</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Assay run in the absence of serum.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Dose of 0.5 mg/kg IV.</p></div></div></div><div class="NLM_p">Rapid evaluation of the C3 position helped to focus our efforts on confirmation of the stereochemistry required for potent CCR4 antagonism in this series. From previous literature and our extensive in-house SAR, we knew the benzylic methyl position on the northern fragment required the <i>R</i>-stereochemistry. With an enantioselective route to the C3-methyl core in hand (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Methods">Experimental Methods</a> for details), determination of the stereochemistry about the piperidinyl-piperidine side chain was undertaken. Chiral resolution of <i>trans</i>-3-methylpiperidin-4-yl pivalate enabled a stereoselective route for the <i>cis</i>-enantiomers of 3′-methyl-1,4′-bipiperidine (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Methods">Experimental Methods</a> for details). Appending these side chains onto the C3-Me-core revealed that the (<i>R</i>, <i>S</i>)-diastereomer <b>16</b> was 19-fold more potent than the (<i>S</i>, <i>R</i>)-diastereomer <b>17</b> toward inhibiting calcium flux (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stereochemical analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After completing the stereochemical analysis of this series, the path was cleared to evaluate the SAR of the basic amine containing side chain. Antagonists that inhibited calcium flux in the double-digit nanomolar range were also run in a physiologically more relevant chemotaxis (CTX) assay to evaluate their ability to inhibit CCL22-mediated migration of CCR4 expressing CEM cells. This 96-well migration platform is considered the gold standard assay for interrogating in vitro cellular migration.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Importantly, this medium-throughput assay can be adapted for use with relevant primary immune cells (i.e., T<sub>reg</sub>). Since the assay is run in 100% human serum (HS), the reported potencies reflect the protein binding of the compounds. Although calcium flux allowed us to triage compounds based on their CCR4 affinity, a significant shift in CTX potency was often observed, likely due to plasma protein binding.</div><div class="NLM_p">Expansion or contraction of the distal piperidine ring to afford the 4-, 5-, 6-, and 7-membered rings (<b>16</b>, <b>18</b>–<b>20</b>) resulted in antagonists that inhibit calcium flux with similar potencies (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Unfortunately, these compounds suffered a severe shift in potency when evaluated in the CTX assay. While the size of the outermost ring had little effect on the potency of these compounds, focusing on the 5-membered pyrrolidines allowed for  installation of a variety of commercially available, enantiopure substituted heterocycles. To this end, both enantiomers of 2-methylpyrrolidine were explored to replace the simple pyrrolidine ring (<b>18</b>). While installation of the 2-methyl substituent did not suppress the shift in potency between calcium flux and CTX, the (<i>R</i>)-2-methyl-pyrrolidine used in <b>21</b> provided a 4-fold more potent compound than the (<i>S</i>)-enantiomer <b>22</b>. To probe what effect the cLogP would have on the CTX shift, several polar functionalities were evaluated including amides (<b>23</b>, <b>24</b>), sulfone (<b>25</b>), sulfonamide (<b>26</b>), nitrile (<b>27</b>), and carboxylic acid (<b>28</b>). Unfortunately, lowering the cLogP by introduction of these polar groups had little influence on the CTX shift. Surprisingly, attenuating the oxidation state of the carboxylic acid <b>28</b> to the prolinol-derived <b>29</b> produced a compound with a CTX IC<sub>50</sub> = 151 nM. Further, replacement of the C3-Me core in <b>29</b> with a C3-CN core to afford <b>30</b> resulted in one of the first compounds to exhibit an extremely low CTX shift with a CTX IC<sub>50</sub> = 58 nM.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of the 3,4-Substituted Piperidinyl Side Chain</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0011.gif" alt="" id="gr6" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center">Ca<sup>2+</sup> flux IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CTX IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>16</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">H</td><td class="colsep0 rowsep0">2</td><td class="colsep0 rowsep0">42</td><td class="colsep0 rowsep0">361</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>18</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">H</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">69</td><td class="colsep0 rowsep0">N.D.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>19</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">H</td><td class="colsep0 rowsep0">0</td><td class="colsep0 rowsep0">58</td><td class="colsep0 rowsep0">218</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>20</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">H</td><td class="colsep0 rowsep0">3</td><td class="colsep0 rowsep0">23</td><td class="colsep0 rowsep0">195</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>21</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">47</td><td class="colsep0 rowsep0">381</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>22</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">Me (<i>S</i>)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">172</td><td class="colsep0 rowsep0">N.D.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>23</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">C(O)NH<sub>2</sub></td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">170</td><td class="colsep0 rowsep0">N.D.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>24</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">CH<sub>2</sub>CH<sub>2</sub>C(O)NH<sub>2</sub></td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">37</td><td class="colsep0 rowsep0">355</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>25</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">CH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">104</td><td class="colsep0 rowsep0">N.D.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>26</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">CH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>NH<sub>2</sub></td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">32</td><td class="colsep0 rowsep0">259</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>27</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">CH<sub>2</sub>CH<sub>2</sub>CN</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">41</td><td class="colsep0 rowsep0">865</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>28</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">COOH</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">670</td><td class="colsep0 rowsep0">N.D.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>29</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">32</td><td class="colsep0 rowsep0">151</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>30</b></td><td class="colsep0 rowsep0">CN</td><td class="colsep0 rowsep0">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">27</td><td class="colsep0 rowsep0">58</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Assay run in absence of serum.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Assay run in 100% human serum (HS).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Opposite enantiomer used.</p></div></div></div><div class="NLM_p">Encouraged by these results, we evaluated <b>30</b> in several in vitro and in vivo assays (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). While it did not display any inhibition of CYP enzymes, when exposing compound <b>30</b> to human and rat hepatocytes, a substantial amount remained in human (74%) while rat showed a significant decrease in recovery (19%). The low in vitro metabolic stability in rat hepatocytes correlated well with the superhepatic clearance that was observed in vivo. In addition to extremely high clearance (114.6 mL/min/kg), <b>30</b> suffered from low bioavailability (% <i>F</i> = 7) and a high volume of distribution (13.4 L/kg).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Profile of Piperidine 30</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0012.gif" alt="" id="gr7" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assays</th><th class="colsep0 rowsep0" align="center">compound <b>30</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ca<sup>2+</sup> flux IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CTX IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP inhibition IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">% remaining hHep/rHep</td><td class="colsep0 rowsep0" align="left">74/19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">rat in vivo PK<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">114.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i>ss (L/kg)</td><td class="colsep0 rowsep0" align="left">13.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO AUC<sub>0–∞</sub> (h·ng/mL)</td><td class="colsep0 rowsep0" align="left">23.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Assay run in 100% human serum (HS).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Enzymes tested: 1A2, 2C9, 2C19, 2D6, 3A4.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Dose of 0.5 mg/kg IV or 2 mg/kg PO.</p></div></div></div><div class="NLM_p">To address these issues, we hypothesized that by replacing the piperidine nitrogen attached to the core in compound <b>30</b> with a carbon, the shift in cLogP may bring about more favorable pharmacokinetics for these antagonists. Up to this point, none of the nitrogen-linked antagonists displayed acceptable pharmacokinetic properties; therefore, we integrated the carbon–carbon link similar to our earlier antagonists <b>8</b> and <b>9</b>. The requisite carbon–carbon bond to achieve this goal brought about a significant synthetic challenge, and thus, we envisioned first replacing the 3-Me-piperidine ring with a 3-Me-cyclohexene ring (vide infra).</div><div class="NLM_p">Given the properties of prolinol-piperidine <b>30</b>, the cyclohexenyl compound <b>31</b> was also evaluated in several in vitro and in vivo studies (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Replacement of the anilinic nitrogen connection to the core with a styrenyl bond gave a compound that was equipotent in the CTX assay, no inhibition of CYP enzymes, and similar in vitro hepatic stability in human and rat hepatocytes, 81% and 32% remaining, respectively. Interestingly, the in vivo pharmacokinetic properties of <b>31</b> were far superior to that of compound <b>30</b>, displaying a longer terminal half-life (<i>T</i><sub>1/2</sub>) and a 4-fold higher bioavailability (% <i>F</i> = 28).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Profile of Cyclohexene 31</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0013.gif" alt="" id="gr8" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assays</th><th class="colsep0 rowsep0" align="center">compound <b>31</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">Ca<sup>2+</sup> flux IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CTX IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CYP Inhibition IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">% remaining hHep/rHep</td><td class="colsep0 rowsep0">81/32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2">rat in vivo PK<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">Cl (mL/min/kg)</td><td class="colsep0 rowsep0">74.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><i>V</i>ss (L/kg)</td><td class="colsep0 rowsep0">9.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">PO AUC<sub>0–∞</sub> (h·ng/mL)</td><td class="colsep0 rowsep0">125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><i>F</i> (%)</td><td class="colsep0 rowsep0">28</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Assay run in 100% human serum (HS).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Enzymes tested: 1A2, 2C9, 2C19, 2D6, 3A4.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Dose of 0.5 mg/kg IV or 2 mg/kg PO.</p></div></div></div><div class="NLM_p">Encouraged by the in vivo pharmacokinetics of compound <b>31</b>, the SAR of these cyclohexenyl antagonists was further assessed (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). To begin, the C3 position of the core (R<sup>1</sup>) was again interrogated. Replacing the C3-nitrile in <b>31</b> with a C3-methyl substituent (<b>32</b>) resulted in an almost 3-fold drop in potency within the CTX assay and little change in the in vitro hepatic stability. Given these data, the C3-nitrile was conserved throughout to focus our efforts on the R<sup>2</sup> substituents on the pyrrolidine ring. Building steric hindrance around the primary alcohol in <b>31</b> to give the tertiary alcohol in <b>33</b> resulted in a significant loss of potency in the CTX assay. Replacement of prolinol with prolinamine (<b>34</b>) or prolinamide (<b>35</b>) increased the stability of these compounds toward human and rat hepatocytes. However, the increase in stability was accompanied by a significant decrease in potency in the CTX assay. Interestingly, installation of a 2-(<i>R</i>)-Me-pyrrolidine (<b>36</b>) resulted in a compound that was equipotent to <b>31</b> and displayed higher in vitro hepatic stability in rats. Replacement of the R<sup>2</sup> methyl with a more lipophilic trifluoromethyl substituent (<b>37</b>) rendered the compound completely inactive.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Primary SAR of Cyclohexenyl Antagonists</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0014.gif" alt="" id="gr9" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">example</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">Ca<sup>2+</sup> flux IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CTX IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">% remaining hHep/rHep</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>31</b></td><td class="colsep0 rowsep0">CN</td><td class="colsep0 rowsep0">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0">40</td><td class="colsep0 rowsep0">70</td><td class="colsep0 rowsep0">81/32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>32</b></td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0">36</td><td class="colsep0 rowsep0">179</td><td class="colsep0 rowsep0">99/35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>33</b></td><td class="colsep0 rowsep0">CN</td><td class="colsep0 rowsep0">C(Me)<sub>2</sub>OH</td><td class="colsep0 rowsep0">384</td><td class="colsep0 rowsep0">1200</td><td class="colsep0 rowsep0">N.D.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>34</b></td><td class="colsep0 rowsep0">CN</td><td class="colsep0 rowsep0">CH<sub>2</sub>NH<sub>2</sub></td><td class="colsep0 rowsep0">229</td><td class="colsep0 rowsep0">638</td><td class="colsep0 rowsep0">100/100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>35</b></td><td class="colsep0 rowsep0">CN</td><td class="colsep0 rowsep0">C(O)NH<sub>2</sub></td><td class="colsep0 rowsep0">54</td><td class="colsep0 rowsep0">1380</td><td class="colsep0 rowsep0">97/71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>36</b></td><td class="colsep0 rowsep0">CN</td><td class="colsep0 rowsep0">Me</td><td class="colsep0 rowsep0">34</td><td class="colsep0 rowsep0">44</td><td class="colsep0 rowsep0">86/72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>37</b></td><td class="colsep0 rowsep0">CN</td><td class="colsep0 rowsep0">CF<sub>3</sub></td><td class="colsep0 rowsep0">>5000</td><td class="colsep0 rowsep0">N.D.</td><td class="colsep0 rowsep0">N.D.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Assay run in absence of serum.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Assay run in 100% human serum (HS).</p></div></div></div><div class="NLM_p">Compounds <b>31</b> and <b>36</b> were the most potent analogs in their ability to inhibit CCL22-mediated CTX of CCR4 expressing CEM cells in 100% human serum. These compounds were further assessed for their ability to inhibit CTX in mouse induced T<sub>reg</sub> (miT<sub>reg</sub>) and for their PK characteristics in mice. Although the in vivo clearance in mice was lower for <b>36</b> (1.17 vs 12.0 mL/min/kg), leading to a substantially longer <i>T</i><sub>1/2</sub> (30 h vs 7.6, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), the superior potency, synthetic availability, and lower lipophilicity of compound <b>31</b> ultimately led us to advance this compound into an in vivo mouse model to determine its ability to suppress T<sub>reg</sub> trafficking into the tumor microenvironment.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Comparison of Compounds <b>31</b> and <b>36</b> in iT<sub>reg</sub> CTX and Mouse in Vivo PK</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0015.gif" alt="" id="gr10" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">example</th><th class="colsep0 rowsep0" align="center" char=".">cLogP/tPSA</th><th class="colsep0 rowsep0" align="center">miT<sub>reg</sub> CTX IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">mouse in vivo PK: Cl/Vss/<i>T</i><sub>1/2</sub>/%F</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">4.5/87.6</td><td class="colsep0 rowsep0" align="left">165</td><td class="colsep0 rowsep0" align="char" char=".">12.0/5.7/7.6/26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">5.6/67.4</td><td class="colsep0 rowsep0" align="left">325</td><td class="colsep0 rowsep0" align="char" char=".">1.17/4.9/30.3/27</td></tr></tbody></table></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vivo Pharmacology in Mouse</h3><div class="NLM_p">Various murine tumor models were examined to assess their levels of CCR4 ligand (CCL17 and CCL22) expression, and it was found that the pancreatic ductal adenocarcinoma (Pan02) model displayed a high expression of these ligands.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Compound <b>31</b> was dosed QD for 6 days at 10 and 30 mg/kg in mice bearing Pan02 tumors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Mouse T<sub>reg</sub> were generated in vitro from naive CD4<sup>+</sup> T cells isolated from Foxp3<sup>+</sup>GFP<sup>+</sup> transgenic mice (GFP<sup>+</sup> miT<sub>reg</sub>)<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> as described in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>. These GFP<sup>+</sup> miT<sub>reg</sub> were injected into the animals 24 h after the first dose. Inhibition of the migration of GFP<sup>+</sup> miT<sub>reg</sub> into tumor and other tissues was compared to vehicle-treated animals (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). A significant dose-dependent decrease in the number of GFP<sup>+</sup> miT<sub>reg</sub> was found in the tumor tissue when compared to the vehicle group. The 30 mg/kg dose showed nearly complete suppression of T<sub>reg</sub> migration into the tumor. Plasma levels at 24-h post dose for <b>31</b> showed that 30 mg/kg QD covered the approximate IC<sub>90</sub> of the miT<sub>reg</sub> CTX. Importantly, compound <b>31</b> was able to selectively inhibit T<sub>reg</sub> trafficking into the tumor without affecting the migration of these cells into the spleen (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), further demonstrating that these antagonists may not disrupt the functions of T<sub>reg</sub> in other healthy tissues.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Treatment with compound <b>31</b> selectively reduces T<sub>reg</sub> trafficking into the tumor. (A) Schematic outline of treatment and tumor model that is used in this study. (B) Number of GFP<sup>+</sup> T<sub>reg</sub> in tumor (left) and spleen (right). Plasma concentration of compound <b>31</b> is measured 24 h after last treatment (bottom). For statistical analysis,  one-way ANOVA was used.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetic Profiling of 31</h3><div class="NLM_p">Results from the T<sub>reg</sub> migration study were encouraging and led to further profiling the in vivo pharmacokinetics of compound <b>31</b> in rat, dog, and cyno (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Additionally, the predicted hepatic clearance of <b>31</b> was found across species by monitoring the in vitro metabolic stability of <b>31</b> in a time-course assay with hepatocytes. The in vivo CL of all species were within 2-fold of their predicted hepatic CL, demonstrating good in vivo/in vitro correlation. When comparing the in vivo hepatic clearance across species, <b>31</b> suffered from very high clearance in rats while displaying lower clearance in dog and cynomolgus monkeys.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. PK Profile of <b>31</b> Across Species<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">dog<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">cyno<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">pred. hepatic CL (mL/min/kg)</td><td class="colsep0 rowsep0">45.0</td><td class="colsep0 rowsep0">18.3</td><td class="colsep0 rowsep0">12.5</td><td class="colsep0 rowsep0">7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">in vivo CL (mL/min/kg)</td><td class="colsep0 rowsep0">74.7</td><td class="colsep0 rowsep0">10.7</td><td class="colsep0 rowsep0">11.3</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">IV terminal half life (h)</td><td class="colsep0 rowsep0">2.2</td><td class="colsep0 rowsep0">16.4</td><td class="colsep0 rowsep0">9.9</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><i>F</i> (%)</td><td class="colsep0 rowsep0">28</td><td class="colsep0 rowsep0">75</td><td class="colsep0 rowsep0">30</td><td class="colsep0 rowsep0"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Three animals per group were used in each study.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Dose of 0.5 mg/kg IV or 2 mg/kg PO.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Synthetic Chemistry</h3><div class="NLM_p">Synthetic efforts began by devising similar routes for piperidinyl amides <b>8</b> and <b>9</b>. Coupling of pyrazinyl chlorides <b>38</b> and <b>39</b> to <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate via a Pd-catalyzed Suzuki coupling in the presence of aqueous base yielded the desired C–C bond formation (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Removal of the Boc-protecting group followed by a HATU coupling resulted in the installation of the basic piperidyl left-hand piece. Finally, treatment with 4 N HCl in dioxane revealed the basic amine to furnish compounds <b>8</b> and <b>9</b>.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Compounds <b>8</b> and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate, 1 M Na<sub>2</sub>CO<sub>3</sub> (aq.), Pd(dppf)Cl<sub>2</sub>, THF, 80–100 °C; (b) 4 N HCl (in dioxane), MeOH, rt; (c) HATU, DIPEA, DMF, rt; (d) 4 N HCl (in dioxane), MeOH, rt.</p></p></figure><div class="NLM_p">As a representative example of the piperidyl-pyrrolidine series, the synthesis of compound <b>30</b> is shown (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The core structure was prepared by first heating hydrazine <b>40</b> (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Methods">Experimental Methods</a> for synthesis) with glyoxylate <b>41</b> in THF to form a mixture of hydrazones <b>42</b> and <b>43</b>. Treating these hydrazones with NaH in THF initiated an intramolecular S<sub>N</sub>Ar to form the pyrazolo portion of the core structure in <b>44</b>. Conversion of ester <b>44</b> to the final nitrile core <b>46</b> proceeded cleanly upon stirring with NH<sub>4</sub>OH to form <b>45</b>, followed by dehydration with Burgess reagent. Reductive amination of prolinol <b>47</b> with ketone <b>48</b> followed by treatment with TFA to remove the Boc-protecting group provided the requisite amino side chain <b>49</b> as a mixture of stereoisomers. Completion of compound <b>30</b> was achieved via simple S<sub>N</sub>Ar of <b>49</b> with the chloropyrazine core <b>46</b> under thermal conditions to afford the desired antagonist <b>30</b> after chiral separation. Stereochemical confirmation for these antagonists was confirmed via an enantioselective synthesis of a similar analogue (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Methods">Experimental Methods</a> for details).</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0007.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) THF, 80 °C; (b) NaH, THF, 0 °C to rt, 50% yield over two steps; (c) NH<sub>4</sub>OH (29% in water), dioxane, rt, 95% yield; (d) Burgess reagent, CH<sub>2</sub>Cl<sub>2</sub>, rt, 88%; (e) Na(OAc)<sub>3</sub>BH, AcOH, 1,2-DCE, rt; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40% over two steps (g) DIPEA, DMF, 100 °C, 10%.</p></p></figure><div class="NLM_p">Synthesis of the cyclohexenyl CCR4 antagonists created a significant challenge and is represented in the synthesis of compound <b>31</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Gilman addition of methyl cuprate to the α,β-unsaturated ketone <b>50</b> was accomplished to form <b>51</b>. Deprotonation of <b>51</b> with LDA and treatment with phenyl triflimide gave triflate <b>52</b> as a mixture of olefin regioisomers, which underwent a palladium-catalyzed formation of the Bpin-<b>53</b>. Separation of the desired olefin isomer followed by Suzuki–Miyaura coupling with chloride <b>46</b> gave ketal <b>54</b>, followed by treatment with TFA to unmask ketone <b>55</b>. Formation of the final analogue was completed via a simple reductive amination with (<i>R</i>)-prolinol (<b>47</b>) and ketone <b>55</b> followed by chiral separation to afford compound <b>31</b>.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0008.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Cyclohexenyl CCR4 Antagonist <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MeLi, CuCN, TMSCl, Et<sub>2</sub>O:THF, −40 °C; (b) LDA, then PhNTf<sub>2</sub>, THF, −78 °C, 53% over two steps; (c) Bpin<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>, KOAc, KBr, dioxane, 95 °C; (d) Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, THF:H<sub>2</sub>O, 90 °C; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) NaBH<sub>3</sub>CN, AcOH, 1,2-DCE, rt.</p></p></figure><div class="NLM_p">For larger scale synthesis of <b>31</b>, a more selective route was needed that avoided chiral separations in the final step (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Reductive amination between ketone <b>56</b> and (<i>R</i>)-a-methylbenzylamine (<b>57</b>) set the stereocenters on the cyclohexane ring in >10:1 selectivity, with the desired isomer being easily isolated by silica gel chromatography. Subsequent protecting group manipulation and formation of the vinyl triflate proceeded in >30:1 regioselectivity of olefin <b>61</b>. Suzuki coupling with Bpin-<b>62</b> (obtained from <b>46</b>) provided compound <b>63</b> in good yield. Removal of the Boc group and bisalkylation with <b>65</b> afforded the desired protected prolinol <b>66</b>, which after a final TBS deprotection yielded compound <b>31</b> as a single isomer.</div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0009.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Second-Generation Synthesis of Cyclohexenyl CCR4 Antagonist <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzene, 95 °C, quant. yield; (b) NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>:AcOH (10:1), rt, 65%; (c) Pd(OH)<sub>2</sub>, H<sub>2</sub>, MeOH, rt, 97%; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 98%; (e) TsOH, THF:H<sub>2</sub>O, rt, 70%; (f) LiHMDS, PhNTf<sub>2</sub>, THF, −78 °C, 97%; (g) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene:EtOH:H<sub>2</sub>O, 90 °C, 76%; (h) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, rt, quant. yield; (i) DIPEA, MeCN, rt, 75%; (j) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, rt, 82%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A novel, orally bioavailable cyclohexenyl series of CCR4 antagonists has been discovered that is potent and selective (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a> for data) against CCR4. Compound <b>31</b> exhibits good in vitro and in vivo ADME properties, but importantly, it inhibits T<sub>reg</sub> trafficking into the tumor microenvironment without suppressing the number of T<sub>reg</sub> in healthy tissues. In order to achieve near complete blockade of this migration, we targeted trough concentrations that approximated the IC<sub>90</sub> in a mouse chemotaxis assay. This is consistent with other PK/PD relationships observed for other chemokine receptor antagonists.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> These studies helped lead to the design and discovery of FLX475, which is currently in human clinical trials.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Methods for Chemistry</h3><div class="NLM_p last">All commercial reagents and solvents were used as received unless otherwise noted. An inert atmosphere of nitrogen was used for reactions involving air- or moisture-sensitive reagents. Analytical thin layer chromatography (TLC) was performed using 2.5 × 7.5 cm Merck silica gel 60 F<sub>254</sub> thin layer plates (EMD Millipore 1.15341.0001) visualized using combinations of UV visualization, <i>p</i>-anisaldehyde, potassium permanganate, and iodine staining. Silica gel column chromatography was performed using Teledyne ISCO RediSep Rf normal phase (35–70 μm) silica gel columns on a Teledyne ISCO CombiFlash Rf or CombiFlash Rf+ purification system (detection at 254 nm). Reverse phase preparative HPLC was carried out using a Gemini-NX-C18 column (10 μm, 250 × 30 mm, Phenomenex, Torrance, CA) eluting with a linear gradient from 5% to 100% acetonitrile in water containing 0.1% trifluoroacetic acid over 30 min on a Teledyne ISCO EZ Prep, Teledyne ISCO ACCQPrep HP125, or Agilent 1200 Series purification system. Analytical reverse phase HPLC was performed using a Gemini-NX-C18 column (5 μm, 250 × 4.6 mm, Phenomenex, Torrance, CA) eluting with MeCN in water with 0.1% TFA on an Agilent 1200 Series purification system (detection at 254 nm). Proton NMR spectra were recorded on a Varian Oxford 400 MHz spectrometer, and carbon NMR spectra were recorded at 101 MHz. Chemical shifts are expressed in δ ppm referenced to tetramethylsilane (δ = 0 ppm). Abbreviations used in describing peak signal multiplicity are as follows: s = singlet, d = doublet, dd = double doublets, t = triplet, q = quartet, m = multiplet, br = broad peak. Analytical LC-MS was performed using a ZORBAX SB-C18 column (1.8 μm, 2.1 × 50 mm, 600 bar, Agilent, Santa Clara, CA) eluting with a linear gradient from 0% to 100% B over 2 min and then 100% B for 3 min (A = 5% MeCN in H2O with 0.1% formic acid, B = MeCN + 0.1% formic acid, flow rate 0.4 mL/min) using an Agilent 1260 Infinity II LC System (detection at 254 nm) equipped with an Agilent 6120 Quadrupole LC/MS in electrospray ionization mode (ESI+). The purity of all compounds used in bioassays was determined by this method to be >95% pure. X-ray structures of intermediates for compounds <b>16</b> and <b>17</b> were deposited in the Cambridge Crystallographic Data Centre under deposition numbers 1915201 (<b>16</b>) and 1915202 (<b>17</b>). The authors will release the atomic coordinates upon article publication.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure A for S<sub>N</sub>Ar</h3><div class="NLM_p last">The appropriate heteroaryl chloride and amine (1.0–2.0 equiv) were dissolved in DMF, DMSO, or CH<sub>2</sub>Cl<sub>2</sub>, and <i>N</i>,<i>N</i>-diisopropylethylamine (2.0–3.0 equiv) was added. The reaction was heated to 40–100 °C until  complete consumption of starting material was observed by either LC-MS or TLC. After cooling, the mixture was diluted with water and ethyl acetate and the layers were separated. The organic layer was washed with brine solution, dried over sodium sulfate, and concentrated via rotary evaporation, and the residue was purified by silica gel chromatography or reverse phase preparative HPLC.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure B for Suzuki Coupling</h3><div class="NLM_p last">The appropriate aryl halide and aryl or alkenyl pinacol boronate (1.0–1.5 equiv) was dissolved in THF (0.2 M), and 1 M aqueous Na<sub>2</sub>CO<sub>3</sub> (2.0–5.0 equiv) was added. [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (15 mol %) was added, and the reaction was heated to 80–100 °C until complete consumption of starting material was observed by LC-MS or TLC. After cooling, the mixture was diluted with water and ethyl acetate and the layers were separated. The organic layer was washed with brine solution, dried over sodium sulfate, and concentrated via rotary evaporation, and the residue was purified by silica gel chromatography unless otherwise noted.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure C for HATU Coupling</h3><div class="NLM_p last">The appropriate carboxylic acid and amine (1.0–2.0 equiv) were dissolved in DMF (0.2 M), and <i>N</i>,<i>N</i>-diisopropylethylamine (3.0–5.0 equiv) was added. HATU (1.1 equiv) was added, and the reaction was stirred at room temperature until complete consumption of the starting material was observed by LC-MS or TLC. The mixture was diluted with ethyl acetate, washed with water, washed with brine solution, dried over sodium sulfate, and concentrated by rotary evaporation. The residue was purified by silica gel chromatography or reverse phase preparative HPLC.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure D for Reductive Amination</h3><div class="NLM_p last">The appropriate ketone and amine (1.2 equiv) were dissolved in 1,2-dichloroethane (0.3 M); then acetic acid (1.5 equiv) and sodium triacetoxyborohydride or sodium cyanoborohydride (1.5 equiv) were added. The mixture was stirred at room temperature until the desired product was formed, monitoring by LC-MS. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate and concentrated via rotary evaporation to afford the desired product, which was purified by silica gel chromatography or preparative reverse phase HPLC or used without further purification.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (4-(6-(((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)amino)pyrazin-2-yl)-3,6-dihydropyridin-1(2<i>H</i>)-yl)((<i>R</i>)-piperidin-2-yl)methanone Hydrochloride (<b>8</b>)</h3><div class="NLM_p">Step 1: The Suzuki coupling was performed according to general procedure B using (<i>R</i>)-6-chloro-<i>N</i>-(1-(2,4-dichlorophenyl)ethyl)pyrazin-2-amine (1.0 g, 3.30 mmol) and <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (1.0 equiv) at 100 °C for 18 h. The residue was purified by silica gel chromatography (50% ethyl acetate in hexanes) to afford <i>tert</i>-butyl (<i>R</i>)-4-(6-((1-(2,4-dichlorophenyl)ethyl)amino)pyrazin-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (67% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 449.2; found, 449.</div><div class="NLM_p">Step 2: <i>tert</i>-Butyl (<i>R</i>)-4-(6-((1-(2,4-dichlorophenyl)ethyl)amino)pyrazin-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (414 mg, 0.92 mmol) was dissolved in MeOH (15 mL), and HCl (4 N in 1,4-dioxane, 5 mL) was added. The reaction was stirred at 23 °C for 2 h. The mixture was basified with 1 N NaOH and diluted with CH<sub>2</sub>Cl<sub>2</sub>, and the layers were separated. The organic layer was washed with brine solution, dried over sodium sulfate, concentrated via rotary evaporation, and used in the next step without purification. The HATU coupling was performed according to general procedure C using the deprotected amine (275 mg, 0.79 mmol), (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-2-carboxylic acid (1.0 equiv), <i>N,N</i>-diisopropylethylamine (2.0 equiv), and HATU (1.1 equiv) in DMF (2.5 mL) at 23 °C for 14 h. The residue was purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to afford <i>tert</i>-butyl (<i>R</i>)-2-(4-(6-(((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)amino)pyrazin-2-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)piperidine-1-carboxylate (69% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 560.2; found, 560.</div><div class="NLM_p last">Step 3: <i>tert</i>-Butyl (<i>R</i>)-2-(4-(6-(((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)amino)pyrazin-2-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)piperidine-1-carboxylate (305 mg, 0.54 mmol) was dissolved in MeOH (10 mL), and HCl (4 N in 1,4-dioxane, 5 mL) was added. The mixture was stirred at 23 °C for 5 h. The solution was basified with 1 N NaOH and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with brine solution, dried over sodium sulfate,  concentrated via rotary evaporation, and used in the next step without further purification. The deprotected amine (250 mg, 0.543 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and HCl (4 N in 1,4-dioxane, 0.136 mL, 0.543 mmol) was added dropwise. The reaction was stirred for 10 min and concentrated via rotary evaporation to afford (4-(6-(((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)amino)pyrazin-2-yl)-3,6-dihydropyridin-1(2<i>H</i>)-yl)((<i>R</i>)-piperidin-2-yl)methanone hydrochloride (<b>8</b>, 100% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; HCl salt) δ 7.89 (d, <i>J</i> = 3.2 Hz, 1H), 7.66 (d, <i>J</i> = 3.3 Hz, 1H), 7.38 (d, <i>J</i> = 2.1 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 6.69–6.38 (m, 1H), 5.37–5.17 (m, 1H), 5.08 (d, <i>J</i> = 5.6 Hz, 1H), 3.87–3.54 (m, 2H), 3.28–2.96 (m, 3H), 2.70 (q, <i>J</i> = 11.6, 11.1 Hz, 1H), 2.53 (s, 2H), 1.92 (d, <i>J</i> = 9.8 Hz, 1H), 1.76 (d, <i>J</i> = 12.6 Hz, 1H), 1.60 (t, <i>J</i> = 13.7 Hz, 1H), 1.53 (d, <i>J</i> = 6.8 Hz, 3H), 1.41 (dd, <i>J</i> = 26.8, 12.7 Hz, 1H), 1.31–1.19 (m, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 460.2; found, 460.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (4-(1-(1-(2,4-Dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3,6-dihydropyridin-1(2<i>H</i>)-yl)((<i>H</i>)-piperidin-2-yl)methanone 2,2,2-trifluoroacetate (<b>9</b>)</h3><div class="NLM_p">Step 1: The Suzuki coupling was performed according to general procedure B using 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (0.275 mmol) and <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (1.0 equiv) at 100 °C for 18 h. The residue was purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to afford <i>tert</i>-butyl 4-(1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (60% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 474.2; found, 474.</div><div class="NLM_p last">Step 2: <i>tert</i>-Butyl 4-(1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (0.120 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL), and TFA (0.5 mL) was added. The reaction was stirred at 23 °C for 2 h. The mixture was basified with 1 N NaOH and  diluted with CH<sub>2</sub>Cl<sub>2</sub>, and the layers were separated. The organic layer was washed with brine solution, dried over sodium sulfate, concentrated via rotary evaporation, and used in the next step without purification. The HATU coupling was performed according to general procedure C using the deprotected amine (275 mg, 0.79 mmol), (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-2-carboxylic acid (180 mg, 0.79 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (0.14 mL, 1.58 mmol), and HATU (1.1 equiv) in DMF (2.5 mL). The residue was purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to afford <i>tert</i>-butyl (<i>R</i>)-2-(4-(6-(((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)amino)pyrazin-2-yl)-1,2,3,6-tetrahydropyridine-1-carbonyl)piperidine-1-carboxylate. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL), and TFA (0.5 mL) was added. The reaction was stirred 1 h at room temperature and concentrated to afford (4-(1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3,6-dihydropyridin-1(2<i>H</i>)-yl)((<i>R</i>)-piperidin-2-yl)methanone 2,2,2-trifluoroacetate (<b>9</b>, 69% yield). <sup>1</sup>H NMR (400 MHz; CDCl<sub>3</sub>; TFA Salt) δ 8.78 (br s, 2H), 8.30 (s, 1H), 7.43–7.41 (m, 2H), 7.20–7.17 (m, 1H), 6.76–6.63 (m, 2H), 5.49 (br s, 1H), 3.80–3.72 (m, 4H), 3.14–2.79 (m, 2H), 2.05–1.97 (m, 11 H), 1.26–1.19 (m, 3 H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> = 485.2; found, 485.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 6-([1,4′-Bipiperidin]-1′-yl)-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine 2,2,2-trifluoroacetate (<b>10</b>)</h3><div class="NLM_p last">The S<sub>N</sub>Ar was performed according to general procedure A using 1,4′-bipiperidine (2.0 equiv), 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>39</b>, 90 mg, 0.275 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (2.0 equiv) in DMF (5 mL) at 100 °C for 2 h. It was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 6-([1,4′-bipiperidin]-1′-yl)-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine 2,2,2-trifluoroacetate (<b>10</b>) as a mixture of diastereomers (7% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; TFA salt) δ 11.21 (bs, 1H), 8.21 (s, 1H), 8.10 (s, 1H), 7.38 (d, <i>J</i> = 2.2 Hz, 1H), 7.37 (d, <i>J</i> = 4.1 Hz, 1H), 7.17 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.41 (q, <i>J</i> = 7.1 Hz, 1H), 4.63 (t, <i>J</i> = 12.3 Hz, 2H), 3.62–3.42 (m, 3H), 3.09–2.98 (m, 2H), 2.82–2.65 (m, 2H), 2.20 (t, <i>J</i> = 12.4 Hz, 2H), 2.12–1.98 (m, 2H), 1.94 (d, <i>J</i> = 7.1 Hz, 3H), 1.92–1.87 (m, 2H), 1.83–1.66 (m, 2H), 1.48–1.22 (m, 2H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 459.2; found, 459.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 1-(1-(2,4-Dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>11</b>)</h3><div class="NLM_p last">The S<sub>N</sub>Ar was performed according to general procedure A using 3′-methyl-1,4′-bipiperidine (2.0 equiv), 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>39</b>, 90 mg, 0.275 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (2.0 equiv) in DMF (5 mL) at 100 °C for 2 h. It was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min. The TFA salt was neutralized by passing it through a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as the eluent and concentrated under reduced pressure. HCl (1 N in diethyl ether, 1 mL) was added and stirred 10 min. The mixture was concentrated under reduced pressure to afford 1-(1-(2,4-dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>11</b>) as a mixture of diastereomers (6% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; HCl salt) δ 11.22 (bs, 1H), 8.21 (s, 0.66H), 8.20 (s, 0.34H), 8.09 (s, 0.66H), 8.09 (s, 0.34H), 7.40–7.35 (m, 2H), 7.17 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 6.39 (q, <i>J</i> = 7.2 Hz, 1H), 4.86–4.63 (m, 3H), 4.57–4.47 (m, 1H), 3.88–3.78 (m, 1H), 3.73–3.64 (m, 1H), 3.34–3.23 (m, 1H), 3.13–3.04 (m, 1H), 2.98–2.88 (m, 1H), 2.83–2.69 (m, 2H), 2.64–2.54 (m, 1H), 2.26–2.00 (m, 3H), 1.93 (d, <i>J</i> = 7.0 Hz, 3H), 1.91–1.88 (m, 2H), 1.52–1.40 (m, 1H), 1.21 (d, <i>J</i> = 6.6 Hz, 2H), 1.13 (d, <i>J</i> = 6.6 Hz, 1H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 473.2; found, 473.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 1-(1-(2,4-Dichlorophenyl)ethyl)-6-((3′<i>R</i>,4’<i>S</i>)-3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile hydrochloride (<b>12</b>)</h3><div class="NLM_p">Step 1: To a solution of <i>n</i>-BuLi (2.5 M in hexanes, 132 mL, 0.329 mol) was added 2,2,6,6-tetramethylpiperidine (56 mL, 0.329 mol) in THF (200 mL) at −78 °C over 15 min. The yellow slurry was stirred at −78 °C for 15 min. In a separate flask, diethyl oxalate (41 mL, 0.302 mol) and 2,6-dichloropyrazine (40 g, 0.274 mol) were dissolved in THF (685 mL) and cooled to −78 °C. The lithium 2,2,6,6-tetramethylpiperidine solution was added to the 2,6-dichloropyrazine solution via cannula over 15 min at −78 °C. The reaction was stirred at −78 °C for 30 min before  addition of AcOH (20 mL). The mixture was warmed to room temperature and quenched with saturated aqueous NH<sub>4</sub>Cl. The mixture was extracted with EtOAc, and combined organic layers were washed with saturated aqueous NH<sub>4</sub>Cl, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue was dissolved in EtOH (50 mL), and (1-(2,4-dichlorophenyl)ethyl)hydrazine hydrochloride (9.83 g, 40.7 mmol) was added. The reaction was stirred at room temperature for 16 h, and saturated aqueous NaHCO<sub>3</sub> was added. The mixture was concentrated under reduced pressure to remove the EtOH, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0–20% ethyl acetate in hexanes) to afford ethyl (<i>E</i>)-2-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazineylidene)-2-(3,5-dichloropyrazin-2-yl)acetate and ethyl (<i>Z</i>)-2-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazineylidene)-2-(3,5-dichloropyrazin-2-yl)acetate as a mixture of isomers (57% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 435.0; found, 435.</div><div class="NLM_p">Step 2: A mixture of ethyl (<i>E</i>)-2-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)-2-(3,5-dichloropyrazin-2-yl)acetate and ethyl (<i>Z</i>)-2-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)-2-(3,5-dichloropyrazin-2-yl)acetate (54 g, 126 mmol) was dissolved in THF (500 mL) and cooled to 5 °C. NaH (60% dispersion in oil, 5.56 g, 139 mmol) was added portionwise, and the mixture was warmed to room temperature and then stirred for 1 h. An additional portion of NaH (60% dispersion in oil, 5.0 g, 126 mmol) was added portionwise, and the mixture was stirred at room temperature for 2 h. <i>tert-</i>BuOH (5 drops) was added, and the mixture was stirred at room temperature for 10 days. The mixture was diluted with saturated aqueous NH<sub>4</sub>Cl and extracted with ethyl acetate. The organic layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was recrystallized from dichloromethane and hexanes to afford ethyl 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate (60% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>13</sub>Cl<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 399.0; found, 399.</div><div class="NLM_p">Step 3: The S<sub>N</sub>Ar was performed following general procedure A using ethyl 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate (0.388 mmol), 3′-methyl-1,4′-bipiperidine 2,2,2-trifluoroacetate (0.388 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.776 mmol) in DMSO (1.0 mL) at room temperature for 16 h. The residue was purified by silica gel chromatography (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford ethyl 1-(1-(2,4-dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate (50% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 545.2; found, 545.</div><div class="NLM_p last">Step 4: Ethyl 1-(1-(2,4-dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate (35 mg, 0.064 mmol) was suspended in a mixture of EtOH (0.26 mL), THF (0.26 mL), and water (0.13 mL). Lithium hydroxide (12 mg, 0.52 mmol) was added, and the mixture was heated to 60 °C for 16 h. The reaction was cooled to room temperature, and the solvent was removed under reduced pressure to afford 1-(1-(2,4-dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylic acid, which was used without further purification. To a solution of the carboxylic acid (13 mg, 0.025 mmol) in DMF (0.15 mL) was added HATU (12 mg, 0.030 mmol) and <i>N,N</i>-diisopropylethylamine (9 μL, 0.050 mmol). Ammonia gas was bubbled through the solution for 2 min; then the solution was stirred under ammonia atmosphere for 10 min. A 0.5 M aqueous HCl solution (10 mL) was added; the solid was collected by filtration and washed with an additional 0.5 M aqueous HCl solution. The solid was dried under reduced pressure to afford 1-(1-(2,4-dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide hydrochloride (<b>12</b>) as a mixture of diastereomers (98% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, HCl salt; 1:1 mix of isomers) δ 8.47 (s, 0.5H), 8.46 (s, 0.5H), 7.50–7.38 (m, 2H), 7.30–7.24 (m, 1H), 6.51–6.44 (m, 1H), 3.79–3.61 (m, 2H), 3.54–3.46 (m, 1H), 3.20–3.12 (m, 1H), 3.11–2.88 (m, 4H), 2.68–2.58 (m, 1H), 2.24 (d, <i>J</i> = 12.6 Hz, 1H), 2.01 (s, 2H), 1.95 (dd, <i>J</i> = 7.0, 1.1 Hz, 3H), 1.91–1.65 (m, 4H), 1.58 (s, 1H), 1.28 (s, 1H), 1.03 (d, <i>J</i> = 6.9 Hz, 1.5H), 0.94 (d, <i>J</i> = 7.0 Hz, 1.5H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> = 516.2; found, 516.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 1-(1-(2,4-Dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile 2,2,2-trifluoroacetate (<b>13</b>)</h3><div class="NLM_p last">Step 1: To a solution of 1-(1-(2,4-dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide hydrochloride (<b>12</b>, 12 mg, 0.023 mmol) was added <i>N,N</i>-diisopropylethylamine (6 μL, 0.035 mmol) and methyl <i>N</i>-(triethylammoniosulfonyl)carbamate (36 mg, 0.15 mmol). The reaction mixture was stirred at room temperature for 16 h before and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 1-(1-(2,4-dichlorophenyl)ethyl)-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile 2,2,2-trifluoroacetate (<b>13</b>) as a mixture of diastereomers (30% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, TFA salt; 1:1 mix of isomers) δ 8.52 (d, J = 5.3 Hz, 1H), 7.49 (td, J = 1.4, 0.7 Hz, 1H), 7.42–7.31 (m, 2H), 6.48 (q, <i>J</i> = 7.1 Hz, 1H), 3.79–3.62 (m, 2H), 3.55–3.47 (m, 1H), 3.24–2.89 (m, 4H), 2.68–2.58 (m, 1H), 2.25 (d, <i>J</i> = 12.8 Hz, 1H), 2.07–1.96 (m, 2H), 1.93 (dd, <i>J</i> = 7.1, 0.8 Hz, 3H), 1.90–1.51 (m, 4H), 1.31–1.26 (m, 1H), 1.02 (d, <i>J</i> = 6.9 Hz, 1.5H), 0.92 (d, <i>J</i> = 6.9 Hz, 1.5H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>7</sub> [M + H]<sup>+</sup> = 498.2; found, 498.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 1-(1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine 2,2,2-trifluoroacetate (<b>14</b>)</h3><div class="NLM_p">Step 1: (1-(2,4-dichlorophenyl)ethyl)hydrazine hydrochloride (5.0 g, 20.7 mmol) was dissolved in ethanol (35 mL) at room temperature, and 1-(3,5-dichloropyrazin-2-yl)ethan-1-one (3.6 g, 18.8 mmol) was added. The mixture was stirred at room temperature for 8 h and then concentrated under reduced pressure. The residue was suspended in 20% ethyl acetate in hexanes (20 mL) and filtered through a silica gel plug, eluting with 20% ethyl acetate in hexanes. The filtrate was concentrated under reduced pressure to give (<i>Z</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)ethyl)pyrazine and (<i>E</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)ethyl)pyrazine (9:1) as a viscous orange oil, which were used in the next step without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>12</sub>Cl<sub>4</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 377.0; found, 377.</div><div class="NLM_p">Step 2: A mixture of (<i>Z</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)ethyl)pyrazine and (<i>E</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)ethyl)pyrazine (9:1) (3.4 g, 9.2 mmol) was dissolved in <i>N</i>-methyl-2-pyrrolidone (20 mL) at room temperature, and 2,6-lutidine (3.2 mL, 27.6 mmol) was added. The mixture was degassed with nitrogen and then heated to 100 °C under nitrogen for 8 h. The reaction mixture was cooled to room temperature and poured into a separatory funnel containing 50 mL of 1 M HCl in water and 50 mL of ethyl acetate. The layers were separated, and the organic layer was washed with 50 mL of 1 M HCl in water, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0–20% (1:1 MTBE:CH<sub>2</sub>Cl<sub>2</sub>) in hexanes) to provide 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine as off-white solid (65% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>11</sub>Cl<sub>3</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 341.0; found, 341.</div><div class="NLM_p last">Step 3: The S<sub>N</sub>Ar was performed following general procedure A using 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (181 mg, 0.53 mmol), 3′-methyl-1,4′-bipiperidine (146 mg, 0.80 mmol), and <i>N,N</i>-diisopropylethylamine (0.50 mL, 3.18 mmol) in DMSO (2.0 mL) at 100 °C for 2 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min, to afford 1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine 2,2,2-trifluoroacetate (<b>14</b>) as a 1.6:1 mixture of diastereomers (10% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; TFA Salt) δ 8.27 (s, 0.6H), 8.25 (s, 0.4H), 7.45–7.43 (m, 1H), 7.40 (d, <i>J</i> = 8.5 Hz, 0.6H), 7.34 (d, <i>J</i> = 8.5 Hz, 0.4H), 7.28–7.23 (m, 1H), 6.30 (q, <i>J</i> = 7.1 Hz, 1H), 4.82–4.70 (m, 1H), 4.70–4.55 (m, 1H), 3.75 (d, <i>J</i> = 12.4 Hz, 1H), 3.65 (m, <i>J</i> = 12.6 Hz, 1H), 3.49 (dt, <i>J</i> = 12.4, 4.0 Hz, 1H), 3.17–3.08 (m, 1H), 3.05–2.88 (m, 3H), 2.64–2.55 (m, 1H), 2.50 (s, 3H), 2.22 (d, <i>J</i> = 12.4 Hz, 1H), 2.06–1.94 (m, 2H), 1.90–1.68 (m, 7H), 1.62–1.48 (m, 1H), 1.02 (d, <i>J</i> = 6.8 Hz, 1.8H), 0.94 (d, <i>J</i> = 6.9 Hz, 1.2H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 487.2; found, 487.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 1-(1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>15</b>)</h3><div class="NLM_p">Step 1: To a solution of 2,2,6,6-tetramethylpiperidine (13.7 mL, 80.6 mmol) in THF (200 mL) at −40 °C was added <i>n</i>-BuLi (2.5 M in hexanes, 34.9 mL, 87.3 mmol). The mixture was stirred at −40 °C for 30 min. In a separate flask, ethyl 2,2,2-trifluoroacetate (10.4 mL, 87.3 mmol) and 2,6-dichloropyrazine (10.0 g, 67.1 mmol) were dissolved in THF (200 mL) and cooled to −90 °C. The lithium 2,2,6,6-tetramethylpiperidine solution was added to the 2,6-dichloropyrazine solution via cannula over 30 min at −90 °C. The mixture was stirred at −90 °C for 30 min, and then (1-(2,4-dichlorophenyl)ethyl)hydrazine hydrochloride (9.73 g, 40.3 mmol) was added, and the mixture was warmed to room temperature. The mixture was concentrated under reduced pressure and then ethanol (200 mL) was added, and the mixture was stirred at room temperature for 24 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to provide (<i>E</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)-2,2,2-trifluoroethyl)pyrazine and (<i>Z</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl) hydrazono)-2,2,2-trifluoroethyl)pyrazine (21% yield) as a viscous orange oil. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>9</sub>Cl<sub>4</sub>F<sub>3</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 431.0; found, 431.</div><div class="NLM_p">Step 2: (<i>E</i>)-3,5-Dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)-2,2,2-trifluoroethyl)pyrazine and (<i>Z</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl) hydrazono)-2,2,2-trifluoroethyl)pyrazine (2.5 g, 5.79 mmol) were dissolved in THF (58 mL), and the solution was cooled to 0 °C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (1.73 mL, 11.6 mmol) was added dropwise. After the addition was complete, the mixture was warmed to room temperature and stirred for 10 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (0–20% ethyl acetate in hexanes) to provide 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (79% yield) as a light orange oil. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 395.0; found, 395.</div><div class="NLM_p last">Step 3: The S<sub>N</sub>Ar was performed following general procedure A using 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-(trifluoromethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (0.253 mmol), 3′-methyl-1,4′-bipiperidine (51 mg, 0.278 mmol), and <i>N,N</i>-diisopropylethylamine (88 μL, 0.506 mmol) in dichloromethane (5 mL) at room temperature for 8 h. The residue was purified by silica gel chromatography (0–20% methanol in dichloromethane). After concentrating the fractions containing the desired product, HCl (1 N in diethyl ether, 1 mL) was added and stirred 1 min. The mixture was concentrated under reduced pressure to provide 1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-(3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>15</b>) as a mixture of diastereomers (78% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; HCl Salt) δ 8.28 (s, 0.6H), 8.28 (s, 0.4H), 7.41–7.33 (m, 2H), 7.22–7.15 (m, 1H), 6.49–6.40 (m, 1H), 4.59 (d, <i>J</i> = 13.2 Hz, 1H), 4.40 (t, <i>J</i> = 13.1 Hz, 1H), 3.06 (d, <i>J</i> = 12.9 Hz, 1H), 2.88 (t, <i>J</i> = 13.1 Hz, 1H), 2.55–2.38 (m, 4H), 2.36–2.19 (m, 2H), 1.93 (d, <i>J</i> = 7.1 Hz, 3H), 1.60 (m, 6H), 1.50–1.41 (m, 2H), 0.91 (d, <i>J</i> = 6.9 Hz, 1.8H), 0.84 (d, <i>J</i> = 6.8 Hz, 1.2H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>29</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 541.2; found, 541.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-((3′<i>R</i>,4′<i>S</i>)-3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>16</b>)</h3><div class="NLM_p">Step 1: To a solution of <i>trans</i>-methylpiperidin-4-yl pivalate (1.93 g, 9.65 mmol) in EtOAc (8 mL) at room temperature was added a solution of (+)-<i>O,O’</i>-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartaric acid (1.73 g, 4.8 mmol) in EtOAc (13 mL). A precipitate formed immediately, and the solution was  cooled to 0 °C and then filtered through a Buchner funnel. The crystals were washed with cold EtOAc and dried in vacuo. The crystals were recrystallized in refluxing MeOH (14 mL), slowly cooled to room temperature, and filtered with a Buchner funnel to afford a white solid which was washed with minimal cold MeOH. The product was dried in vacuo, taken up in diethyl ether, and washed with 1 N NaOH three times. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to afford (3<i>R</i>,4<i>R</i>)-3-methylpiperidin-4-yl pivalate (38% yield). <sup>1</sup>H NMR and LCMS matched literature values previously reported.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Stereochemistry was confirmed by obtaining a single-crystal structure of the tartrate salt (Cambridge Crystallographic Data Centre Deposition Number 1915201, authors will release the atomic coordinates upon article publication).</div><div class="NLM_p">Step 2: To a solution of (3<i>R</i>,4<i>R</i>)-3-methylpiperidin-4-yl pivalate (0.73 g, 3.65 mmol) and benzaldehyde (0.46 g, 4.4 mmol) in dichloromethane (10 mL) at room temperature was added sodium triacetoxyborohydride. The solution was stirred overnight. The reaction was quenched with sat. aq. NaHCO<sub>3</sub>, extracted with EtOAc, dried over sodium sulfate, filtered, and concentrated via rotary evaporation to afford the desired product which was used without further purification. This crude oil was then taken up in MeOH (20 mL) and treated with NaOMe (25% in MeOH, 4 mL). The solution was refluxed overnight, cooled to room temperature, and concentrated. The crude material was diluted with diethyl ether, washed with 1N NaOH (×2), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified via silica gel chromatography (0–20% MeOH in dichloromethane) to afford (3<i>R</i>,4<i>R</i>)-1-benzyl-3-methylpiperidin-4-ol (33% yield). ee: 83% Chiralpak IF-3; 250 mm × 4.6 mm, 10% EtOH in heptanes (with 0.1% Et<sub>2</sub>NH); flow rate 1 mL/min; detection at 254 nm; <i>t</i><sub>1</sub> = 4.3 min (minor), <i>t</i><sub>2</sub> = 6.2 min (major). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>19</sub>NO [M + H]<sup>+</sup> = 206.2; found, 206.</div><div class="NLM_p">Step 3: To a solution of (3<i>R</i>,4<i>R</i>)-1-benzyl-3-methylpiperidin-4-ol (690 mg, 3.2 mmol) in dichloromethane (10 mL) at 0 °C was added triethylamine (0.49 mL, 3.5 mmol) and methanesulfonyl chloride (0.25 mL, 3.2 mmol) in that order. After 1 h the solution was treated with sat. aq. NaHCO<sub>3</sub>, extracted with dichloromethane, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified via silica gel chromatography (0–100% EtOAc in hexanes) to afford (3<i>R</i>,4<i>R</i>)-1-benzyl-3-methylpiperidin-4-yl methanesulfonate (70% yield). To a solution of (3<i>R</i>,4<i>R</i>)-1-benzyl-3-methylpiperidin-4-yl methanesulfonate (636 mg, 2.24 mmol) in DMF (10 mL) was added sodium azide (291 mg, 4.48 mmol) at room temperature, and the reaction was heated to 60 °C for 18 h. The solution was cooled to room temperature, diluted with water, and extracted with diethyl ether (x3). The combined organic phases were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified via silica gel chromatography (0–100% EtOAc in hexanes) to afford (3<i>R</i>,4<i>S</i>)-4-azido-1-benzyl-3-methylpiperidine (39% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>18</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 231.2; found, 231.</div><div class="NLM_p">Step 4: To a solution of (3<i>R</i>,4<i>S</i>)-4-azido-1-benzyl-3-methylpiperidine (200 mg, 0.87 mmol) in diethyl ether (16 mL) at 0 °C was added lithium aluminum hydride (1.0 mL, 4 M in diethyl ether), and the solution was left to slowly warm to room temperature overnight. The reaction mixture was quenched using the standard Fieser workup, filtered through a plug of Celite with EtOAc, and concentrated in vacuo to afford (3<i>R</i>,4<i>S</i>)-1-benzyl-3-methylpiperidin-4-amine, which was used without further purification. To a solution of the crude amine (30 mg, 0.15 mmol) in acetonitrile (2 mL) was added 1,5-dibromopentane (18 μL, 0.14 mmol) and potassium carbonate (37 mg, 0.27 mmol) at room temperature. The solution was heated to 60 °C for 18 h, cooled to room temperature, and filtered through a pad of Celite with MeOH. The mixture was concentrated in vacuo and purified via reversed phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min, to afford (3′<i>R</i>,4′<i>S</i>)-1′-benzyl-3′-methyl-1,4′-bipiperidine (22% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>28</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 273.2; found, 273.</div><div class="NLM_p">Step 5: A solution of (3′<i>R</i>,4′<i>S</i>)-1′-benzyl-3′-methyl-1,4′-bipiperidine (50 mg, 0.18 mmol) in MeOH (0.8 mL), AcOH (0.2 mL), and EtOAc (1.0 mL) was sparged with argon gas for 10 min. To this solution was added palladium hydroxide (3 mg, 10 mol %), and the solution was sparged with hydrogen gas for 10 min. The reaction as stirred under a hydrogen atmosphere overnight at room temperature. The suspension was sparged with argon gas for 10 min and then filtered through a pad of Celite with MeOH to afford crude (3′<i>R</i>,4′<i>S</i>)-3′-methyl-1,4′-bipiperidine which was used in the next step without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>22</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 183.2; found, 183.</div><div class="NLM_p last">Step 6: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 180 mg, 0.51 mmol), (3′<i>R</i>,4’<i>S</i>)-3′-methyl-1,4′-bipiperidine (95 mg, 0.51 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.17 mL, 1.0 mmol) in DMF (2 mL) at 80 °C for 16 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to give a mixture of stereoisomers. The mixture of stereoisomers was basified using a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as the eluent and concentrated under reduced pressure. The residue was dissolved in ethanol, treated with 2 N HCl in Et<sub>2</sub>O (0.2 mL), and concentrated under reduced pressure to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-((3′<i>R</i>,4’<i>S</i>)-3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>16</b>, 46% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN; HCl Salt) δ 8.17 (s, 1H), 7.47 (d, <i>J</i> = 2.2 Hz, 1H), 7.41 (d, <i>J</i> = 8.6 Hz, 1H), 7.26 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.25 (q, <i>J</i> = 7.1 Hz, 1H), 4.53 (ddt, <i>J</i> = 13.3, 4.8, 2.5 Hz, 1H), 4.40 (dt, <i>J</i> = 13.5, 2.7 Hz, 1H), 3.00 (dd, <i>J</i> = 13.5, 2.9 Hz, 1H), 2.82 (td, <i>J</i> = 13.2, 3.1 Hz, 1H), 2.43 (s, 3H), 2.42–2.35 (m, 4H), 2.31–2.21 (m, 1H), 2.20–2.15 (m, 1H), 1.88–1.82 (m, 1H), 1.84 (d, <i>J</i> = 7.1 Hz, 3H), 1.58–1.47 (m, 4H), 1.47–1.35 (m, 3H), 0.81 (d, <i>J</i> = 7.0 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 487.2; found, 487.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-((3′<i>S</i>,4’<i>R</i>)-3′-methyl-[1,4′-bipiperidin]-1′-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>17</b>)</h3><div class="NLM_p last">The inactive isomer was prepared via the same route; however, during the chiral resolution (−)-<i>O,O’</i>-dibenzoyl-<span class="smallcaps smallerCapital">l</span>-tartaric acid was used in place of (+)-<i>O,O′</i>-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartaric acid to afford (3<i>S</i>,4<i>S</i>)-3-methylpiperidin-4-yl pivalate (a single-crystal X-ray of this tartrate was also obtained, Cambridge Crystallographic Data Centre Deposition Number 1915202, authors will release the atomic coordinates upon article publication). This side chain was found to yield the less active isomer <b>17</b>, and thus, the stereochemistry of this series was based on these results. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN; HCl salt) δ 8.16 (s, 1H), 7.46 (d, <i>J</i> = 2.2 Hz, 1H), 7.39 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.25 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.25 (q, <i>J</i> = 7.1 Hz, 1H), 4.53 (ddt, <i>J</i> = 13.1, 4.5, 2.4 Hz, 1H), 4.45 (dt, <i>J</i> = 13.5, 2.7 Hz, 1H), 3.00 (dd, <i>J</i> = 13.4, 2.8 Hz, 1H), 2.82 (td, <i>J</i> = 13.2, 3.1 Hz, 1H), 2.43 (s, 3H), 2.46–2.37 (m, 4H), 2.29–2.22 (m, 1H), 2.21–2.15 (m, 1H), 1.90–1.84 (m, 1H), 1.83 (d, <i>J</i> = 7.1 Hz, 3H), 1.57–1.47 (m, 4H), 1.47–1.36 (m, 3H), 0.75 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 487.2; found, 487.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-((3<i>R</i>,4<i>R</i>)-3-methyl-4-(pyrrolidin-1-yl)piperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>18</b>)</h3><div class="NLM_p">Step 1: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (213 mg, 1.0 mmol), pyrrolidine (0.12 mL, 1.5 mmol), and sodium triacetoxyborohydride (316 mg, 1.5 mmol) in 1,2-dichloroethane (2.5 mL) at room temperature for 16 h. The crude residue was dissolved in methanol (0.5 mL), and HCl (4 N in 1,4-dioxane, 2 mL, 8 mmol) was added. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to afford 3-methyl-4-(pyrrolidin-1-yl)piperidine hydrochloride which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>20</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 168.2; found, 168.</div><div class="NLM_p last">Step 2: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 75 mg, 0.22 mmol), 3-methyl-4-(pyrrolidin-1-yl)piperidine hydrochloride (41 mg, 0.2 mmol), and <i>N,N</i>-diisopropylethylamine (0.15 mL, 0.86 mmol) in DMF (1.0 mL) at 80 °C for 1 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to give a mixture of stereoisomers. The stereoisomers were basified using a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as the eluent and concentrated under reduced pressure. The residue was azeotroped with ethanol, and the residue was further purified using chiral HPLC (OZ-H, Chiralpak, Daicel Corp., West Chester, PA), eluent 20% ethanol in heptanes, with heptanes containing 0.1% diethylamine, 30 min. The first eluting isomer was isolated, and the free base was dissolved in ethanol, treated with 2 N HCl in Et<sub>2</sub>O (0.2 mL), and concentrated under reduced pressure to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-((3<i>R</i>,4<i>S</i>)-3-methyl-4-(pyrrolidin-1-yl)piperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>18</b>, 7% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 8.31 (s, 1H), 7.46 (d, <i>J</i> = 2.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.28 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.32 (q, <i>J</i> = 6.9 Hz, 1H), 4.75 (dm, <i>J</i> = 14.1 Hz, 1H), 4.60 (dm, <i>J</i> = 13.8 Hz, 1H), 3.76–3.67 (m, 2H), 3.52–3.45 (m, 1H), 3.26–3.11 (m, 3H), 3.01 (td, <i>J</i> = 13.6, 3.0 Hz, 1H), 2.57–2.50 (m, 1H), 2.52 (s, 3H), 2.24–2.16 (m, 2H), 2.14–1.98 (m, 3H), 1.96–1.83 (m, 1H), 1.89 (d, <i>J</i> = 7.1 Hz, 3H), 1.05 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 473.2; found, 473.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 6-((3<i>R</i>,4<i>S</i>)-4-(Azetidin-1-yl)-3-methylpiperidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>19</b>)</h3><div class="NLM_p">Step 1: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (213 mg, 1.0 mmol), azetidine (0.10 mL, 1.5 mmol), and sodium triacetoxyborohydride (316 mg, 1.5 mmol) in 1,2-dichloroethane (2.5 mL) at room temperature for 16 h. The crude residue was dissolved in methanol (0.5 mL) and HCl (4 N in 1,4-dioxane, 2 mL, 8 mmol) was added. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to afford 4-(azetidin-1-yl)-3-methylpiperidine hydrochloride, which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>9</sub>H<sub>18</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 155.2; found, 155.</div><div class="NLM_p last">Step 2: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 75 mg, 0.22 mmol), 4-(azetidin-1-yl)-3-methylpiperidine hydrochloride (38 mg, 0.2 mmol), and <i>N,N</i>-diisopropylethylamine (0.15 mL, 0.86 mmol) in DMF (1.0 mL) at 80 °C for 1 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford a mixture of stereoisomers. The stereoisomers were basified using a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as the eluent and concentrated under reduced pressure. The residue was azeotroped with ethanol, and the residue was further purified using chiral HPLC (OZ-H, Chiralpak, Daicel Corp., West Chester, PA), eluent 20% ethanol in heptanes, with heptanes containing 0.1% diethylamine, 30 min. The first eluting isomer was isolated, and the free base was dissolved in ethanol, treated with 2 N HCl in Et<sub>2</sub>O (0.2 mL), and concentrated under reduced pressure to afford 6-((3<i>R</i>,4<i>S</i>)-4-(azetidin-1-yl)-3-methylpiperidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>19</b>, 5% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 8.32 (s, 1H), 7.46 (s, <i>J</i> = 2.1 Hz, 1H), 7.44 (d, <i>J</i> = 8.5 Hz, 1H), 7.29 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.31 (q, <i>J</i> = 7.1 Hz, 1H), 4.70 (dm, <i>J</i> = 13.5 Hz, 1H), 4.57 (dt, <i>J</i> = 13.8, 2.4 Hz, 1H), 4.37–4.09 (m, 4H), 3.64 (dt, <i>J</i> = 12.2, 4.3 Hz, 1H), 3.18 (dd, <i>J</i> = 14.0, 2.6 Hz, 1H), 3.06–2.97 (m, 1H), 2.74–2.58 (m, 1H), 2.52 (s, 3H), 2.47–2.32 (m, 2H), 1.96–1.88 (m, 1H), 1.89 (d, <i>J</i> = 7.1 Hz, 3H), 1.71–1.56 (m, 1H), 0.92 (d, <i>J</i> = 7.0 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 459.2; found, 459.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 6-((3<i>R</i>,4<i>S</i>)-4-(Azepan-1-yl)-3-methylpiperidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>20</b>)</h3><div class="NLM_p">Step 1: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (213 mg, 1.0 mmol), azepane (0.17 mL, 1.5 mmol), and sodium triacetoxyborohydride (316 mg, 1.5 mmol) in 1,2-dichloroethane (2.5 mL) at room temperature for 16 h. The crude residue was dissolved in methanol (0.5 mL), and HCl (4 N in 1,4-dioxane, 2 mL, 8 mmol) was added. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to afford 1-(3-methylpiperidin-4-yl)azepane hydrochloride which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>24</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 197.2; found, 197.</div><div class="NLM_p last">Step 2: The S<sub>N</sub>Ar was performed following general procedure A (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 75 mg, 0.22 mmol), 1-(3-methylpiperidin-4-yl)azepane hydrochloride (47 mg, 0.2 mmol), and <i>N,N</i>-diisopropylethylamine (0.15 mL, 0.86 mmol) in DMF (1.0 mL) at 80 °C for 1 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to give a mixture of stereoisomers. The stereoisomers were basified using a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as the eluent and concentrated under reduced pressure. The residue was azeotroped with ethanol, and the residue was further purified using chiral HPLC (OZ-H, Chiralpak, Daicel Corp., West Chester, PA), eluent 20% ethanol in heptanes, with heptanes containing 0.1% diethylamine, 30 min. The first eluting isomer was isolated, and the free base was dissolved in ethanol, treated with 2 N HCl in Et<sub>2</sub>O (0.2 mL), and concentrated under reduced pressure to afford 6-((3<i>R</i>,4<i>S</i>)-4-(azepan-1-yl)-3-methylpiperidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>20</b>, 10% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 8.11 (s, 1H), 7.21 (d, <i>J</i> = 2.1 Hz, 1H), 7.14 (d, <i>J</i> = 8.5 Hz, 1H), 7.04 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.09 (q, <i>J</i> = 7.2 Hz, 1H), 4.56–4.38 (m, 2H), 3.42 (dt, <i>J</i> = 7.0, 3.7 Hz, 1H), 3.35–3.07 (m, 4H), 2.95 (dd, <i>J</i> = 14.0, 2.2 Hz, 1H), 2.87–2.78 (m, 1H), 2.37 (s, 1H), 2.33–2.27 (m, 1H), 2.29 (s, 3H), 1.94 (br d, <i>J</i> = 11.0 Hz, 1H), 1.74 (d, <i>J</i> = 25.2 Hz, 4H), 1.65 (d, <i>J</i> = 7.1 Hz, 3H), 1.61–1.45 (m, 4H), 0.73 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 501.2; found, 501.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-((3<i>R</i>,4<i>S</i>)-3-methyl-4-((<i>R</i>)-2-methylpyrrolidin-1-yl)piperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>21</b>)</h3><div class="NLM_p">Step 1: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (213 mg, 1.0 mmol), (<i>R</i>)-2-methylpyrrolidine (128 mg, 1.5 mmol), and sodium triacetoxyborohydride (316 mg, 1.5 mmol) in 1,2-dichloroethane (2.5 mL) at room temperature for 16 h. The crude residue was dissolved in methanol (0.5 mL) and HCl (4 N in 1,4-dioxane, 2 mL, 8 mmol) was added. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to give 3-methyl-4-((<i>R</i>)-2-methylpyrrolidin-1-yl)piperidine hydrochloride which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>22</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 183.2; found, 183.</div><div class="NLM_p last">Step 2: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 75 mg, 0.22 mmol), 3-methyl-4-((<i>R</i>)-2-methylpyrrolidin-1-yl)piperidine hydrochloride (44 mg, 0.2 mmol), and <i>N,N</i>-diisopropylethylamine (0.15 mL, 0.86 mmol) in DMF (1.0 mL) at 80 °C for 1 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to give a mixture of stereoisomers. The stereoisomers were basified using a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as the eluent and concentrated under reduced pressure. The residue was azeotroped with ethanol, and the residue was further purified using chiral HPLC (ID-3, Chiralpak, Daicel Corp., West Chester, PA), eluent 20% ethanol in heptanes, with heptanes containing 0.1% diethylamine, 30 min. The first eluting isomer was isolated, and the free base was dissolved in ethanol, treated with 2 N HCl in Et<sub>2</sub>O (0.2 mL), and concentrated under reduced pressure to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-((3<i>R</i>,4<i>S</i>)-3-methyl-4-((<i>R</i>)-2-methylpyrrolidin-1-yl)piperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>21</b>, 5% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3;</sub> HCl salt): δ 8.09 (s, 1H), 7.40 (d, <i>J</i> = 8.5 Hz, 1H), 7.35 (d, <i>J</i> = 2.1 Hz, 1H), 7.14 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.31 (q, <i>J</i> = 7.1 Hz, 1H), 4.55–4.47 (m, 1H), 4.37–4.31 (m, 1H), 3.15–3.07 (m, 1H), 3.05–2.98 (m, 1H), 2.86 (td, <i>J</i> = 12.8, 3.6 Hz, 1H), 2.79–2.72 (m, 1H), 2.68–2.60 (m, 1H), 2.58–2.53 (m, 4H), 2.18–2.11 (m, 1H), 1.90 (d, <i>J</i> = 7.1 Hz, 3H), 1.83–1.63 (m, 5H), 1.50–1.42 (m, 1H), 0.99–0.93 (m, 6H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 487.2; found, 487.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-((3<i>R</i>,4<i>S</i>)-3-methyl-4-((<i>S</i>)-2-methylpyrrolidin-1-yl)piperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>22</b>)</h3><div class="NLM_p">Step 1: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (213 mg, 1.0 mmol), (<i>S</i>)-2-methylpyrrolidine (128 mg, 1.5 mmol), and sodium triacetoxyborohydride (316 mg, 1.5 mmol) in 1,2-dichloroethane (2.5 mL) at room temperature for 16 h. The crude residue was dissolved in methanol (0.5 mL), and HCl (4 N in 1,4-dioxane, 2 mL, 8 mmol) was added. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to give 3-methyl-4-((<i>S</i>)-2-methylpyrrolidin-1-yl)piperidine hydrochloride, which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>22</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 183.2; found, 183.</div><div class="NLM_p last">Step 2: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 75 mg, 0.22 mmol), 3-methyl-4-((<i>S</i>)-2-methylpyrrolidin-1-yl)piperidine hydrochloride (44 mg, 0.2 mmol), and <i>N,N</i>-diisopropylethylamine (0.15 mL, 0.86 mmol) in DMF (1.0 mL) at 80 °C for 1 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to give a mixture of stereoisomers. The stereoisomers were basified using a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as the eluent and concentrated under reduced pressure. The residue was azeotroped with ethanol, and the residue was further purified using chiral HPLC (ID-3, Chiralpak, Daicel Corp., West Chester, PA), eluent 20% ethanol in heptanes, with heptanes containing 0.1% diethylamine, 30 min. The first eluting isomer was isolated, and the free base was dissolved in ethanol, treated with 2 N HCl in Et<sub>2</sub>O (0.2 mL), and concentrated under reduced pressure to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-((3<i>R</i>,4<i>S</i>)-3-methyl-4-((<i>S</i>)-2-methylpyrrolidin-1-yl)piperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>22</b>, 5% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; HCl salt): δ 8.08 (s, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.34 (d, <i>J</i> = 2.1 Hz, 1H), 7.15–7.11 (m, 1H), 6.35–6.29 (m, 1H), 4.58–4.51 (m, 1H), 4.38–4.33 (m, 1H), 3.18–2.98 (m, 2H), 2.92–2.61 (m, 3H), 2.56 (s, 3H), 2.19–2.10 (m, 1H), 1.90 (d, <i>J</i> = 7.1 Hz, 4H), 1.83–1.60 (m, 2H), 1.49–1.42 (m, 1H), 1.32–1.23 (m, 3H), 0.95 (d, <i>J</i> = 6.3 Hz, 3H), 0.87 (d, <i>J</i> = 6.7 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 487.2; found, 487.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidine-2-carboxamide Hydrochloride (<b>23</b>)</h3><div class="NLM_p">Step 1: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (1.5 g, 7.03 mmol), <span class="smallcaps smallerCapital">l</span>-prolinamide (1.2 g, 10.5 mmol), AcOH (0.6 mL, 10.5 mmol), and sodium triacetoxyborohydride (2.22 g, 10.7 mmol) in 1,2-dichloroethane (20 mL) at room temperature for 16 h. The residue was purified by silica gel chromatography (0–5% methanol in dichloromethane) to afford a mixture of diastereomers. The residue was dissolved in dichloromethane (20 mL), and HCl (4 N in 1,4-dioxane, 5 mL) was added. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to afford (2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidine-2-carboxamide hydrochloride, which was used in the next step without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 212.2; found, 212.</div><div class="NLM_p last">Step 2: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 204 mg, 0.60 mmol), (2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidine-2-carboxamide hydrochloride (150 mg, 0.61 mmol), and <i>N,N</i>-diisopropylethylamine (0.31 mL, 1.8 mmol) in DMSO (1.2 mL) at 80 °C for 16 h. The residue was purified by silica gel chromatography (0–10% methanol in dichloromethane) to afford a mixture of diastereomers. The mixture was further purified by preparative SFC (AD-H (2 × 25 cm), 35% isopropanol with 0.1% DEA and CO<sub>2</sub> at 100 bar, 55 mL/min). The first eluting isomer was isolated from this purification and converted to the HCl salt by diluting in dichloromethane (2 mL), adding HCl (2 N in diethyl ether, 0.5 mL), and concentrating to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile hydrochloride (<b>23</b>, 15% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; TFA salt) δ 8.07 (s, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 1H), 7.36 (d, <i>J</i> = 2.1 Hz, 1H), 7.13 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.08 (d, <i>J</i> = 5.8 Hz, 1H), 6.30 (q, <i>J</i> = 7.1 Hz, 1H), 5.37 (d, <i>J</i> = 5.7 Hz, 1H), 4.49 (d, <i>J</i> = 13.4 Hz, 1H), 4.37 (d, <i>J</i> = 13.6 Hz, 1H), 4.07–3.95 (m, 1H), 3.48 (s, 1H), 3.32–3.15 (m, 2H), 3.04 (dd, <i>J</i> = 13.5, 2.9 Hz, 1H), 2.82 (td, <i>J</i> = 12.9, 3.2 Hz, 1H), 2.45–2.30 (m, 1H), 2.28–2.11 (m, 2H), 2.02–1.94 (m, 1H), 1.89 (d, <i>J</i> = 7.2 Hz, 3H), 1.88–1.56 (m, 4H), 1.35 (d, <i>J</i> = 4.4 Hz, 1H), 1.23–1.16 (m, 1H), 0.99 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 516.2; found, 516.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 3-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)propenamide Hydrochloride (<b>24</b>)</h3><div class="NLM_p">Step 1: To a cooled suspension of sodium <i>tert</i>-butoxide (2.41 g, 25.1 mmol) in THF (100 mL) at 0 °C was added trimethylphosphonoacetate (4.5 mL, 27.6 mmol). After 1 h, the solution was transferred via cannula into a solution of <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-prolinal (5.0 g, 25.1 mmol) in THF (50 mL). After 30 min, the mixture was poured into saturated aqueous sodium bicarbonate solution, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to afford the intermediate <i>tert</i>-butyl (<i>S</i>,<i>E</i>)-2-(3-methoxy-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate, which was used without further purification (99% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>21</sub>NO<sub>4</sub> [M + H]<sup>+</sup> = 256.2; found, 256.</div><div class="NLM_p">Step 2: A solution of <i>tert</i>-butyl (<i>S</i>,<i>E</i>)-2-(3-methoxy-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate (6.38 g, 25.0 mmol) and 10% palladium on carbon (1.3 g, 1.25 mmol) in methanol (100 mL) was stirred under a hydrogen atmosphere for 16 h. Nitrogen gas was bubbled through the solution for 15 min before it was carefully filtered through Celite using MeOH and concentrated under reduced pressure to afford <i>tert</i>-butyl (<i>S</i>)-2-(3-methoxy-3-oxopropyl)pyrrolidine-1-carboxylate, which was used without further purification. To a cooled solution of <i>tert</i>-butyl (<i>S</i>)-2-(3-methoxy-3-oxopropyl)pyrrolidine-1-carboxylate (25.0 mmol) in dichloromethane (100 mL) at 0 °C was added trifluoroacetic acid (19 mL, 250 mmol). The mixture was stirred at room temperature for 16 h and concentrated via rotary evaporation. The residue was redissolved in dichloromethane, and potassium carbonate (17.3 g, 125 mmol) was added. After 30 min of stirring, the solution was filtered and the solvent was removed under reduced pressure to afford methyl (<i>S</i>)-3-(pyrrolidin-2-yl)propanoate, which was used without further purification (99% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>15</sub>NO<sub>2</sub> [M + H]<sup>+</sup> = 158.1; found, 158.</div><div class="NLM_p">Step 3: The reductive amination was performed following general procedure D using <i>tert</i>-butyl 3-methyl-4-oxopiperidine-1-carboxylate (2.24 g, 10.6 mmol), methyl (<i>S</i>)-3-(pyrrolidin-2-yl)propanoate (2 g, 12.73 mmol), sodium triacetoxyborohydride (3.4 g, 15.8 mmol), and acetic acid (0.9 mL, 15.8 mmol) in dichloromethane (25 mL) at room temperature for 16 h. The residue was loaded onto silica gel and purified by normal-phase column chromatography (0–50% ethyl acetate in hexanes) to afford <i>tert</i>-butyl 4-((<i>S</i>)-2-(3-methoxy-3-oxopropyl)pyrrolidin-1-yl)-3-methylpiperidine-1-carboxylate (75% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>34</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> = 355.3; found, 355.</div><div class="NLM_p">Step 4: To a solution of <i>tert</i>-butyl 4-((<i>S</i>)-2-(3-methoxy-3-oxopropyl)pyrrolidin-1-yl)-3-methylpiperidine-1-carboxylate (2.03 g, 5.97 mmol) in THF (20 mL) and water (10 mL) was added lithium hydroxide (215 mg, 8.96 mmol). The reaction was heated to 50 °C for 16 h and cooled to room temperature, and the solvent was removed under reduced pressure to afford 3-((2<i>S</i>)-1-(1-(<i>tert</i>-butoxycarbonyl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)propanoic acid, which was used without further purification. The residue was dissolved in dichloromethane (30 mL), and trifluoroacetic acid (4.6 mL, 59.7 mmol) was added. The reaction was stirred at room temperature for 16 h and concentrated via rotary evaporation to afford 3-((2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidin-2-yl)propanoic acid 2,2,2-trifluoroacetate, which was used without further purification (99% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>34</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> = 355.3; found, 355.</div><div class="NLM_p">Step 5: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 512 mg, 1.50 mmol), 3-((2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidin-2-yl)propanoic acid 2,2,2-trifluoroacetate (721 mg, 3.00 mmol), and <i>N,N</i>-diisopropylethylamine (0.78 mL, 4.50 mmol) in DMSO (3.0 mL) at 80 °C for 16 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 35–40% acetonitrile in water, both eluents containing 0.1% ammonium formate, gradient over 20 min, to afford the formate salt of the desired product as the second eluting isomer. The formate salt was suspended in saturated aqueous sodium bicarbonate solution and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was redissolved in dichloromethane (3.0 mL), treated with 2 M HCl in Et<sub>2</sub>O (0.3 mL), and concentrated under reduced pressure to afford 3-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)propanoic acid hydrochloride (17% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN, HCl salt) δ 8.31 (s, 1H), 8.17 (s, 1H), 7.46 (d, <i>J</i> = 2.2 Hz, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.27–7.22 (m, 1H), 6.26 (q, <i>J</i> = 7.1 Hz, 1H), 4.63–4.53 (m, 1H), 4.45 (dt, <i>J</i> = 13.6, 2.6 Hz, 1H), 3.66–3.57 (m, <i>J</i> = 5.9, 3.2 Hz, 1H), 3.31–3.20 (m, 1H), 3.06–2.80 (m, 4H), 2.49 (ddd, <i>J</i> = 17.6, 9.9, 3.0 Hz, 1H), 2.43 (s, <i>J</i> = 1.4 Hz, 3H), 2.41–2.33 (m, 2H), 2.15–1.96 (m, 3H), 1.93–1.85 (m, 2H), 1.83 (d, <i>J</i> = 7.1 Hz, 3H), 1.81–1.68 (m, 3H), 0.98 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 545.2; found, 545.</div><div class="NLM_p last">Step 6: The HATU coupling was performed following general procedure C using 3-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)propanoic acid hydrochloride (30 mg, 0.055 mmol), ammonia gas (excess), <i>N,N</i>-diisopropylethylamine (19 μL, 0.110 mmol), and HATU (23 mg, 0.061 mmol) in DMF (1.0 mL) at room temperature for 10 min. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 3-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)propenamide (<b>24</b>, 99% yield).). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> = 544.2; found, 544.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-((3<i>R</i>,4<i>S</i>)-3-methyl-4-((<i>S</i>)-2-(2-(methylsulfonyl)ethyl)pyrrolidin-1-yl)piperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine Hydrochloride (<b>25</b>)</h3><div class="NLM_p">Step 1: Dimethyl ((methylsulfonyl)methyl)phosphonate (1.22 g, 6.02 mmol) was dissolved in THF (20 mL), and the solution was cooled to 0 °C. Sodium <i>tert</i>-butoxide (0.579 g, 6.02 mmol) was added, and then the mixture was stirred for 30 min at 0 °C. <i>tert</i>-Butyl (<i>S</i>)-2-formylpyrrolidine-1-carboxylate was then added (dissolved in 5 mL of THF). The reaction was stirred vigorously for 2 h at room temperature and then quenched with saturated aqueous sodium bicarbonate. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide <i>tert</i>-butyl (<i>S</i>,<i>E</i>)-2-(2-(methylsulfonyl)vinyl)pyrrolidine-1-carboxylate (98% yield) as a colorless oil which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>21</sub>NO<sub>4</sub>S [M + H]<sup>+</sup> = 276.1; found, 276.</div><div class="NLM_p">Step 2: <i>tert</i>-Butyl (<i>S</i>,<i>E</i>)-2-(2-(methylsulfonyl)vinyl)pyrrolidine-1-carboxylate (1.2 g, 4.36 mmol) was dissolved in MeOH (20 mL), and then PtO<sub>2</sub> (9.9 mg, 0.044 mmol) was added. The mixture was purged twice with nitrogen and then twice with hydrogen. The reaction was then placed under an atmosphere of hydrogen and stirred for 1 h at room temperature. The mixture was flushed with nitrogen, filtered carefully through a silica gel plug, and concentrated under reduced pressure to provide <i>tert</i>-butyl (<i>S</i>)-2-(2-(methylsulfonyl)ethyl)pyrrolidine-1-carboxylate (99% yield) as a colorless oil which was used in the next step without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>23</sub>NO<sub>4</sub>S [M + H]<sup>+</sup> = 278.1; found, 278.</div><div class="NLM_p">Step 3: <i>tert-</i>Butyl (<i>S</i>)-2-(2-(methylsulfonyl)ethyl)pyrrolidine-1-carboxylate (1.3 g, 4.69 mmol) was dissolved in CH<sub>2</sub>C1<sub>2</sub> (10 mL), and HCl (4 N in 1,4-dioxane, 3.5 mL, 14.1 mmol) was added. The reaction was stirred for 4 h at room temperature. The mixture was diluted with dichloromethane and washed with saturated aqueous sodium carbonate. The organic fraction was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide (<i>S</i>)-2-(2-(methylsulfonyl)ethyl)pyrrolidine hydrochloride (99% yield) which was used without further purifiaction. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>7</sub>H<sub>15</sub>NO<sub>2</sub>S [M + H]<sup>+</sup> = 178.1; found, 178.</div><div class="NLM_p">Step 4: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (1.0 g, 4.69 mmol), (<i>S</i>)-2-(2-(methylsulfonyl)ethyl)pyrrolidine hydrochloride (1.0 g, 4.69 mmol), and sodium triacetoxyborohydride (2.98 g, 14.07 mmol) in 1,2-dichloroethane (10 mL) at room temperature for 6 h. The crude residue was used without further purification. The residue was dissolved in dichloromethane (20 mL), and HCl (4 N in 1,4-dioxane, 3.5 mL) was added. The mixture was stirred at room temperature for 4 h and then concentrated under reduced pressure to afford (2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidine-2-carboxamide hydrochloride (96% yield), which was used in the next step without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup> = 275.2; found, 275.</div><div class="NLM_p last">Step 5: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 500 mg, 1.46 mmol), (2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidine-2-carboxamide hydrochloride (500 mg, 1.61 mmol), and <i>N,N</i>-diisopropylethylamine (0.76 mL, 4.39 mmol) in DMF (15 mL) at 80 °C for 8 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to give a mixture of stereoisomers. The stereoisomers were basified using a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as the eluent and concentrated under reduced pressure. The residue was azeotroped with ethanol, and the residue was further purified using chiral HPLC (IF-3, Chiralpak, Daicel Corp., West Chester, PA), eluent 45% ethanol in heptanes, with heptanes containing 0.1% diethylamine, 30 min. The first eluting isomer was isolated, and the free base was dissolved in ethanol, treated with 2 N HCl in Et<sub>2</sub>O (0.2 mL), and concentrated under reduced pressure to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-((3<i>R</i>,4<i>S</i>)-3-methyl-4-((<i>R</i>)-2-methylpyrrolidin-1-yl)piperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine hydrochloride (<b>25</b>, 6% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; HCl salt) δ 8.09 (s, 1H), 7.41 (d, <i>J</i> = 8.5 Hz, 1H), 7.37 (d, <i>J</i> = 2.0 Hz, 1H), 7.15 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 6.31 (q, <i>J</i> = 7.1 Hz, 1H), 4.52 (d, <i>J</i> = 13.3 Hz, 1H), 4.35 (d, <i>J</i> = 13.3 Hz, 1H), 3.22–3.07 (m, 2H), 3.06–2.92 (m, 3H), 2.90 (s, 3H), 2.89–2.80 (m, 1H), 2.57 (s, 3H), 2.49–2.43 (m, 1H), 2.21–2.09 (m, 1H), 2.00–1.92 (m, 3H), 1.91 (d, <i>J</i> = 7.1 Hz, 3H), 1.87–1.62 (m, 5H), 1.59–1.50 (m, 1H), 0.95 (d, <i>J</i> = 6.8 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>36</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> = 579.2; found, 579.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)ethane-1-sulfonamide (<b>26</b>)</h3><div class="NLM_p">Step 1: Triethylamine (1.0 mL, 7.4 mmol) was added to <i>tert</i>-butyl (<i>S</i>)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate (800 mg, 3.7 mmol) in dichloromethane (10 mL). The mixture was cooled in to 0 °C, and methanesulfonyl chloride (0.35 mL, 4.44 mmol) was added. After 1.5 h, the reaction mixture was quenched with water (10 mL) and the layers were separated. The organic layer was dried over sodium sulfate, filtered, and concentrated via rotary evaporation to afford an oil which was used directly in the following step without further purification. The intermediate mesylate (∼3.7 mmol) was dissolved in DMF (10 mL), and potassium thioacetate (845 mg, 7.4 mmol) was added. The mixture was heated to 50 °C, upon which copious precipitate appeared. An additional 10 mL of DMF was added to the mixture, and the reaction was stirred for an additional 1 h. The reaction mixture was then partitioned between 50% ethyl acetate in hexanes (100 mL) and water (100 mL). The organic layer was washed with water (2 × 50 mL), dried over sodium sulfate, filtered, and concentrated via rotary evaporation. The residue was purified by silica gel chromatography (0–50% ethyl acetate in hexanes) to afford <i>tert</i>-butyl (<i>S</i>)-2-(2-(acetylthio)ethyl)pyrrolidine-1-carboxylate as a white solid (68% over 2 steps). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>23</sub>NO<sub>3</sub>S [M + H]<sup>+</sup> = 274.2; found, 274.</div><div class="NLM_p">Step 2: <i>N</i>-Chlorosuccinimide (1.33 g, 10 mmol) was added to a mixture of 2 N aqueous HCl (1.24 mL, 2.5 mmol) in acetonitrile (16.5 mL) at room temperature. The mixture was stirred for 10 min before being cooled to 0 °C. <i>tert</i>-Butyl (<i>S</i>)-2-(2-(acetylthio)ethyl)pyrrolidine-1-carboxylate (678 mg, 2.5 mmol) was then added to the reaction mixture dropwise as a solution in acetonitrile (4 mL). The reaction was warmed to room temperature and stirred for 10 min before diluting with ethyl acetate (100 mL) and water (100 mL). The organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated via rotary evaporation to afford the sulfonyl chloride intermediate as a white solid which was used in the next step without further purification. The sulfonyl chloride intermediate (∼2.5 mmol) was dissolved in acetonitrile (16.5 mL), and concentrated aqueous ammonia (33%, 2.48 mL) was added. The mixture was stirred for 15 min and then diluted with ethyl acetate (50 mL) and water (50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated via rotary evaporation. The residue was treated with HCl (4 N in 1,4-dioxane, 10 mL) and stirred overnight. After concentrating, the solid was taken up in methanol (10 mL) and filtered through a basification column (PL-HCO3MP SPE, Agilent) to afford (<i>S</i>)-2-(pyrrolidin-2-yl)ethane-1-sulfonamide which was used directly in the next step without further purification (93% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>6</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup> = 179.1; found, 179.</div><div class="NLM_p">Step 3: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (213 mg, 1.0 mmol), (<i>S</i>)-2-(pyrrolidin-2-yl)ethane-1-sulfonamide (267 mg, 1.5 mmol), and sodium triacetoxyborohydride (316 mg, 1.5 mmol) in 1,2-dichloroethane at room temperature for 16 h. The crude residue was dissolved in dichloromethane (6 mL), and trifluoroacetic acid (2 mL) was added. The reaction was stirred at room temperature for 1 h and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (0–30% methanol in dichloromethane) to afford 2-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)ethane-1-sulfonamide as the first eluting diastereomer (22% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>6</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup> = 275.2; found, 275.</div><div class="NLM_p last">Step 4: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 75 mg, 0.22 mmol), 2-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)ethane-1-sulfonamide (55 mg, 0.2 mmol), and <i>N,N</i>-diisopropylethylamine (0.15 mL, 0.861 mmol) in DMF (0.5 mL) at 80 °C for 1 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford the trifluoroacetate salt. The salt was dissolved in methanol and filtered through a basification column (PL-HCO3MP SPE, Agilent), and the filtrate was treated with HCl (2 N in diethyl ether, 0.5 mL) and concentrated under reduced pressure to afford 2-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)ethane-1-sulfonamide (<b>26</b>, 15% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, HCl salt) δ 8.25 (s, 1H), 7.40 (d, <i>J</i> = 2.1 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.22 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.28 (q, <i>J</i> = 7.1 Hz, 1H), 4.75 (dm, <i>J</i> = 13.7 Hz, 1H), 4.59 (dm, <i>J</i> = 13.8 Hz, 1H), 4.19–4.04 (m, 1H), 3.78–3.57 (m, 2H), 3.43–3.32 (m, 1H), 3.29–3.25 (m, 2H), 3.15 (br d, <i>J</i> = 13.6 Hz, 1H), 3.02 (br t, <i>J</i> = 11.9 Hz, 1H), 2.55 (br s, 1H), 2.49 (s, 3H), 2.39–1.91 (m, 10H), 1.85 (d, <i>J</i> = 7.1 Hz, 3H), 1.07 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> = 580.2; found, 580.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)propanenitrile 2,2,2-Trifluoroacetate (<b>27</b>)</h3><div class="NLM_p last">To a solution of 3-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)propanamide (<b>24</b>, 30 mg, 0.055 mmol) was added Burgess reagent (26 mg, 0.110 mmol). The reaction was stirred at room temperature for 16 h before being concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 3-((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)propanenitrile 2,2,2-trifluoroacetate (<b>27</b>, 30% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TFA salt) δ 8.11 (s, 1H), 7.39–7.34 (m, 2H), 7.15 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.31 (q, <i>J</i> = 7.1 Hz, 1H), 4.65 (d, <i>J</i> = 13.7 Hz, 1H), 4.52 (d, <i>J</i> = 13.8 Hz, 1H), 3.89 (s, 1H), 3.66 (s, 1H), 3.47 (d, <i>J</i> = 11.9 Hz, 1H), 3.15 (s, 1H), 3.06 (d, <i>J</i> = 13.6 Hz, 1H), 2.97 (t, <i>J</i> = 12.9 Hz, 1H), 2.79–2.66 (m, 1H), 2.58 (s, 3H), 2.50–1.92 (m, 10H), 1.90 (d, <i>J</i> = 7.1 Hz, 3H), 1.20 (d, <i>J</i> = 6.7 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>7</sub> [M + H]<sup>+</sup> = 526.2; found, 526.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> ((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)-<span class="smallcaps smallerCapital">l</span>-proline 2,2,2-Trifluoroacetate (<b>28</b>)</h3><div class="NLM_p">Step 1: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (2.83 g, 13.3 mmol), <span class="smallcaps smallerCapital">l</span>-proline (1.84 g, 16 mmol), AcOH (1.14 mL, 20 mmol), and sodium triacetoxyborohydride (4.24 g, 20 mmol) in 1,2-dichloroethane (30 mL) at room temperature for 16 h. The residue was purified by silica gel chromatography (0–50% ethyl acetate in hexanes) to afford a mixture of diastereomers. The residue was dissolved in dichloromethane (50 mL), and trifluoroacetic acid (16.5 mL) was added. The mixture was stirred at room temperature for 16 h and then concentrated under reduced pressure to afford (3-methylpiperidin-4-yl)-<span class="smallcaps smallerCapital">l</span>-proline trifluoroacetate which was used in the next step without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>20</sub>CN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 213.2; found, 213.</div><div class="NLM_p last">Step 2: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 75 mg, 0.22 mmol), (3-methylpiperidin-4-yl)-<span class="smallcaps smallerCapital">l</span>-proline trifluoroacetate (65 mg, 0.2 mmol), and <i>N,N</i>-diisopropylethylamine (0.15 mL, 0.86 mmol) in DMSO (1.0 mL) at 80 °C for 1 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford ((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)-<span class="smallcaps smallerCapital">l</span>-proline trifluoroacetate as the second eluting isomer (<b>28</b>, 7% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN; TFA salt): δ 8.20 (s, 1H), 7.48–7.43 (m, 2H), 7.27 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.29 (q, 1H), 4.66–4.51 (m, 2H), 4.47 (dd, <i>J</i> = 10.2, 4.0 Hz, 1H), 3.90–3.80 (m, 1H), 3.63–3.50 (m, 1H), 3.32–3.17 (m, 1H), 3.07 (d, <i>J</i> = 13.7 Hz, 1H), 2.97–2.85 (m, 1H), 2.56–2.46 (m, 2H), 2.46 (s, 3H), 2.35–2.24 (m, 1H), 2.20–2.09 (m, 1H), 2.06–1.95 (m, 1H), 1.93–1.87 (m, 2H), 1.85 (d, <i>J</i> = 7.1 Hz, 3H), 1.09 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 517.2; found, 517.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> ((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)methanol (<b>29</b>)</h3><div class="NLM_p">Step 1: The reductive amination was performed following general procedure D using 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (213 mg, 1.0 mmol), (<i>S</i>)-pyrrolidin-2-ylmethanol (152 mg, 1.5 mmol), and sodium triacetoxyborohydride (316 mg, 1.5 mmol) in 1,2-dichloroethane (2.5 mL) at room temperature for 16 h. The residue was purified by silica gel chromatography (0–20% methanol in dichloromethane) to afford the cis diastereomer of <i>tert</i>-butyl 4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-3-methylpiperidine-1-carboxylate (40% yield). The residue was dissolved in dichloromethane (2.0 mL), and trifluoroacetic acid (0.5 mL) was added. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to afford the cis diastereomer of ((2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidin-2-yl)methanol 2,2,2-trifluoroacetate which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>22</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 199.2; found, 199.</div><div class="NLM_p last">Step 2: The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 75 mg, 0.22 mmol), the cis diastereomer of ((2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidin-2-yl)methanol 2,2,2-trifluoroacetate (62 mg, 0.2 mmol), and <i>N,N</i>-diisopropylethylamine (0.15 mL, 0.86 mmol) in DMF (1.0 mL) at 80 °C for 1 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford the 2,2,2-trifluoroacetate salt of the title compound. The residue was dissolved in dichloromethane, washed with saturated aqueous sodium bicarbonate, and concentrated under reduced pressure. The organic layer was treated with HCl (2 N in diethyl ether, 1.0 mL), and the volatiles were removed to afford ((<i>S</i>)-1-((3<i>R</i>,4<i>S</i>)-1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-3-methylpiperidin-4-yl)pyrrolidin-2-yl)methanol (<b>29</b>, 15% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN; HCl salt): δ 8.20 (s, 1H), 7.47–7.42 (m, 2H), 7.26 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.27 (q, <i>J</i> = 7.1 Hz, 1H), 4.66–4.57 (m, 1H), 4.52 (dt, <i>J</i> = 13.8, 2.5, 1H), 4.02–3.92 (m, 1H), 3.71 (dd, <i>J</i> = 12.3, 4.2 Hz, 1H), 3.66–3.52 (m, 2H), 3.46–3.35 (m, 1H), 3.34–3.22 (m, 1H), 3.04 (dd, <i>J</i> = 13.7, 2.4 Hz, 1H), 2.53–2.46 (m, 1H), 2.44 (s, 3H), 2.19–2.08 (m, 2H), 2.06–1.85 (m, 4H), 1.84 (d, <i>J</i> = 7.1 Hz, 3H), 1.85–1.77 (m, 1H), 1.01 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> = 503.2; found, 503.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-((3<i>R</i>,4<i>S</i>)-4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-3-methylpiperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>30</b>)</h3><div class="NLM_p last">The S<sub>N</sub>Ar was performed following general procedure A using (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>46</b>, 75 mg, 0.22 mmol), the cis diastereomer of ((2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidin-2-yl)methanol 2,2,2-trifluoroacetate (42, 62 mg, 0.2 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.15 mL, 0.86 mmol) in DMF (1.0 mL). The mixture was heated at 80 °C for 1 h and concentrated. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min. The residue was dissolved in dichloromethane, washed with saturated aqueous sodium bicarbonate, and concentrated under reduced pressure. The organic layer was treated with HCl (2 N in diethyl ether, 1.0 mL), and the volatiles were removed to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-((3<i>R</i>,4<i>S</i>)-4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-3-methylpiperidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile hydrochloride (<b>30</b>, 10% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN; HCl salt): δ 8.43 (s, 1H), 7.52 (d, <i>J</i> = 2.2 Hz, 1H), 7.46 (d, <i>J</i> = 8.5 Hz, 1H), 7.33 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.45 (q, <i>J</i> = 7.0 Hz, 1H), 4.72–4.54 (m, 2H), 4.02–3.90 (m, 1H), 3.74–3.68 (m, 2H), 3.65–3.55 (m, 1H), 3.46–3.36 (m, 1H), 3.35–3.25 (m, 1H), 3.09 (dd, <i>J</i> = 13.7, 1.9 Hz, 1H), 2.99 (dt, <i>J</i> = 13.4, 3.0 Hz, 1H), 2.59–2.50 (m, 1H), 2.28–2.20 (m, 1H), 2.19–1.93 (m, 4H), 1.91 (d, <i>J</i> = 7.1 Hz, 3H), 1.88–1.78 (m, 1H), 1.06 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> = 514.2; found, 514.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile Hydrochloride (<b>31</b>)</h3><div class="NLM_p last">1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(5-methyl-4-oxocyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>55</b>, 350 mg, 0.82 mmol), <span class="smallcaps smallerCapital">l</span>-prolinol (<b>47</b>, 330 mg, 3.2 mmol), NaBH<sub>3</sub>CN (130 mg, 1.98 mmol), and AcOH (0.146 mL) were dissolved in 1,2-dichloroethane (3 mL) and stirred at room temperature for 16 h. After concentrating, the residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford a 4:1:1 mixture of diastereomers. The mixture was further purified by preparative SFC (AD-H (2 × 25 cm), 40% isopropanol with 0.1% DEA and CO<sub>2</sub> at 100 bar, 50 mL/min). The third eluting isomer was isolated from this purification and converted to the HCl salt by diluting in dichloromethane (2 mL), adding HCl (2 N in diethyl ether, 0.5 mL), and concentrating to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile hydrochloride (<b>31</b>, 10% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 9.08 (s, 1H), 7.46 (dd, <i>J</i> = 6.7, 2.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.31 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.02–6.92 (m, 1H), 6.72 (q, <i>J</i> = 7.0 Hz, 1H), 4.01 (tt, <i>J</i> = 8.7, 4.2 Hz, 1H), 3.81 (dd, <i>J</i> = 12.0, 4.8 Hz, 1H), 3.71 (dd, iJ = 12.0, 7.8 Hz, 2H), 3.65–3.57 (m, 1H), 3.44 (td, <i>J</i> = 10.6, 6.4 Hz, 1H), 3.02 (dt, J = 10.7, 3.8 Hz, 1H), 2.97–2.48 (m, 4H), 2.31–2.02 (m, 2H), 1.99 (d, <i>J</i> = 7.0 Hz, 3H), 1.97–1.87 (m, 2H), 1.14 (d, <i>J</i> = 6.7 Hz, 3H); <i>m</i>/<i>z</i> 511.1 (M + H<sup>+</sup>). <sup>13</sup>C NMR (101 MHz; CDCl<sub>3</sub>; HCl salt) δ 152.2, 142.0, 141.5, 136.2, 135.0, 133.4, 133.0, 132.5, 129.6, 129.1, 128.8, 128.0, 118.6, 111.9, 72.1, 66.7, 62.0, 53.6, 52.9, 33.4, 28.0, 26.8, 26.6, 24.7, 20.3, 13.6. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> = 511.2; found, 511.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Second-Generation Synthesis of 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile Hydrochloride (<b>31</b>)</h3><div class="NLM_p last">To a solution of 6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>66</b>, 432 mg, 0.69 mmol) in dichloromethane (6.9 mL) was added 4 N HCl in 1,4-dioxane (0.69 mL, 2.76 mmol). After 4 h at room temperature, the solution was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (0–20% methanol in dichloromethane) to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>31</b>, 82% yield). <sup>1</sup>H NMR and LCMS data matched previous prepared lots.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> ((2<i>S</i>)-1-(4-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-yl)pyrrolidin-2-yl)methanol 2,2,2-Trifluoroacetate (<b>32</b>)</h3><div class="NLM_p">Step 1: A 300 mL sealed tube was charged with a mixture of 4,4,5,5-tetramethyl-2-(10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane, 4,4,5,5-tetramethyl-2-(6-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane (<b>53</b>, 1.40 g, 5.00 mmol), (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>, 1.14 g, 3.33 mmol), Pd(dppf)Cl<sub>2</sub> (183 mg, 0.250 mmol), 4:1 THF:H<sub>2</sub>O (11.2 mL), and Na<sub>2</sub>CO<sub>3</sub> (882 mg, 8.33 mmol). Nitrogen gas was bubbled through the reaction mixture for 35 min before placing the reaction vessel in a preheated oil bath at 90 °C for 4 h. The reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub> and extracted with EtOAc (2×). The combined organic layers were washed with brine, dried over sodium sulfate, concentrated, and purified by silica gel chromatography (10–25% EtOAc in hexanes) to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-(10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine as the second eluting peak (21% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.69 (d, <i>J</i> = 1.1 Hz, 1H), 7.41 (dd, <i>J</i> = 8.4, 5.9 Hz, 1H), 7.35 (d, <i>J</i> = 2.1 Hz, 1H), 7.16–7.12 (m, 1H), 6.71–6.67 (m, 1H), 6.54 (q, <i>J</i> = 7.1 Hz, 1H), 4.06–3.96 (m, 4H), 3.03–2.87 (m, 1H), 2.65 (s, 2H), 2.63–2.42 (m, 3H), 2.23–2.12 (m, 1H), 1.94 (d, <i>J</i> = 7.1 Hz, 3H), 1.06 (d, <i>J</i> = 6.8, 3.4, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 459.1; found, 459.</div><div class="NLM_p">Step 2: 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-(10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (320 mg, 0.670 mmol) was diluted with dichloromethane (6 mL) and TFA (1.5 mL). The resulting clear, red solution was stirred at room temperature for 20 h. The reaction was then carefully quenched with saturated aqueous NaHCO<sub>3</sub> and extracted with dichloromethane (3×). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to afford 4-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-one (92% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.74 (d, <i>J</i> = 1.4 Hz, 1H), 7.45 (dd, <i>J</i> = 8.5, 1.4 Hz, 1H), 7.37 (dd, <i>J</i> = 2.9, 2.1 Hz, 1H), 7.21–7.14 (m, 1H), 6.79 (ddt, <i>J</i> = 5.9, 4.0, 2.0 Hz, 1H), 6.57 (qd, <i>J</i> = 7.0, 1.2 Hz, 1H), 3.45–3.32 (m, 1H), 3.31–3.07 (m, 2H), 2.80 (dq, <i>J</i> = 12.3, 6.3 Hz, 1H), 2.68 (d, <i>J</i> = 0.5 Hz, 3H), 2.65–2.53 (m, 1H), 1.96 (d, <i>J</i> = 7.1 Hz, 3H), 1.24 (d, <i>J</i> = 6.6 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>20</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>1</sub> [M + H]<sup>+</sup> = 415.1; found, 415.</div><div class="NLM_p last">Step 3: The reductive amination was performed following general procedure D using 4-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-one (287 mg, 0.690 mmol), <span class="smallcaps smallerCapital">l</span>-prolinol (349 mg, 3.46 mmol), NaBH<sub>3</sub>CN (87 mg, 1.4 mmol), and AcOH (0.19 mL) in 1,2-dichloroethane (2 mL) at room temperature overnight. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 45–75% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford ((2<i>S</i>)-1-(4-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-yl)pyrrolidin-2-yl)methanol 2,2,2-trifluoroacetate (<b>32</b>, 5% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; TFA salt) δ 8.81 (s, 0.5H), 8.80 (s, 0.5H), 7.54–7.40 (m, 2H), 7.27 (ddd, <i>J</i> = 8.5, 3.7, 2.0 Hz, 1H), 6.88–6.75 (m, 1H), 6.54 (qd, <i>J</i> = 7.1, 2.5 Hz, 1H), 4.15–3.35 (m, 6H), 3.13–2.73 (m, 3.5H), 2.73–2.50 (m, 4H), 2.38–1.99 (m, 3.5H), 1.99–1.84 (m, 4H), 1.22–1.01 (m, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 500.2; found, 500.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(4-((<i>S</i>)-2-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile 2,2,2-Trifluoroacetate (<b>33</b>)</h3><div class="NLM_p last">The reductive amination was performed following general procedure D using 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(5-methyl-4-oxocyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>55</b>, 256 mg, 0.60 mmol), (<i>S</i>)-2-(pyrrolidin-2-yl)propan-2-ol (78 mg, 0.60 mmol), and sodium triacetoxyborohydride (381 mg, 1.8 mmol) in 1,2-dichloroethane (2.0 mL) at room temperature for 16 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(4-((<i>S</i>)-2-(2-hydroxypropan-2-yl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile trifluoroacetate as a mixture of diastereomers (<b>33</b>, 3% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; TFA Salt) δ 9.10 (s, 1H), 7.52–7.49 (m, 1H), 7.47–7.41 (m, 1H), 7.36–7.31 (m, 1H), 7.04–6.95 (m, 1H), 6.74 (q, <i>J</i> = 7.0 Hz, 1H), 4.04–3.88 (m, 1H), 3.72–3.60 (m, 2H), 3.56–3.40 (m, 1H), 3.23–2.92 (m, 2H), 2.91–2.62 (m, 2H), 2.33–2.20 (m, 2H), 2.19–2.03 (m, 4H), 2.00 (d, <i>J</i> = 7.2 Hz, 3H), 1.41–1.27 (m, 9H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>32</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>6</sub>O [M + H]<sup>+</sup> = 538.2; found, 538.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(Aminomethyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1-((R)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile Hydrochloride (<b>34</b>)</h3><div class="NLM_p last">The reductive amination was performed following general procedure D using 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(5-methyl-4-oxocyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>55</b>, 120 mg, 0.28 mmol), <i>tert</i>-butyl (<i>S</i>)-(pyrrolidin-2-ylmethyl)carbamate (62 mg, 0.31 mmol), and sodium triacetoxyborohydride (120 mg, 0.56 mmol) in 1,2-dichloroethane (1.1 mL) at room temperature for 16 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford the desired isomer as the second eluting peak. The residue was diluted with dichloromethane, washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, and concentrated by rotary evaporation. The free base was treated with HCl (4 N in 1,4-dioxane, 1 mL), stirred for 1 h, and concentrated under reduced pressure to afford 6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(aminomethyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile hydrochloride (<b>34</b>, 5% yield). <sup>1</sup>H NMR (400 MHz; CD<sub>3</sub>OD; HCl salt) δ 9.10 (s, 1H), 7.50 (d, <i>J</i> = 2.1 Hz, 1H), 7.45 (d, <i>J</i> = 8.5 Hz, 1H), 7.34 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.99–6.93 (m, 1H), 6.74 (q, <i>J</i> = 7.0 Hz, 1H), 4.27–4.18 (m, 1H), 3.86–3.77 (m, 2H), 3.77–3.70 (m, 2H), 3.69–3.63 (m, 4H), 3.60–3.54 (m, 2H), 3.49–3.38 (m, 2H), 2.96–2.82 (m, 2H), 2.74–2.62 (m, 1H), 2.44–2.30 (m, 1H), 2.28–2.08 (m, 2H), 2.01 (d, <i>J</i> = 7.1 Hz, 3H), 1.18 (d, <i>J</i> = 6.0 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>7</sub> [M + H]<sup>+</sup> = 510.2; found, 510.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>S</i>)-1-((1<i>S</i>,6<i>R</i>)-4-(3-Cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-yl)pyrrolidine-2-carboxamide Hydrochloride (<b>35</b>)</h3><div class="NLM_p last">The reductive amination was performed following general procedure D using 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(5-methyl-4-oxocyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>55</b>, 120 mg, 0.28 mmol), <span class="smallcaps smallerCapital">l</span>-prolinamide (46 mg, 0.40 mmol), and sodium triacetoxyborohydride (119 mg, 0.56 mmol) in 1,2-dichloroethane (1.1 mL) at room temperature for 16 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford the desired isomer. The residue was diluted with dichloromethane, washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, and concentrated by rotary evaporation. The free base was treated with HCl (4 N in 1,4-dioxane, 1 mL), stirred for 1 h, and concentrated under reduced pressure to afford (<i>S</i>)-1-((1<i>S</i>,6<i>R</i>)-4-(3-cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-yl)pyrrolidine-2-carboxamide hydrochloride (<b>35</b>, 8% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN; HCl salt) δ 9.02 (s, 1H), 7.55–7.48 (m, 2H), 7.36 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.08 (s, 1H), 6.92–6.78 (m, 1H), 6.77–6.63 (m, 2H), 4.43 (dd, <i>J</i> = 10.4, 3.6 Hz, 1H), 4.02–3.89 (m, 1H), 3.69–3.61 (m, 1H), 2.89–2.35 (m, 8H), 2.25–2.13 (m, 2H), 1.99 (d, <i>J</i> = 7.0 Hz, 3H), 1.14 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> = 524.2; found, 524.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-((4<i>S</i>,5<i>R</i>)-5-methyl-4-((<i>R</i>)-2-methylpyrrolidin-1-yl)cyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile Hydrochloride (<b>36</b>)</h3><div class="NLM_p last">The reductive amination was performed following general procedure D using 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(5-methyl-4-oxocyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>55</b>, 120 mg, 0.28 mmol), (<i>R</i>)-2-methylpyrrolidine (34 mg, 0.4 mmol), and sodium triacetoxyborohydride (119 mg, 0.56 mmol) in 1,2-dichloroethane (1.1 mL) at room temperature for 16 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford a mixture of diastereomers. The mixture was further purified using chiral preparative SFC (OD-H (2 × 25 cm), 30% methanol with 0.1% diethyl amine, and CO<sub>2</sub> at 100 bar, 60 mL/min). The third eluting isomer was isolated from this purification and converted to the HCl salt by diluting in dichloromethane (2 mL), adding HCl (2 N in diethyl ether, 0.5 mL), and concentrating to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-((4<i>S</i>,5<i>R</i>)-5-methyl-4-((<i>R</i>)-2-methylpyrrolidin-1-yl)cyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile hydrochloride (<b>36</b>, 7% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>,HCl salt) δ 8.94 (s, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.39 (d, <i>J</i> = 2.2 Hz, 1H), 7.22 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.90–6.84 (m, 1H), 6.74 (q, <i>J</i> = 7.1 Hz, 1H), 3.34–3.07 (m, 1H), 2.86–2.24 (m, 8H), 1.99 (d, <i>J</i> = 7.1 Hz, 4H), 1.90–1.71 (m, 2H), 1.55–1.42 (m, 1H), 0.99 (t, <i>J</i> = 7.4 Hz, 6H). <sup>13</sup>C NMR (101 MHz; CDCl<sub>3</sub>; HCl salt) δ 152.4, 142.0, 141.5, 136.1, 134.9, 133.4, 132.8, 132.3, 129.6, 129.2, 129.1, 128.0, 118.4, 111.9, 67.1, 60.1, 57.6, 53.6, 49.6, 32.6, 30.1, 28.1, 25.7, 20.3, 19.9, 13.7, 13.5. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 495.2; found, 495.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(5-methyl-4-((<i>S</i>)-2-(trifluoromethyl)pyrrolidin-1-yl)cyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile Hydrochloride (<b>37</b>)</h3><div class="NLM_p last">The reductive amination was performed following general procedure D using 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(5-methyl-4-oxocyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>55</b>, 120 mg, 0.28 mmol), (<i>S</i>)-2-(trifluoromethyl)pyrrolidine (43 mg, 0.31 mmol), and sodium triacetoxyborohydride (120 mg, 0.56 mmol) in 1,2-dichloroethane (1.1 mL) at room temperature for 16 h. The residue was purified by reverse phase preparative HPLC (Gemini-NX, 10 μm, 250 × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford the desired product as a mixture of isomers. The residue was diluted with dichloromethane, washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, and concentrated by rotary evaporation. The free base was treated with HCl (4 N in 1,4-dioxane, 1 mL), stirred for 1 h, and concentrated under reduced pressure to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(5-methyl-4-((<i>S</i>)-2-(trifluoromethyl)pyrrolidin-1-yl)cyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile hydrochloride (<b>37</b>, 6% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl Salt) δ 9.04 (s, 1H), 7.47 (d, <i>J</i> = 2.1 Hz, 1H), 7.45 (d, <i>J</i> = 8.5 Hz, 1H), 7.31 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.01 (dd, <i>J</i> = 5.9, 2.1 Hz, 1H), 6.72 (q, <i>J</i> = 7.0 Hz, 1H), 4.39–4.23 (m, 1H), 3.54–3.43 (m, 1H), 3.28–3.21 (m, 1H), 3.20–3.09 (m, 1H), 2.98–2.88 (m, 2H), 2.70–2.56 (m, 1H), 2.30–2.11 (m, 3H), 2.10–2.00 (m, 2H), 1.99 (d, <i>J</i> = 7.1 Hz, 3H), 1.99–1.85 (m, 1H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>25</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 549.2; found, 549.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>R</i>)-6-Chloro-<i>N</i>-(1-(2,4-dichlorophenyl)ethyl)pyrazin-2-amine (<b>38</b>)</h3><div class="NLM_p last">The S<sub>N</sub>Ar was performed according to general procedure A using 2,6-dichloropyrazine (3.0 g, 20.1 mmol) and (<i>R</i>)-1-(2,4-dichlorophenyl)ethan-1-amine (1.0 equiv) in DMSO (40 mL) along with the addition of CsF (3.0 equiv) at 75 °C for 45 min. The residue was purified by silica gel chromatography (50% ethyl acetate in hexanes) to afford (<i>R</i>)-6-chloro-<i>N</i>-(1-(2,4-dichlorophenyl)ethyl)pyrazin-2-amine (<b>38</b>, 79% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>10</sub>Cl<sub>3</sub>N<sub>3</sub> [M + H]<sup>+</sup> = 302.0; found, 302.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 6-Chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>39</b>)</h3><div class="NLM_p">Step 1: To a solution of 1-(2,4-dichlorophenyl)ethan-1-one (10.3 g, 54.4 mmol) in EtOH (50 mL) at room temperature was added <i>tert</i>-butyl carbazate (21.6 g, 163.5 mmol). The reaction was stirred at room temperature for 2 days and then at 50 °C for 1 h. The mixture was cooled to 0 °C and filtered. The filtrate was concentrated, and the residue was recrystallized from EtOH. The solids were combined and purified using silica gel chromatography (0–25% ethyl acetate in hexanes). The residue was dissolved in EtOH (125 mL), and one crystal of bromocresol green was added. NaCNBH<sub>3</sub> (11.8 g, 188 mmol) was added, and AcOH was added dropwise to maintain a yellow color. The reaction was stirred at 60 °C for 2 days, and AcOH was added dropwise to maintain a yellow color. The mixture was cooled to room temperature, concentrated, and purified by silica gel chromatography (10–20% MTBE in hexanes). The residue was dissolved in dioxane (0.17 M), and HCl (4 N in 1,4-dioxane, 10 equiv) was added. The mixture was stirred at 50 °C for 16 h, and a white precipitate formed. The mixture was cooled to room temperature and concentrated under reduced pressure to afford (1-(2,4-dichlorophenyl)ethyl)hydrazine hydrochloride (75% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 205.0; found, 205.</div><div class="NLM_p">Step 2: To a solution of 2,2,6,6-tetramethylpiperidine (22.9 mL, 134.3 mmol) in THF (200 mL) at −40 °C was added <i>n</i>-BuLi (2.5 M in hexanes, 56.4 mL, 141.0 mmol). The mixture was stirred at −40 °C for 30 min. In a separate flask, ethyl formate (10.9 mL, 134.3 mmol) and 2,6-dichloropyrazine (10.0 g, 67.1 mmol) were dissolved in THF (200 mL) and cooled to −90 °C. The lithium 2,2,6,6-tetramethylpiperidine solution was added to the 2,6-dichloropyrazine solution via cannula over 30 min at −90 °C. The mixture was stirred at −90 °C for 1 h, and then acetic acid (7.68 mL, 134.3 mmol) was added, followed by (1-(2,4-dichlorophenyl)ethyl)hydrazine hydrochloride (8.11 g, 33.56 mmol). The reaction was warmed to room temperature and stirred at room temperature for 6 h. The mixture was filtered through a silica gel-Celite plug and concentrated under reduced pressure, and then the residue was purified by normal-phase column chromatography on silica gel (20–100% ethyl acetate in hexanes) to afford a mixture of (<i>Z</i>)-3,5-dichloro-2-((2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)methyl)pyrazine and (<i>E</i>)-3,5-dichloro-2-((2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)methyl)pyrazine (25% yield) as a viscous orange oil. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>10</sub>Cl<sub>4</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 363.0; found, 363.</div><div class="NLM_p last">Step 3: (<i>Z</i>)-3,5-Dichloro-2-((2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)methyl)pyrazine and (<i>E</i>)-3,5-dichloro-2-((2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)methyl)pyrazine (1.0 g, 2.75 mmol) were dissolved in DMF (50 mL), and the solution was degassed. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.82 mL, 5.49 mmol) was added, and the mixture was heated to 140 °C for 2 h. After cooling, the mixture was diluted with water and ethyl acetate and the layers were separated. The organic layer was washed with brine solution, dried over sodium sulfate, and concentrated via rotary evaporation, and the residue was purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to afford 6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>39</b>, 10% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>9</sub>Cl<sub>3</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 327.0; found, 327.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>R</i>)-(1-(2,4-Dichlorophenyl)ethyl)hydrazine Hydrochloride (<b>40</b>)</h3><div class="NLM_p">Step 1: To a 6 L flask equipped with an overhead stirrer was added (<i>R</i>)-1-(2,4-dichlorophenyl)ethan-1-amine (211 g, 1.11 mol), water (3.4 L), and concentrated HCl (92.5 mL, 1.11 mol). To the slurry was added solid KOCN (90 g, 1.11 mol) in one portion at room temperature. All solids went into solution, and a white precipitate began to form after 1 h. The white precipitate was isolated by filtration. The filtrate was left standing at room temperature, and more precipitate formed. The precipitate was again isolated by filtration. This was repeated several times until no more precipitate formed in the filtrate upon standing at room temperature for 1 day. All of the solids were combined and dried under high vacuum, yielding (<i>R</i>)-1-(1-(2,4-dichlorophenyl)ethyl)urea (78% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>9</sub>H<sub>10</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 232.0; found, 232.</div><div class="NLM_p">Step 2: (<i>R</i>)-1-(1-(2,4-Dichlorophenyl)ethyl)urea (50 g, 214.6 mmol) was milled into a fine powder and placed into an oven-dried 2 L flask. The 2 L flask was purged with nitrogen gas, and a degassed mixture of 1 L of toluene and 375 mL of <i>t-</i>BuOH was added via cannula under nitrogen. Solid <i>t-</i>BuOK (240.3 g, 2146 mmol) was milled into fine powder and added to a separate 5 L, 3-neck flask. The 5 L flask was purged with nitrogen, and a degassed mixture of 1 L of toluene and 650 mL of <i>t-</i>BuOH was added via cannula under nitrogen gas. The 2 and  5 L mixtures were slurries and  cooled to −20 °C. The lights inside the hood were turned off before <i>t</i>BuOCl (23.18 g, 24 mL, 214.6 mmol) was added to the 2 L flask at −20 °C. The −20 °C bath was removed, and the mixture was placed in a 0 °C bath. As soon as the slurry went all into solution, the mixture was transferred to the 5 L flask via cannula under nitrogen at −20 °C. The lights in the hood were turned on, the −20 °C bath was removed, and the mixture was placed into a 0 °C bath. The mixture was stirred at 0 °C for 10 min and then warmed to room temperature, at which time the mixture was poured onto ice. The mixture was extracted with EtOAc (×2), and the combined organic layers were washed with 1 L of water, 500 mL of saturated sodium thiosulfate, and 1 L of brine solution. The solvents were concentrated under reduced pressure to afford <i>tert</i>-butyl (<i>R</i>)-2-(1-(2,4-dichlorophenyl)ethyl)hydrazine-1-carboxylate (99% yield). ee: 99% Chiralpak IF-3; 250 mm × 4.6 mm, 5% iPrOH in heptanes; flow rate 1 mL/min; detection at 254 nm; <i>t</i><sub>1</sub> = 4.5 min (minor), <i>t</i><sub>2</sub> = 5.3 min (major). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 306.2; found, 306. Note: vigorous stirring of the solution is critical for the success of this reaction.</div><div class="NLM_p last">The residue was dissolved in 250 mL of dioxane, and HCl (4 N in 1,4-dioxane, 161 mL, 643.8 mmol) was added at room temperature. The mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was triturated from 25% ethyl acetate in hexanes (1 mL of solvent per 1 g of residue) to afford (<i>R</i>)-(1-(2,4-dichlorophenyl)ethyl)hydrazine hydrochloride (<b>40</b>, 78% yield). <sup>1</sup>H NMR (300 MHz, methanol-<i>d</i>) δ 7.63 (d, <i>J</i> = 8.4 Hz, 1H), 7.52 (d, <i>J</i> = 2.1 Hz, 1H), 7.42 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 4.67 (q, <i>J</i> = 6.9 Hz, 1H), 1.40 (d, <i>J</i> = 6.9 Hz, 3H). ee: 98% Chiralpak IF-3; 250 mm × 4.6 mm, 20% iPrOH in heptanes; flow rate 1 mL/min; detection at 254 nm; <i>t</i><sub>1</sub> = 4.7 min (major), <i>t</i><sub>2</sub> = 6.9 min (minor). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> = 206.2; found, 206.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>R</i>)-6-Chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate (<b>44</b>)</h3><div class="NLM_p">Step 1: Ethyl 2-(3,5-dichloropyrazin-2-yl)-2-oxoacetate (<b>41</b>, 14.5 g, 58.4 mmol) and (<i>R</i>)-(1-(2,4-dichlorophenyl)ethyl)hydrazine hydrochloride (<b>40</b>, 11.7 g, 48.7 mmol) were dissolved in THF (97 mL), heated to 80 °C for 2 h, and stirred at room temperature for 16 h. The mixture was diluted with brine and extracted with ethyl acetate, and the combined organic layers were dried over magnesium sulfate and concentrated to afford a mixture of ethyl (<i>R</i>,<i>E</i>)-2-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazineylidene)-2-(3,5-dichloropyrazin-2-yl)acetate (<b>42</b>) and (<i>R</i>,<i>Z</i>)-2-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazineylidene)-2-(3,5-dichloropyrazin-2-yl)acetate (<b>43</b>) as a red oil, which was used directly in the next reaction without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 435.0; found, 435.</div><div class="NLM_p last">Step 2: The mixture of ethyl (<i>R</i>,<i>E</i>)-2-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)-2-(3,5-dichloropyrazin-2-yl)acetate (<b>42</b>) and (<i>R</i>,<i>Z</i>)-2-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazineylidene)-2-(3,5-dichloropyrazin-2-yl)acetate (<b>43</b>) was diluted with THF (240 mL) and cooled to 0 °C, and NaH (60% dispersion in mineral oil, 3.89 g, 97.4 mmol) was added carefully. The reaction was stirred overnight, monitoring by TLC and LC-MS. The reaction was slowly poured into a mixture of crushed ice (∼500 mL) and saturated aqueous ammonium chloride (300 mL) under vigorous stirring. The aqueous layer was extracted with EtOAc (2 × 400 mL). The combined organic layers were dried over sodium sulfate and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (10–20% ethyl acetate in hexanes) to afford ethyl (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate (<b>44</b>) as a sticky orange oil (50% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>13</sub>Cl<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 399.0; found, 399.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>R</i>)-6-Chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (<b>45</b>)</h3><div class="NLM_p last">Ethyl (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate (<b>44</b>, 4.0 g, 10 mmol) was dissolved in 1,4-dioxane (40 mL) in a sealed tube. The reaction solution was diluted with 29% ammonium hydroxide in water (40 mL), and the tube was quickly sealed. The reaction was stirred at room temperature for 3 days, monitoring by LC-MS. The reaction was driven to completion by bubbling ammonia gas gently through the solution. The crude mixture was poured into 200 mL of water, and a white precipitate formed. The white precipitate was collected and rinsed with 200 mL of water and 50 mL of hexanes. The resulting solid was dried overnight on high vacuum to afford (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (<b>45</b>) as an off-white powder (95% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>10</sub>Cl<sub>3</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 370.0; found, 370.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (<i>R</i>)-6-Chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>46</b>)</h3><div class="NLM_p last">(<i>R</i>)-6-Chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (<b>45</b>, 4.47 g, 12.1 mmol) was dissolved in dry dichloromethane (30 mL) under argon gas before adding Burgess’ reagent (4.3 g, 18.1 mmol). The reaction was stirred at room temperature and monitored by TLC. Upon  disappearance of starting material, the reaction was diluted with saturated aqueous sodium bicarbonate and dichloromethane. The organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over magnesium sulfate and concentrated. The crude product was purified by silica gel chromatography (5–20% ethyl acetate in hexanes) to afford (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>46</b>) as a clear, colorless, sticky solid (88% yield). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.69 (s, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.41 (d, <i>J</i> = 2.2 Hz, 1H), 7.27 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.68 (q, <i>J</i> = 7.0 Hz, 1H), 1.98 (d, <i>J</i> = 7.0 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>8</sub>Cl<sub>3</sub>N<sub>5</sub> [M + H]<sup>+</sup> = 352.0; found, 352.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> ((2<i>S</i>)-1-(3-Methylpiperidin-4-yl)pyrrolidin-2-yl)methanol 2,2,2-Trifluoroacetate (<b>49</b>)</h3><div class="NLM_p last">To a solution of <span class="smallcaps smallerCapital">l</span>-prolinol (<b>47</b>, 152 mg, 1.5 mmol) and 1-<i>tert</i>-butoxycarbonyl-3-methyl-4-piperidone (<b>48</b>, 213 mg, 1.0 mmol) in 1,2-dichloroethane (0.3 M) was added acetic acid (1.5 equiv) and sodium triacetoxyborohydride (316 mg, 1.5 mmol). The solution was stirred at room temperature for 16 h, and the residue was purified by silica gel chromatography (0–20% methanol in dichloromethane) to afford the cis diastereomer of <i>tert</i>-butyl 4-((<i>S</i>)-2-(hydroxymethyl)pyrrolidin-1-yl)-3-methylpiperidine-1-carboxylate (40% yield). The residue was dissolved in dichloromethane (2.0 mL), and trifluoroacetic acid (0.5 mL) was added. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to afford the cis diastereomer of ((2<i>S</i>)-1-(3-methylpiperidin-4-yl)pyrrolidin-2-yl)methanol 2,2,2-trifluoroacetate (<b>49</b>) which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>22</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 199.2; found, 199.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 6-Methyl-1,4-dioxaspiro[4.5]decan-8-one (<b>51</b>)</h3><div class="NLM_p last">To a 2 L flask equipped with a stir bar was added CuCN (58.1 g, 0.649 mol) and Et<sub>2</sub>O (1.6 L). The solution was cooled to −40 °C before slowly adding MeLi (209 mL, 3.1 M in DME, 0.649 mol). As time passed the reaction produced a bright yellow precipitate. In a separate 5 L flask, 1,4-dioxaspiro[4.5]dec-6-en-8-one (<b>50</b>, 50 g, 0.324 mol) was dissolved in a mixture of Et<sub>2</sub>O (640 mL) and THF (640 mL). The solution was cooled to −40 °C before slowly adding TMSCl (80 mL, 0.63 mol). After the cuprate solution had stirred for 30 min, it was cannulated into the enone solution at −40 °C (some yellow solid remained in cuprate flask). The reaction was stirred at −40 °C for 1 h, then quenched with 800 mL of 3:1 saturated aqueous NH<sub>4</sub>Cl/NH<sub>4</sub>OH solution, and slowly warmed to room temperature. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated via rotary evaporation. The residue was purified by silica gel chromatography (50% EtOAc in hexanes) to afford a mixture of desired product and the corresponding silyl enol ether. The mixture was resuspended dichloromethane, washed twice with 1 N aqueous HCl solution, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford 6-methyl-1,4-dioxaspiro[4.5]decan-8-one (<b>51</b>) as an orange oil, which was carried forward without further purification (98% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.03 (s, 4H), 2.57–2.31 (m, 4H), 2.29–2.15 (m, 1H), 2.10–1.98 (m, 1H), 1.88–1.78 (m, 1H), 0.96 (d, <i>J</i> = 6.7 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>9</sub>H<sub>15</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 171.1; found, 171.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>54</b>)</h3><div class="NLM_p">Step 1: To a solution of <i>i</i>-Pr<sub>2</sub>NH (53.5 mL, 0.381 mol) in THF (200 mL) cooled to −78 °C was added <i>n</i>-BuLi (152 mL, 2.5 M in hexanes, 0.380 mol). The mixture was warmed to 0 °C and stirred for 30 min. In a separate flask 6-methyl-1,4-dioxaspiro[4.5]decan-8-one (<b>51</b>, 54 g, 0.317 mol) was dissolved in THF (1.15 L). The solution was cooled to −78 °C before slowly adding the LDA solution. After stirring for 30 min, a solution of PhNTf<sub>2</sub> (136 g, 0.381 mol) in THF (400 mL) was added, and the resulting mixture was warmed to room temperature and stirred overnight. The reaction was partitioned between EtOAc and saturated aqueous NaHCO<sub>3</sub>. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (5–10% EtOAc in hexanes) to provide a mixture of desired product and PhNHTf. The mixture was resuspended in EtOAc, washed three times with 1 N aqueous NaOH, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford a 2:1 mixture of olefin isomers 10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate and 6-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate (<b>52</b>) as a clear, colorless oil (36% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.61 (tt, <i>J</i> = 3.7, 1.4 Hz, 0.66H; diagnostic peak for major isomer), 5.56 (dt, <i>J</i> = 3.6, 1.4 Hz, 0.34H; diagnostic peak for minor isomer), 4.04–3.92 (m, 4H), 2.64–2.56 (m, 1H), 2.54–2.35 (m, 1H), 2.34–2.25 (m, 1H), 2.18–1.74 (m, 2H), 1.06 (d, <i>J</i> = 7.1 Hz, 1H; diagnostic peak for minor isomer), 1.00 (d, <i>J</i> = 6.8 Hz, 2H; diagnostic peak for major isomer). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>14</sub>F<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup> = 303.1; found, 303.</div><div class="NLM_p">Step 2: To a solution of 10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate (<b>52</b>, 6.5 g, 21.5 mmol) in 1,4-dioxane (108 mL) was added bis(pinacolato)diboron (13.7 g, 53.8 mmol), KOAc (6.33 g, 64.5 mmol), and KBr (2.81 g, 23.7 mmol). The mixture was degassed by bubbling nitrogen gas through the solution for 10 min, then Pd(dppf)Cl<sub>2</sub> (787 mg, 1.08 mmol) was added, and the resulting solution was degassed for another 15 min. The reaction was heated to 95 °C for 16 h. After the mixture was cooled to room temperature, it was partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (0–10% EtOAc in dichloromethane) to afford a 2:1 mixture of olefin isomers 4,4,5,5-tetramethyl-2-(10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane and 4,4,5,5-tetramethyl-2-(6-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane (<b>53</b>) as a yellow oil (81% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.41 (tt, <i>J</i> = 3.9, 1.9 Hz, 0.66H; diagnostic peak for major isomer), 6.32 (dt, <i>J</i> = 3.2, 2.0 Hz, 0.33H; diagnostic peak for minor isomer), 4.01–3.90 (m, 4H), 2.53–2.21 (m, 3H), 2.17–2.07 (m, 1H), 2.00–1.55 (m, 1H), 1.24 (s, 12H), 1.02 (d, <i>J</i> = 7.3 Hz, 1H; diagnostic peak for minor isomer), 0.92 (d, <i>J</i> = 6.7 Hz, 2H; diagnostic peak for major isomer). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>26</sub>BO<sub>4</sub> [M + H]<sup>+</sup> = 281.2; found, 281.</div><div class="NLM_p last">Step 3: To a solution of (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>46</b>, 1.67 g, 4.74 mmol), 4,4,5,5-tetramethyl-2-(10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane (<b>53</b>, 1.99 g, 7.10 mmol), and 1 N aqueous Na<sub>2</sub>CO<sub>3</sub> (14.2 mL, 14.2 mmol) in 1,4-dioxane (15.8 mL) was added Pd(dppf)<sub>2</sub>Cl<sub>2</sub> (0.20 g, 0.240 mmol). The reaction mixture was degassed by bubbling nitrogen through the solution for 15 min before heating the reaction to 95 °C for 75 min. The reaction was concentrated to dryness, and the residue was partitioned between EtOAc and saturated aqueous NaHCO<sub>3</sub>. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (20–30% EtOAc in pentanes) to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>54</b>) as the second eluting isomer as a pale orange foam (47% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.95 (d, <i>J</i> = 1.8 Hz, 1H), 7.42 (dd, <i>J</i> = 8.5, 4.5 Hz, 1H), 7.39 (dd, <i>J</i> = 2.2, 0.4 Hz, 1H), 7.23 (ddt, <i>J</i> = 8.5, 2.2, 0.5 Hz, 1H), 6.82 (tt, <i>J</i> = 4.2, 2.2 Hz, 1H), 6.73 (q, <i>J</i> = 7.0 Hz, 1H), 4.10–3.95 (m, 4H), 3.03–2.86 (m, 1H), 2.66–2.46 (m, 3H), 2.19 (h, <i>J</i> = 7.2 Hz, 1H), 1.99 (d, <i>J</i> = 7.1 Hz, 3H), 1.07 (dd, <i>J</i> = 6.8, 3.8 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 470.1; found, 470.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(5-methyl-4-oxocyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>55</b>)</h3><div class="NLM_p last">To a solution of 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(10-methyl-1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>54</b>, 6.1 g, 13.0 mmol) in dichloromethane (173 mL) was added trifluoroacetic acid (29.6 mL, 389 mmol). The reaction was stirred 16 h at room temperature. The mixture was concentrated to ∼20% of its original volume, diluted with EtOAc (200 mL), and quenched with saturated aqueous NaHCO<sub>3</sub>. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (25–30% EtOAc in hexanes) to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(5-methyl-4-oxocyclohex-1-en-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>55</b>) as an orange solid (87% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.00 (d, <i>J</i> = 2.7 Hz, 1H), 7.45–7.43 (m, 1H), 7.41 (dd, <i>J</i> = 3.6, 2.1 Hz, 1H), 7.26–7.23 (m, 1H), 6.92 (ddt, <i>J</i> = 6.4, 4.1, 2.1 Hz, 1H), 6.76 (q, <i>J</i> = 7.1 Hz, 1H), 3.45–3.10 (m, 3H), 2.86–2.75 (m, 1H), 2.69–2.54 (m, 1H), 2.00 (dd, <i>J</i> = 7.1, 0.9 Hz, 3H), 1.26 (d, <i>J</i> = 6.6 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 426.1; found, 426.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (7<i>R</i>,8<i>S</i>)-7-Methyl-<i>N</i>-((<i>S</i>)-1-phenylethyl)-1,4-dioxaspiro[4.5]decan-8-amine (<b>58</b>)</h3><div class="NLM_p last">To a solution of 7-methyl-1,4-dioxaspiro[4.5]decan-8-one (<b>56</b>, 20.0 g, 118 mmol) in benzene (14.7 mL) was added (1<i>S</i>)-1-phenylethanamine (<b>57</b>, 15.2 mL, 118 mmol). The solution was heated to reflux overnight using a Dean–Stark apparatus for removal of water. After 24 h, the solution was concentrated under reduced pressure to afford (<i>R</i>,<i>E</i>)-7-methyl-<i>N</i>-((<i>S</i>)-1-phenylethyl)-1,4-dioxaspiro[4.5]decan-8-imine which was used without further purification. Sodium triacetoxyborohydride (316 mg, 1.5 mmol) was added portionwise to a solution of (<i>R</i>,<i>E</i>)-7-methyl-<i>N</i>-((<i>S</i>)-1-phenylethyl)-1,4-dioxaspiro[4.5]decan-8-imine (31.7 g, 117 mmol) in dichloromethane (283 mL) and acetic acid (10 mL). The resulting solution was stirred for 16 h at room temperature before being diluted with dichloromethane (300 mL) and quenched with saturated aqueous NaHCO<sub>3</sub>. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (20–30% EtOAc in hexanes) to afford (7<i>R</i>,8<i>S</i>)-7-methyl-<i>N</i>-((<i>S</i>)-1-phenylethyl)-1,4-dioxaspiro[4.5]decan-8-amine (<b>58</b>, 65% yield; 10:1 dr) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.35–7.25 (m, 4H), 7.22–7.16 (m, 1H), 3.91–3.79 (m, 4H), 3.76 (q, <i>J</i> = 7.1 Hz, 1H), 2.57–2.52 (m, 1H), 1.70–1.49 (m, 3H), 1.47–1.32 (m, 3H), 1.31 (d, <i>J</i> = 6.6 Hz, 3H), 1.25–1.20 (m, 1H), 1.01 (d, <i>J</i> = 7.1 Hz, 3H; diagnostic peak for major isomer), 0.90 (d, <i>J</i> = 7.1 Hz, 0.3H; diagnostic peak for minor isomer). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>26</sub>NO<sub>2</sub> [M + H]<sup>+</sup> = 276.2; found, 276.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>tert</i>-Butyl ((7<i>R</i>,8<i>S</i>)-7-Methyl-1,4-dioxaspiro[4.5]decan-8-yl)carbamate (<b>59</b>)</h3><div class="NLM_p last">A suspension of (7<i>R</i>,8<i>S</i>)-7-methyl-<i>N</i>-((<i>S</i>)-1-phenylethyl)-1,4-dioxaspiro[4.5]decan-8-amine (<b>58</b>, 12 g, 43.6 mmol) and 20% Pd(OH)<sub>2</sub> on carbon (1.2 g, 1.71 mmol, 0.04 equiv) in methanol (80 mL) was placed under a hydrogen atmosphere using a Parr apparatus (40 psi) for 72 h. After sparging with nitrogen gas for 30 min, the mixture was filtered through Celite with methanol and the filtrate was concentrated under reduced pressure to afford (7<i>R</i>,8<i>S</i>)-7-methyl-1,4-dioxaspiro[4.5]decan-8-amine (99% yield) as a colorless oil. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>9</sub>H<sub>18</sub>NO<sub>2</sub> [M + H]<sup>+</sup> = 172.1; found, 172. To a solution of (7<i>R</i>,8<i>S</i>)-7-methyl-1,4-dioxaspiro[4.5]decan-8-amine (7.88 g, 46.0 mmol) and triethylamine (6.4 mL, 46.0 mmol) in THF (92 mL) was added di-<i>tert</i>-butyl dicarbonate (10.0 g, 46.0 mmol) at room temperature. The resulting solution was stirred for 16 h at room temperature before being diluted with water (200 mL). The aqueous layer was extracted 3 times with dichloromethane; the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated by rotary evaporation to afford <i>tert</i>-butyl ((7<i>R</i>,8<i>S</i>)-7-methyl-1,4-dioxaspiro[4.5]decan-8-yl)carbamate (<b>59</b>, 98% yield) as a white solid that was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>26</sub>NO<sub>4</sub> [M + H]<sup>+</sup> = 272.2; found, 272.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>tert</i>-Butyl <i>N</i>-[(1<i>S</i>,2<i>R</i>)-2-Methyl-4-oxo-cyclohexyl]carbamate (<b>60</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl ((7<i>R</i>,8<i>S</i>)-7-methyl-1,4-dioxaspiro[4.5]decan-8-yl)carbamate (<b>59</b>, 6.54 g, 24.0 mmol) in THF (42 mL) and water (42 mL) was added <i>p</i>-toluenesulfonic acid monohydrate (9.67 g, 50.8 mmol) at room temperature. The resulting solution was stirred for 16 h at room temperature before being quenched with saturated aqueous NaHCO<sub>3</sub>. The aqueous layer was extracted twice with ethyl acetate; then the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (0–100% EtOAc in hexanes) to afford <i>tert</i>-butyl <i>N</i>-[(1<i>S</i>,2<i>R</i>)-2-methyl-4-oxo-cyclohexyl]carbamate (<b>60</b> 73% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.28 (br s, 1H), 3.82–3.76 (m, 1H), 2.25–1.95 (m, 5H), 1.85–1.74 (m, 1H), 1.73–1.63 (m, 1H), 1.20 (s, 9H), 0.72 (d, <i>J</i> = 6.5 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>22</sub>NO<sub>3</sub> [M + H]<sup>+</sup> = 228.2; found, 228.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (4<i>S</i>,5<i>R</i>)-4-((<i>tert</i>-Butoxycarbonyl)amino)-5-methylcyclohex-1-en-1-yl Trifluoromethanesulfonate (<b>61</b>)</h3><div class="NLM_p last">To a cooled (−78 °C) solution of <i>tert</i>-butyl <i>N</i>-[(1<i>S</i>,2<i>R</i>)-2-methyl-4-oxo-cyclohexyl]carbamate (<b>60</b>, 1.68 g, 7.39 mmol) in THF (25 mL) was added LiHMDS (1 M in THF, 18.5 mL, 18.5 mmol) dropwise. After 45 min at this temperature, a solution of PhNTf<sub>2</sub> (3.17 g, 8.87 mmol) in THF (10 mL) was added. The reaction was stirred for 15 min at −78 °C, and it was warmed to room temperature. After stirring for 1 h at room temperature, the reaction was quenched with water. The aqueous layer was extracted twice with ethyl acetate; then the combined organic layers were washed with 1 M aq. NaOH (5 times) and brine (once), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated by rotary evaporation to afford (4<i>S</i>,5<i>R</i>)-4-((<i>tert</i>-butoxycarbonyl)amino)-5-methylcyclohex-1-en-1-yl trifluoromethanesulfonate (<b>61</b>, 97% yield, >20:1 dr) as a tan-colored solid that was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.66 (br s, 1H), 4.51 (d, <i>J</i> = 9.2 Hz, 1H), 3.95–3.83 (m, 1H), 2.51–2.42 (m, 2H), 2.21–2.04 (m, 3H), 1.44 (s, 9H), 0.98 (d, <i>J</i> = 6.3 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>5</sub>S [M + H]<sup>+</sup> = 360.1; found, 360.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (<i>R</i>)-1-(1-(2,4-Dichlorophenyl)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>62</b>)</h3><div class="NLM_p last">A sealed tube was charged with a solution of 6-chloro-1-[(1<i>R</i>)-1-(2,4-dichlorophenyl)ethyl]pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>46</b>, 17.6 g, 49.8 mmol) in 1,4-dioxane (245 mL), followed by potassium acetate (16.7 g, 170 mmol), bis(pinacolato)diboron (12.7 g, 49.8 mmol), and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (1.82 g, 2.49 mmol). Nitrogen gas was bubbled through the reaction solution for 15 min. The sealed tube was then placed in an oil bath and heated to 90 °C for 2 h. After cooling to room temperature, the reaction mixture was filtered through a pad of Celite and silica gel (1:1), and the pad was rinsed with ethyl acetate (1 L). The residue was purified by silica gel chromatography (0–100% EtOAc in hexanes) to afford (<i>R</i>)-1-(1-(2,4-dichlorophenyl)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>62</b>, 72% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.12 (s, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 1H), 7.39 (d, <i>J</i> = 2.1 Hz, 1H), 7.26 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.95 (q, <i>J</i> = 7.0 Hz, 1H), 1.97 (d, <i>J</i> = 7.0 Hz, 3H), 1.43 (s, 12H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>21</sub>BCl<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 444.1; found, 444.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>tert</i>-Butyl ((1<i>S</i>,6<i>R</i>)-4-(3-Cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-yl)carbamate (<b>63</b>)</h3><div class="NLM_p last">A sealed tube was charged with a solution of 1-[(1<i>R</i>)-1-(2,4-dichlorophenyl)ethyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>62</b>, 8.2 g, 18.5 mmol) and [(4<i>S</i>,5<i>R</i>)-4-(tert-butoxycarbonylamino)-5-methyl-cyclohexen-1-yl] trifluoromethanesulfonate (<b>61</b>, 6.64g, 18.5 mmol) in water (6 mL) and toluene (62 mL). Sodium carbonate (5.87 g, 55.4 mmol) and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (1.35 g, 1.85 mmol) were added, and nitrogen gas was bubbled through the reaction solution for 15 min. The sealed tube was then placed in an oil bath and heated to 90 °C for 16 h. After cooling to room temperature, the reaction mixture was filtered through a pad of Celite and silica gel (1:1), and the pad was rinsed with ethyl acetate (500 mL). The residue was purified by silica gel chromatography (30–100% EtOAc in hexanes) to afford <i>tert</i>-butyl ((1<i>S</i>,6<i>R</i>)-4-(3-cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-yl)carbamate (<b>63</b>, 83% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.94 (s, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.40 (d, <i>J</i> = 2.1 Hz, 1H), 7.23 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.88 (s, 1H), 6.74 (q, <i>J</i> = 7.1 Hz, 1H), 4.58 (d, <i>J</i> = 9.3 Hz, 1H), 4.04–3.96 (m, 1H), 2.80–2.70 (m, 1H), 2.69–2.59 (m, 1H), 2.46–2.28 (m, 2H), 1.99 (d, <i>J</i> = 7.1 Hz, 3H), 1.45 (s, 9H), 1.07 (d, <i>J</i> = 6.8 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 527.2; found, 527.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 6-((4<i>S</i>,5<i>R</i>)-4-Amino-5-methylcyclohex-1-en-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile Hydrochloride (<b>64</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl ((1<i>S</i>,6<i>R</i>)-4-(3-cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-6-methylcyclohex-3-en-1-yl)carbamate (<b>63</b>, 0.6 g, 1.14 mmol) in dichloromethane (8 mL) was added 4 N HCl in 1,4-dioxane (1.3 mL, 5.05 mmol). After 2 h at room temperature, the solution was concentrated under reduced pressure to afford 6-((4<i>S</i>,5<i>R</i>)-4-amino-5-methylcyclohex-1-en-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile hydrochloride (<b>64</b>, 100% yield) which was used without further purification. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 427.1; found, 427.</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> [(4<i>R</i>)-5-[<i>tert</i>-Butyl(dimethyl)silyl]oxy-4-methylsulfonyloxy-pentyl] Methanesulfonate (<b>65</b>)</h3><div class="NLM_p last">To a cooled (0 °C) solution of (4<i>R</i>)-5-[<i>tert</i>-butyl(dimethyl)silyl]oxypentane-1,4-diol<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (2.14 g, 9.13 mmol) and triethylamine (3.8 mL, 27.4 mmol) in dichloromethane (33 mL) was added methanesulfonyl chloride (1.3 mL, 16.6 mmol) dropwise. The reaction mixture was warmed to room temperature and stirred for 16 h before quenching with saturated aqueous NaHCO<sub>3</sub>. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated by rotary evaporation. The residue was purified by silica gel chromatography (0–100% EtOAc in hexanes) to afford [(4<i>R</i>)-5-[<i>tert</i>-butyl(dimethyl)silyl]oxy-4-methylsulfonyloxy-pentyl] methanesulfonate (<b>65</b>, 79% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.70–4.63 (m, 1H), 4.30–4.18 (m, 2H), 4.11–4.04 (m, 1H), 3.76–3.66 (m, 2H), 3.04 (s, 3H), 2.98 (s, 3H), 1.95–1.67 (m, 4H), 0.86 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>31</sub>O<sub>7</sub>S<sub>2</sub>Si [M + H]<sup>+</sup> = 391.1; found, 391.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>66</b>)</h3><div class="NLM_p last">To a solution of 6-[(4<i>S</i>,5<i>R</i>)-4-amino-5-methyl-cyclohexen-1-yl]-1-[(1<i>R</i>)-1-(2,4-dichlorophenyl)ethyl]pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>64</b>, 482 mg, 1.13 mmol) and [(4<i>R</i>)-5-[<i>tert</i>-butyl(dimethyl)silyl]oxy-4-methylsulfonyloxy-pentyl] methanesulfonate (<b>65</b>, 881 mg, 2.26 mmol) in acetonitrile (5 mL) was added <i>N</i>,<i>N</i>-diisopropylethylamine (1.0 mL, 5.64 mmol). The solution was heated to reflux for 24 h before cooling to room temperature and concentrating under reduced pressure. The residue was purified by silica gel chromatography (0–20% methanol in dichloromethane) to afford 6-((4<i>S</i>,5<i>R</i>)-4-((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>66</b>, 75% yield). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>43</sub>Cl<sub>2</sub>N<sub>6</sub>OSi [M + H]<sup>+</sup> = 625.3; found, 625.</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>R</i>)-6-Chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1H-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>)</h3><div class="NLM_p">Step 1: (<i>R</i>)-(1-(2,4-dichlorophenyl)ethyl)hydrazine hydrochloride (<b>40</b>, 47.3 g, 195.8 mmol) was dissolved in ethanol (356 mL) at room temperature, and 1-(3,5-dichloropyrazin-2-yl)ethan-1-one (34.0 g, 178.0 mmol) was added. The mixture was stirred at room temperature for 8 h and then concentrated under reduced pressure. The residue was suspended in 20% ethyl acetate in hexanes (200 mL) and filtered through a silica gel plug eluting with 20% ethyl acetate in hexanes. The filtrate was concentrated under reduced pressure to give (<i>R</i>,<i>Z</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)ethyl)pyrazine and (<i>R</i>,<i>E</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)ethyl)pyrazine (9:1) as a viscous orange oil. LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>12</sub>Cl<sub>4</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 377.0; found, 377.</div><div class="NLM_p last">Step 2: A mixture of (<i>R</i>,<i>Z</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)ethyl)pyrazine and (<i>R,E</i>)-3,5-dichloro-2-(1-(2-(1-(2,4-dichlorophenyl)ethyl)hydrazono)ethyl)pyrazine (9:1) (33 g, 87.3 mmol) was dissolved in <i>N</i>-methyl-2-pyrrolidone (218 mL) at room temperature, and 2,6-lutidine (30.3 mL, 261.9 mmol) was added. The mixture was degassed with nitrogen and heated to 100 °C under nitrogen for 8 h. The reaction mixture was cooled to room temperature and poured into a separatory funnel containing 500 mL of 1 N HCl in water and 500 mL of ethyl acetate. The layers were separated, and the organic layer was washed with 500 mL of 1 N HCl in water, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0–20% (1:1 MTBE:dichloromethane) in hexanes) to provide (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1H-pyrazolo[3,4-<i>b</i>]pyrazine (<b>67</b>) as off-white solid (67% yield). ee: 98% Chiralpak OZ-H; 250 mm × 4.6 mm, 5% iPrOH in heptanes; flow rate 1 mL/min; detection at 254 nm; <i>R</i><sub>t</sub> = 6.9 min. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.45 (s, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 1H), 7.38 (d, <i>J</i> = 2.1 Hz, 1H), 7.19 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 6.48 (q, <i>J</i> = 6.9 Hz, 1H), 1.93 (d, <i>J</i> = 6.9 Hz, 3H). LRMS-ESI<sup>+</sup>: <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>11</sub>Cl<sub>3</sub>N<sub>4</sub> [M + H]<sup>+</sup> = 341.0; found, 341.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00506" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00506" class="ext-link">10.1021/acs.jmedchem.9b00506</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Assay conditions; hepatocyte stability assay; in vitro safety panel; X-ray structures of synthetic intermediates of <b>16</b> and <b>17</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00506/suppl_file/jm9b00506_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular Formula Strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00506/suppl_file/jm9b00506_si_002.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00506/suppl_file/jm9b00506_si_001.pdf">jm9b00506_si_001.pdf (520.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00506/suppl_file/jm9b00506_si_002.xlsx">jm9b00506_si_002.xlsx (10.83 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00506" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David J. Wustrow</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#523625272126203d2512203322267c313d3f"><span class="__cf_email__" data-cfemail="ef8b989a9c9b9d8098af9d8e9f9bc18c8082">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mikhail Zibinsky</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f5988f9c979c9b869e8cb587948581db969a98"><span class="__cf_email__" data-cfemail="cfa2b5a6ada6a1bca4b68fbdaebfbbe1aca0a2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey
J. Jackson</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7219-5279" title="Orcid link">http://orcid.org/0000-0002-7219-5279</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John M. Ketcham</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        J. M. K.: Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashkaan Younai</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Betty Abraham</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Berenger Biannic</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        B. B.: Pharmacyclics, an AbbVie Company, 995 East Arques Avenue, Sunnyvale, California 94085, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hilary P. Beck</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        H. P. B.: IDEAYA Biosciences, 7000 Shoreline Court, Suite 350, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minna H. T. Bui</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        M. H. T. B.: Exelixis Incorporated, 1851 Harbor Bay Parkway, Alameda, California 94502, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Chian</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gene Cutler</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raymond Diokno</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis X. Hu</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Jacobson</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily Karbarz</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul D. Kassner</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Marshall</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jenny McKinnell</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        J. M. and H. P. S.: Nurix Therapeutics Incorporated, 1700 Owens Street, Suite 205, San Francisco, California 94158, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cesar Meleza</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        C. M.: Arcus Biosciences, 26118 Research Road, Hayward, California 94545, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abood Okal</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        A. O: Takeda Oncology, 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepa Pookot</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maureen K. Reilly</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        M. K. R.: Pliant Therapeutics Inc., 260 Littlefield Avenue, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Omar Robles</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hunter P. Shunatona</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        J. M. and H. P. S.: Nurix Therapeutics Incorporated, 1700 Owens Street, Suite 205, San Francisco, California 94158, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oezcan Talay</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Walker</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        J. R. W.: Sigma-Aldrich Fine Chemicals, 645 Science Drive, Madison, Wisconsin 53711, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Wadsworth</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.J.J. and J.M.K.: These authors contributed equally to the preparation of this manuscript. The manuscript was written through contributions from all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors of this manuscript are or were employees of RAPT Therapeutics.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank all current and former employees for all their hard work and dedication to our CCR4 program. We are grateful to Dr. Antonio DiPasquale for assistance with X-ray crystallography.  RAPT Therapeutics was formerly known as FLX Bio Inc.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">CCR4</td><td class="NLM_def"><p class="first last">CC chemokine receptor 4</p></td></tr><tr><td class="NLM_term">CCL17</td><td class="NLM_def"><p class="first last">CC chemokine ligand 17</p></td></tr><tr><td class="NLM_term">CCL22</td><td class="NLM_def"><p class="first last">CC chemokine ligand 22</p></td></tr><tr><td class="NLM_term">T<sub>reg</sub></td><td class="NLM_def"><p class="first last">regulatory T cells</p></td></tr><tr><td class="NLM_term">IO</td><td class="NLM_def"><p class="first last">immuno-oncology</p></td></tr><tr><td class="NLM_term">T<sub>eff</sub></td><td class="NLM_def"><p class="first last">effector T cells</p></td></tr><tr><td class="NLM_term">TME</td><td class="NLM_def"><p class="first last">tumor microenvironment</p></td></tr><tr><td class="NLM_term">Th2</td><td class="NLM_def"><p class="first last">T helper type 2 cell</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">CTCL</td><td class="NLM_def"><p class="first last">cutaneous T-cell lymphoma</p></td></tr><tr><td class="NLM_term">ADCC</td><td class="NLM_def"><p class="first last">antibody-dependent cell-mediated cytotoxicity</p></td></tr><tr><td class="NLM_term">CTX</td><td class="NLM_def"><p class="first last">chemotaxis</p></td></tr><tr><td class="NLM_term">CD4</td><td class="NLM_def"><p class="first last">cluster of differentiation 4</p></td></tr><tr><td class="NLM_term">CD8</td><td class="NLM_def"><p class="first last">cluster of differentiation 8</p></td></tr><tr><td class="NLM_term">CD25</td><td class="NLM_def"><p class="first last">cluster of differentiation 25</p></td></tr><tr><td class="NLM_term">FOXP3</td><td class="NLM_def"><p class="first last">forkhead box P3</p></td></tr><tr><td class="NLM_term">HS</td><td class="NLM_def"><p class="first last">human serum</p></td></tr><tr><td class="NLM_term">hHep</td><td class="NLM_def"><p class="first last">human hepatocytes</p></td></tr><tr><td class="NLM_term">rHep</td><td class="NLM_def"><p class="first last">rat hepatocytes</p></td></tr><tr><td class="NLM_term">Vss</td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">miTreg</td><td class="NLM_def"><p class="first last">mouse induced regulatory T cells</p></td></tr><tr><td class="NLM_term">GFP</td><td class="NLM_def"><p class="first last">green fluorescent protein</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">Pd</td><td class="NLM_def"><p class="first last">palladium</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">NaH</td><td class="NLM_def"><p class="first last">sodium hydride</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>OH</td><td class="NLM_def"><p class="first last">ammonium hydroxide</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46865" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46865" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">CCR4 as a novel molecular target for immunotherapy of cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2006.00307.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1111%2Fj.1349-7006.2006.00307.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=16952304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFemtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=1139-1146&author=T.+Ishidaauthor=R.+Ueda&title=CCR4+as+a+novel+molecular+target+for+immunotherapy+of+cancer&doi=10.1111%2Fj.1349-7006.2006.00307.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">CCR4 as a novel molecular target for immunotherapy of cancer</span></div><div class="casAuthors">Ishida, Takashi; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1139-1146</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukocyte trafficking, which is critically regulated by chemokines and their receptors, shares many of the characteristics of tumor cell infiltration and metastasis.  Expression of CC chemokine receptor 4 (CCR4) by tumor cells is assocd. with skin involvement, but CCR4 also has an important role in normal and tumor immunity.  In a subset of patients with CCR4+ T-cell leukemia/lymphoma, the tumor cells themselves function as regulatory T (Treg) cells, contributing to tumor survival in the face of host antitumor immune responses.  In other types of cancers, the chemokines TARC/CCL17 and MDC/CCL22, specific ligands for CCR4 that are produced by tumor cells and the tumor microenvironment, attract CCR4+ Treg cells to the tumor, where they create a favorable environment for tumor escape from host immune responses.  A novel humanized anti-CCR4 monoclonal antibody (mAb) has been developed, the Fc region of which is defucosylated to enhance antibody-dependent cellular cytotoxicity by increasing its binding affinity to Fc receptor on effector cells.  We are now conducting a phase I clin. trial of this anti-CCR4 mAb in patients with CCR4+ T-cell leukemia/lymphoma in Japan (clin. trials gov. identifier: NCT00355472).  Anti-CCR4 mAb could be an ideal treatment modality for many different cancers, not only to directly kill the CCR4+ tumor cells, but also to overcome the suppressive effect of CCR4+ Treg cells on the host immune response to tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSaM9sSn_TJbVg90H21EOLACvtfcHk0ljsCVKivOrapQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFemtbjJ&md5=1ae7461548ceb9b10873b891551e4d9e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2006.00307.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2006.00307.x%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DCCR4%2520as%2520a%2520novel%2520molecular%2520target%2520for%2520immunotherapy%2520of%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2006%26volume%3D97%26spage%3D1139%26epage%3D1146%26doi%3D10.1111%2Fj.1349-7006.2006.00307.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanemura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, S.</span></span> <span> </span><span class="NLM_article-title">Anti-CCR4 mAb selectively depletes effector-type FoxP3<sup>+</sup>CD4<sup>+</sup> regulatory T cells, evoking antitumor immune responses in humans</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">17945</span>– <span class="NLM_lpage">17950</span>, <span class="refDoi"> DOI: 10.1073/pnas.1316796110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1073%2Fpnas.1316796110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=24127572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=17945-17950&author=D.+Sugiyamaauthor=H.+Nishikawaauthor=Y.+Maedaauthor=M.+Nishiokaauthor=A.+Tanemuraauthor=I.+Katayamaauthor=S.+Ezoeauthor=Y.+Kanakuraauthor=E.+Satoauthor=Y.+Fukumoriauthor=J.+Karbachauthor=E.+J%C3%A4gerauthor=S.+Sakaguchi&title=Anti-CCR4+mAb+selectively+depletes+effector-type+FoxP3%2BCD4%2B+regulatory+T+cells%2C+evoking+antitumor+immune+responses+in+humans&doi=10.1073%2Fpnas.1316796110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans</span></div><div class="casAuthors">Sugiyama, Daisuke; Nishikawa, Hiroyoshi; Maeda, Yuka; Nishioka, Megumi; Tanemura, Atsushi; Katayama, Ichiro; Ezoe, Sachiko; Kanakura, Yuzuru; Sato, Eiichi; Fukumori, Yasuo; Karbach, Julia; Jager, Elke; Sakaguchi, Shimon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17945-17950,S17945/1-S17945/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">CD4+ Treg cells expressing the transcription factor FOXP3 (forkhead box P3) are abundant in tumor tissues and appear to hinder the induction of effective antitumor immunity.  A substantial no. of T cells, including Treg cells, in tumor tissues and peripheral blood express C-C chemokine receptor 4 (CCR4).  Here we show that CCR4 was specifically expressed by a subset of terminally differentiated and most suppressive CD45RA-FOXP3hiCD4+ Treg cells [designated effector Treg (eTreg) cells], but not by CD45RA+FOXP3loCD4+ naive Treg cells, in peripheral blood of healthy individuals and cancer patients.  In melanoma tissues, CCR4+ eTreg cells were predominant among tumor-infiltrating FOXP3+ T cells and much higher in frequency compared with those in peripheral blood.  With peripheral blood lymphocytes from healthy individuals and melanoma patients, ex vivo depletion of CCR4+ T cells and subsequent in vitro stimulation of the depleted cell population with the cancer/testis antigen NY-ESO-1 efficiently induced NY-ESO-1-specific CD4+ T cells.  Nondepletion failed in the induction.  The magnitude of the responses was comparable with total removal of FOXP3+ Treg cells by CD25+ T-cell depletion.  CCR4+ T-cell depletion also augmented in vitro induction of NY-ESO-1-specific CD8+ T cells in melanoma patients.  Furthermore, in vivo administration of anti-CCR4 mAb markedly reduced the eTreg-cell fraction and augmented NY-ESO-1-specific CD8+ T-cell responses in an adult T-cell leukemia-lymphoma patient whose leukemic cells expressed NY-ESO-1.  Collectively, these findings indicate that anti-CCR4 mAb treatment is instrumental for evoking and augmenting antitumor immunity in cancer patients by selectively depleting eTreg cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDgtUeFW0g-7Vg90H21EOLACvtfcHk0ljsCVKivOrapQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurzL&md5=86531370de010a65e3cf8742b7e88d56</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1316796110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1316796110%26sid%3Dliteratum%253Aachs%26aulast%3DSugiyama%26aufirst%3DD.%26aulast%3DNishikawa%26aufirst%3DH.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DNishioka%26aufirst%3DM.%26aulast%3DTanemura%26aufirst%3DA.%26aulast%3DKatayama%26aufirst%3DI.%26aulast%3DEzoe%26aufirst%3DS.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DE.%26aulast%3DFukumori%26aufirst%3DY.%26aulast%3DKarbach%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DE.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DAnti-CCR4%2520mAb%2520selectively%2520depletes%2520effector-type%2520FoxP3%252BCD4%252B%2520regulatory%2520T%2520cells%252C%2520evoking%2520antitumor%2520immune%2520responses%2520in%2520humans%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D17945%26epage%3D17950%26doi%3D10.1073%2Fpnas.1316796110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinenaite, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munir Ahmad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Met, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westergaard, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klausen, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svane, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. H.</span></span> <span> </span><span class="NLM_article-title">CCL22-specific T cells: Modulating the immunosuppressive tumor microenvironment</span>. <i>Oncoimmunlogy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1238541</span> <span class="refDoi"> DOI: 10.1080/2162402X.2016.1238541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1080%2F2162402X.2016.1238541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=27999757" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=E.+Martinenaiteauthor=S.+Munir+Ahmadauthor=M.+Hansenauthor=O.+Metauthor=M.+W.+Westergaardauthor=S.+K.+Larsenauthor=T.+W.+Klausenauthor=M.+Doniaauthor=I.+M.+Svaneauthor=M.+H.+Andersen&title=CCL22-specific+T+cells%3A+Modulating+the+immunosuppressive+tumor+microenvironment&doi=10.1080%2F2162402X.2016.1238541"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1238541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1238541%26sid%3Dliteratum%253Aachs%26aulast%3DMartinenaite%26aufirst%3DE.%26aulast%3DMunir%2BAhmad%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DMet%26aufirst%3DO.%26aulast%3DWestergaard%26aufirst%3DM.%2BW.%26aulast%3DLarsen%26aufirst%3DS.%2BK.%26aulast%3DKlausen%26aufirst%3DT.%2BW.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DSvane%26aufirst%3DI.%2BM.%26aulast%3DAndersen%26aufirst%3DM.%2BH.%26atitle%3DCCL22-specific%2520T%2520cells%253A%2520Modulating%2520the%2520immunosuppressive%2520tumor%2520microenvironment%26jtitle%3DOncoimmunlogy%26date%3D2016%26volume%3D5%26doi%3D10.1080%2F2162402X.2016.1238541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurowska-Stolarska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolarski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kewin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrigan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirchandani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooijen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSharry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liew, F. Y.</span></span> <span> </span><span class="NLM_article-title">IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">6469</span>– <span class="NLM_lpage">6477</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.4049%2Fjimmunol.0901575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=19841166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKhsbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=6469-6477&author=M.+Kurowska-Stolarskaauthor=B.+Stolarskiauthor=P.+Kewinauthor=G.+Murphyauthor=C.+J.+Corriganauthor=S.+Yingauthor=N.+Pitmanauthor=A.+Mirchandaniauthor=B.+Ranaauthor=N.+van+Rooijenauthor=M.+Shepherdauthor=C.+McSharryauthor=I.+B.+McInnesauthor=D.+Xuauthor=F.+Y.+Liew&title=IL-33+amplifies+the+polarization+of+alternatively+activated+macrophages+that+contribute+to+airway+inflammation&doi=10.4049%2Fjimmunol.0901575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation</span></div><div class="casAuthors">Kurowska-Stolarska, Mariola; Stolarski, Bartosz; Kewin, Peter; Murphy, Grace; Corrigan, Christopher J.; Ying, Sun; Pitman, Nick; Mirchandani, Ananda; Rana, Batika; van Rooijen, Nico; Shepherd, Malcolm; McSharry, Charlie; McInnes, Iain B.; Xu, Damo; Liew, Foo Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6469-6477</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Alternatively activated macrophages (AAM) play a crucial role in type 2 immunity.  Mice deficient in ST2, a receptor for the latest member of the IL-1 family, IL-33, have impaired type 2 immune responses.  We therefore reasoned that IL-33/ST2 signaling may be involved in the differentiation and activation of AAM during airway inflammation.  We report here that IL-33 changed the quiescent phenotype of alveolar macrophages toward an AAM phenotype that expressed mannose receptor, IL-4Rα, and produced high levels of CCL24 and CCL17 in an IL-13-dependent manner during IL-33-induced airway inflammation.  Neutralization of AAM-derived CCL24 led to an amelioration of IL-33-induced eosinophilia in the lungs.  Moreover, depletion of alveolar macrophages reduced IL-33-induced airway inflammation.  Addnl., the attenuated OVA-induced airway inflammation in ST2-/- mice was assocd. with a decrease in AAM differentiation.  In vitro, IL-33 amplified IL-13-induced polarization of alveolar- and bone marrow-derived macrophage toward an AAM phenotype by increasing the expression of arginase I, Ym1, as well as the prodn. of CCL24 and CCL17.  IL-13/IL-4Rα signaling was crucial for IL-33-driven AAM amplification by inducing the expression of ST2L.  Finally, we showed that IL-33 was more abundantly expressed in the lung epithelial cells of asthma patients than those from healthy controls, suggesting that IL-33 may be involved in lung macrophage activation in clin. asthma.  Taken together, we demonstrate here that IL-33/ST2 plays a significant role in the amplification of AAM polarization and chemokine prodn. which contribute to innate and Ag-induced airway inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriG7WXOe7oWbVg90H21EOLACvtfcHk0ljsQTPqvN-jHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKhsbfE&md5=5aef6ccb0faecb16830a499cf2bdbee8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901575%26sid%3Dliteratum%253Aachs%26aulast%3DKurowska-Stolarska%26aufirst%3DM.%26aulast%3DStolarski%26aufirst%3DB.%26aulast%3DKewin%26aufirst%3DP.%26aulast%3DMurphy%26aufirst%3DG.%26aulast%3DCorrigan%26aufirst%3DC.%2BJ.%26aulast%3DYing%26aufirst%3DS.%26aulast%3DPitman%26aufirst%3DN.%26aulast%3DMirchandani%26aufirst%3DA.%26aulast%3DRana%26aufirst%3DB.%26aulast%3Dvan%2BRooijen%26aufirst%3DN.%26aulast%3DShepherd%26aufirst%3DM.%26aulast%3DMcSharry%26aufirst%3DC.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DLiew%26aufirst%3DF.%2BY.%26atitle%3DIL-33%2520amplifies%2520the%2520polarization%2520of%2520alternatively%2520activated%2520macrophages%2520that%2520contribute%2520to%2520airway%2520inflammation%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D6469%26epage%3D6477%26doi%3D10.4049%2Fjimmunol.0901575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdemon-Hogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conejo-Garcia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryczek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span> <span> </span><span class="NLM_article-title">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1038/nm1093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Fnm1093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=15322536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=942-949&author=T.+J.+Curielauthor=G.+Coukosauthor=L.+Zouauthor=X.+Alvarezauthor=P.+Chengauthor=P.+Mottramauthor=M.+Evdemon-Hoganauthor=J.+R.+Conejo-Garciaauthor=L.+Zhangauthor=M.+Burowauthor=Y.+Zhuauthor=S.+Weiauthor=I.+Kryczekauthor=B.+Danielauthor=A.+Gordonauthor=L.+Myersauthor=A.+Lacknerauthor=M.+L.+Disisauthor=K.+L.+Knutsonauthor=L.+Chenauthor=W.+Zou&title=Specific+recruitment+of+regulatory+T+cells+in+ovarian+carcinoma+fosters+immune+privilege+and+predicts+reduced+survival&doi=10.1038%2Fnm1093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span></div><div class="casAuthors">Curiel, Tyler J.; Coukos, George; Zou, Linhua; Alvarez, Xavier; Cheng, Pui; Mottram, Peter; Evdemon-Hogan, Melina; Conejo-Garcia, Jose R.; Zhang, Lin; Burow, Matthew; Zhu, Yun; Wei, Shuang; Kryczek, Ilona; Daniel, Ben; Gordon, Alan; Myers, Leann; Lackner, Andrew; Disis, Mary L.; Knutson, Keith L.; Chen, Lieping; Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">942-949</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Regulatory T (Treg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells.  Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-assocd. antigen-reactive lymphocytes mediated by Treg cells; however, definitive evidence that Treg cells have an immunopathol. role in human cancer is lacking.  Here the authors show, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor Treg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo.  The authors also show that tumor Treg cells are assocd. with a high death hazard and reduced survival.  Human Treg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages.  Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of Treg cells to the tumor.  This specific recruitment of Treg cells represents a mechanism by which tumors may foster immune privilege.  Thus, blocking Treg cell migration or function may help to defeat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUuPjm7zZim7Vg90H21EOLACvtfcHk0ljsQTPqvN-jHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D&md5=eaf598e6096d6e92381c1b26f4b2fe91</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm1093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1093%26sid%3Dliteratum%253Aachs%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DAlvarez%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DP.%26aulast%3DMottram%26aufirst%3DP.%26aulast%3DEvdemon-Hogan%26aufirst%3DM.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBurow%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DKryczek%26aufirst%3DI.%26aulast%3DDaniel%26aufirst%3DB.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DMyers%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DA.%26aulast%3DDisis%26aufirst%3DM.%2BL.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DW.%26atitle%3DSpecific%2520recruitment%2520of%2520regulatory%2520T%2520cells%2520in%2520ovarian%2520carcinoma%2520fosters%2520immune%2520privilege%2520and%2520predicts%2520reduced%2520survival%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D942%26epage%3D949%26doi%3D10.1038%2Fnm1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hadrup, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straten, P.</span></span> <span> </span><span class="NLM_article-title">Effector CD4 and CD8 T cells and their role in the tumor microenvironment</span>. <i>Cancer Microenviron.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1007/s12307-012-0127-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1007%2Fs12307-012-0127-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23242673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOlur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=123-133&author=S.+Hadrupauthor=M.+Doniaauthor=P.+Straten&title=Effector+CD4+and+CD8+T+cells+and+their+role+in+the+tumor+microenvironment&doi=10.1007%2Fs12307-012-0127-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment</span></div><div class="casAuthors">Hadrup, Sine; Donia, Marco; thor Straten, Per</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Microenvironment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-133</span>CODEN:
                <span class="NLM_cas:coden">CMAICW</span>;
        ISSN:<span class="NLM_cas:issn">1875-2284</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  T cells in tumors-the so-called tumor infiltrating lymphocytes (TIL) have been studied intensively over the past years.  Compelling evidence point to a clin. relevance for high nos. of T cells at the tumor site with CD8 memory T cells as a key denominator for overall survival (OS) in patients with colo-rectal cancer (CRC), and also for others solid cancers.  These data goes hand in hand with studies of clonality of TIL showing the T cells among TIL are expanded clonally, and also that tumor specific T cells of CD4 as well as CD8 type are enriched at the tumor site.  The tumor microenvironment is hostile to T cell function e.g., due to expression of enzymes that depletes the amino acids tryptophan and arginine, high concn. of tumor secreted lactate, and presence innate cells or regulatory T cells both with suppressive activity.  Analyses of the specificity of TILs in melanoma demonstrate that quite few known antigens are in fact recognized by these cultures underscoring patient unique and/or mutated antigens may represent important target for recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO_PUIt1Wyz7Vg90H21EOLACvtfcHk0ljsQTPqvN-jHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOlur%252FL&md5=eab48cec4355dedc34341179927989d4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs12307-012-0127-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12307-012-0127-6%26sid%3Dliteratum%253Aachs%26aulast%3DHadrup%26aufirst%3DS.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DStraten%26aufirst%3DP.%26atitle%3DEffector%2520CD4%2520and%2520CD8%2520T%2520cells%2520and%2520their%2520role%2520in%2520the%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Microenviron.%26date%3D2013%26volume%3D6%26spage%3D123%26epage%3D133%26doi%3D10.1007%2Fs12307-012-0127-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krausz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y. X.</span></span> <span> </span><span class="NLM_article-title">Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.1084/jem.20041684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1084%2Fjem.20041684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=15753211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitl2rt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2005&pages=779-791&author=P.+Yuauthor=Y.+Leeauthor=W.+Liuauthor=T.+Krauszauthor=A.+Chongauthor=H.+Schreiberauthor=Y.+X.+Fu&title=Intratumor+depletion+of+CD4%2B+cells+unmasks+tumor+immunogenicity+leading+to+the+rejection+of+late-stage+tumors&doi=10.1084%2Fjem.20041684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors</span></div><div class="casAuthors">Yu, Ping; Lee, Youjin; Liu, Wenhua; Krausz, Thomas; Chong, Anita; Schreiber, Hans; Fu, Yang-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">779-791</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Tumor environment can be crit. for preventing the immunol. destruction of antigenic tumors.  We have obsd. a selective accumulation of CD4+CD25+ T cells inside tumors.  In a murine fibrosarcoma Ld-expressing Ag104, these cells made up the majority of tumor-infiltrating lymphocytes at the late stage of tumor progression, and their depletion during the effector phase, rather than priming phase, successfully enhanced antitumor immunity.  We show here that CD4+CD25+ T cells suppressed the proliferation and interferon-γ prodn. of CD8+ T cells in vivo at the local tumor site.  Blockade of the effects of IL-10 and TGF-β partially reversed the suppression imposed by the CD4+ cells.  Furthermore, local depletion of CD4+ cells inside the tumor resulted in a change of cytokine milieu and led to the eradication of well-established highly aggressive tumors and the development of long-term antitumor memory.  Therefore, CD4+CD25+ T cells maintained an environment in the tumor that concealed the immunogenicity of tumor cells to permit progressive growth of antigenic tumors.  Our study illustrates that the suppression of antitumor immunity by regulatory T cells occurs predominantly at the tumor site, and that local reversal of suppression, even at a late stage of tumor development, can be an effective treatment for well-established cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ldyYnwbG37Vg90H21EOLACvtfcHk0ljziVLJbOaTqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitl2rt7s%253D&md5=63be9bb9913bf4025b1397133c9172f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1084%2Fjem.20041684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20041684%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DChong%26aufirst%3DA.%26aulast%3DSchreiber%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DY.%2BX.%26atitle%3DIntratumor%2520depletion%2520of%2520CD4%252B%2520cells%2520unmasks%2520tumor%2520immunogenicity%2520leading%2520to%2520the%2520rejection%2520of%2520late-stage%2520tumors%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2005%26volume%3D201%26spage%3D779%26epage%3D791%26doi%3D10.1084%2Fjem.20041684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Met, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frosig, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klausen, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svane, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. H.</span></span> <span> </span><span class="NLM_article-title">HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1764</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1158%2F0008-5472.CAN-12-3507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23328583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVGisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1764-1776&author=S.+Munirauthor=G.+H.+Andersenauthor=O.+Metauthor=M.+Doniaauthor=T.+M.+Frosigauthor=S.+K.+Larsenauthor=T.+W.+Klausenauthor=I.+M.+Svaneauthor=M.+H.+Andersen&title=HLA-restricted+cytotoxic+T+cells+that+are+specific+for+the+immune+checkpoint+ligand+PD-L1+occur+with+high+frequency+in+cancer+patients&doi=10.1158%2F0008-5472.CAN-12-3507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients</span></div><div class="casAuthors">Munir, Shamaila; Andersen, Gitte Holmen; Met, Oezcan; Donia, Marco; Frosig, Thomas Morch; Larsen, Stine Kiaer; Klausen, Tobias Wirenfeldt; Svane, Inge Marie; Andersen, Mads Hald</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1764-1776</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PD-L1 (CD274) contributes to functional exhaustion of T cells and limits immune responses in patients with cancer.  In this study, we report the identification of an human leukocyte antigen (HLA)-A2-restricted epitope from PD-L1, and we describe natural, cytolytic T-cell reactivity against PD-L1 in the peripheral blood of patients with cancer and healthy individuals.  Notably, PD-L1-specific T cells were able not only to recognize and kill tumor cells but also PD-L1-expressing dendritic cells in a PD-L1-dependent manner, insofar as PD-L1 ablation rescued dendritic cells from killing.  Furthermore, by incubating nonprofessional antigen-presenting cells with long peptides from PD-L1, we found that PD-L1 was rapidly internalized, processed, and cross-presented by HLA-A2 on the cell surface.  Apparently, this cross-presentation was TAP-independent, as it was conducted not only by B cells but in addn. by TAP-deficient T2-cells.  This is intriguing, as sol. PD-L1 has been detected in the sera from patients with cancer.  PD-L1-specific CTL may boost immunity by the killing of immunosuppressive tumor cells as well as regulatory cells.  However, PD-L1-specific CTLs may as well suppress immunity by the elimination of normal immune cells esp. PD-L1 expressing mature dendritic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGresMlYTnMTSbVg90H21EOLACvtfcHk0ljziVLJbOaTqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVGisrs%253D&md5=72959c46650c347dbe87c7ce53cc36ef</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3507%26sid%3Dliteratum%253Aachs%26aulast%3DMunir%26aufirst%3DS.%26aulast%3DAndersen%26aufirst%3DG.%2BH.%26aulast%3DMet%26aufirst%3DO.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DFrosig%26aufirst%3DT.%2BM.%26aulast%3DLarsen%26aufirst%3DS.%2BK.%26aulast%3DKlausen%26aufirst%3DT.%2BW.%26aulast%3DSvane%26aufirst%3DI.%2BM.%26aulast%3DAndersen%26aufirst%3DM.%2BH.%26atitle%3DHLA-restricted%2520cytotoxic%2520T%2520cells%2520that%2520are%2520specific%2520for%2520the%2520immune%2520checkpoint%2520ligand%2520PD-L1%2520occur%2520with%2520high%2520frequency%2520in%2520cancer%2520patients%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D1764%26epage%3D1776%26doi%3D10.1158%2F0008-5472.CAN-12-3507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treilleux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendriss-Vermare, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard-Leon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arfi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biota, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffin, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqual, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray-Coquard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puisieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J. Y.</span></span> <span> </span><span class="NLM_article-title">Menetrier-Caux, C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1158%2F0008-5472.CAN-08-2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=19244125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFSrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2000-2009&author=M.+Gobertauthor=I.+Treilleuxauthor=N.+Bendriss-Vermareauthor=T.+Bachelotauthor=S.+Goddard-Leonauthor=V.+Arfiauthor=C.+Biotaauthor=A.+C.+Doffinauthor=I.+Durandauthor=D.+Oliveauthor=S.+Perezauthor=M.+Pasqualauthor=C.+Faureauthor=I.+Ray-Coquardauthor=A.+Puisieuxauthor=C.+Cauxauthor=J.+Y.+Blay&title=Menetrier-Caux%2C+C.+Regulatory+T+cells+recruited+through+CCL22%2FCCR4+are+selectively+activated+in+lymphoid+infiltrates+surrounding+primary+breast+tumors+and+lead+to+an+adverse+clinical+outcome&doi=10.1158%2F0008-5472.CAN-08-2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome</span></div><div class="casAuthors">Gobert, Michael; Treilleux, Isabelle; Bendriss-Vermare, Nathalie; Bachelot, Thomas; Goddard-Leon, Sophie; Arfi, Vanessa; Biota, Cathy; Doffin, Anne Claire; Durand, Isabelle; Olive, Daniel; Perez, Solene; Pasqual, Nicolas; Faure, Christelle; Ray-Coquard, Isabelle; Puisieux, Alain; Caux, Christophe; Blay, Jean-Yves; Menetrier-Caux, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immunohistochem. anal. of FOXP3 in primary breast tumors showed that a high no. of tumor-infiltrating regulatory T cells (Ti-Treg) within lymphoid infiltrates surrounding the tumor was predictive of relapse and death, in contrast to those present within the tumor bed.  Ex vivo anal. showed that these tumor-infiltrating FOXP3+ T cells are typical Treg based on their CD4+CD25highCD127lowFOXP3+ phenotype, their anergic state on in vitro stimulation, and their suppressive functions.  These Ti-Treg could be selectively recruited through CCR4 as illustrated by (a) selective blood Treg CCR4 expression and migration to CCR4 ligands, (b) CCR4 down-regulation on Ti-Treg, and (c) correlation between Ti-Treg in lymphoid infiltrates and intratumoral CCL22 expression.  Importantly, in contrast to other T cells, Ti-Treg are selectively activated locally and proliferate in situ, showing T-cell receptor engagement and suggesting specific recognition of tumor-assocd. antigens (TAA).  Immunohistochem. stainings for ICOS, Ki67, and DC-LAMP show that Ti-Treg were close to mature DC-LAMP+ dendritic cells (DC) in lymphoid infiltrates but not in tumor bed and were activated and proliferating.  Furthermore, proximity between Ti-Treg, CD3+, and CD8+ T cells was documented within lymphoid infiltrates.  Altogether, these results show that Treg are selectively recruited within lymphoid infiltrates and activated by mature DC likely through TAA presentation, resulting in the prevention of effector T-cell activation, immune escape, and ultimately tumor progression.  This study sheds new light on Treg physiol. and validates CCR4/CCL22 and ICOS as therapeutic targets in breast tumors, which represent a major health problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqhKbsz9ynO7Vg90H21EOLACvtfcHk0ljziVLJbOaTqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFSrtbg%253D&md5=452bc4cee9c3cba90cfce6cf6dd4994d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2360%26sid%3Dliteratum%253Aachs%26aulast%3DGobert%26aufirst%3DM.%26aulast%3DTreilleux%26aufirst%3DI.%26aulast%3DBendriss-Vermare%26aufirst%3DN.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DGoddard-Leon%26aufirst%3DS.%26aulast%3DArfi%26aufirst%3DV.%26aulast%3DBiota%26aufirst%3DC.%26aulast%3DDoffin%26aufirst%3DA.%2BC.%26aulast%3DDurand%26aufirst%3DI.%26aulast%3DOlive%26aufirst%3DD.%26aulast%3DPerez%26aufirst%3DS.%26aulast%3DPasqual%26aufirst%3DM.%26aulast%3DFaure%26aufirst%3DC.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26atitle%3DMenetrier-Caux%252C%2520C.%2520Regulatory%2520T%2520cells%2520recruited%2520through%2520CCL22%252FCCR4%2520are%2520selectively%2520activated%2520in%2520lymphoid%2520infiltrates%2520surrounding%2520primary%2520breast%2520tumors%2520and%2520lead%2520to%2520an%2520adverse%2520clinical%2520outcome%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D2000%26epage%3D2009%26doi%3D10.1158%2F0008-5472.CAN-08-2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komabayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishibe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkuri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harabuchi, Y.</span></span> <span> </span><span class="NLM_article-title">CCL17 and CCL22/CCR4 signaling is a strong candidate for novel target therapy against nasal natural killer/T-cell lymphoma</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1007/s00262-015-1675-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1007%2Fs00262-015-1675-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25754123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1Omsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=697-705&author=T.+Kumaiauthor=T.+Nagatoauthor=H.+Kobayashiauthor=Y.+Komabayashiauthor=S.+Uedaauthor=K.+Kishibeauthor=T.+Ohkuriauthor=M.+Takaharaauthor=E.+Celisauthor=Y.+Harabuchi&title=CCL17+and+CCL22%2FCCR4+signaling+is+a+strong+candidate+for+novel+target+therapy+against+nasal+natural+killer%2FT-cell+lymphoma&doi=10.1007%2Fs00262-015-1675-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma</span></div><div class="casAuthors">Kumai, Takumi; Nagato, Toshihiro; Kobayashi, Hiroya; Komabayashi, Yuki; Ueda, Seigo; Kishibe, Kan; Ohkuri, Takayuki; Takahara, Miki; Celis, Esteban; Harabuchi, Yasuaki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">697-705</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Nasal natural killer/T-cell lymphoma (NNKTL) is assocd. with Epstein-Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination.  Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematol. malignancies.  The aim of the present study was to det. whether specific chemokines are produced by NNKTL.  We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA.  Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines.  In addn., CCL17 and CCL22 were readily obsd. in the sera of NNKTL patients.  The levels of these chemokines were significantly higher in patients than in healthy controls.  Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients.  Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines.  Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg0g-aCyoytLVg90H21EOLACvtfcHk0lgD8yfb3WvLCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1Omsrk%253D&md5=8d437143dd821e1f2785236b556c1bdd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00262-015-1675-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-015-1675-7%26sid%3Dliteratum%253Aachs%26aulast%3DKumai%26aufirst%3DT.%26aulast%3DNagato%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DKomabayashi%26aufirst%3DY.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DKishibe%26aufirst%3DK.%26aulast%3DOhkuri%26aufirst%3DT.%26aulast%3DTakahara%26aufirst%3DM.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DHarabuchi%26aufirst%3DY.%26atitle%3DCCL17%2520and%2520CCL22%252FCCR4%2520signaling%2520is%2520a%2520strong%2520candidate%2520for%2520novel%2520target%2520therapy%2520against%2520nasal%2520natural%2520killer%252FT-cell%2520lymphoma%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2015%26volume%3D64%26spage%3D697%26epage%3D705%26doi%3D10.1007%2Fs00262-015-1675-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracci, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsuang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemels, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrensch, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiencke, J. K.</span></span> <span> </span><span class="NLM_article-title">Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">826</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1002/ijc.29441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1002%2Fijc.29441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25604093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVajtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=826-836&author=M.+Zhouauthor=P.+M.+Bracciauthor=L.+S.+McCoyauthor=G.+Hsuangauthor=J.+L.+Wiemelsauthor=T.+Riceauthor=S.+Zhengauthor=K.+T.+Kelseyauthor=M.+R.+Wrenschauthor=J.+K.+Wiencke&title=Serum+macrophage-derived+chemokine%2FCCL22+levels+are+associated+with+glioma+risk%2C+CD4+T+cell+lymphopenia+and+survival+time&doi=10.1002%2Fijc.29441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time</span></div><div class="casAuthors">Zhou, Mi; Bracci, Paige M.; McCoy, Lucie S.; Hsuang, George; Wiemels, Joseph L.; Rice, Terri; Zheng, Shichun; Kelsey, Karl T.; Wrensch, Margaret R.; Wiencke, John K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">826-836</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Defects in antigen presenting cell function have been implicated in glioma immunosuppression.  We measured peripheral CCL22, a dendritic cell/macrophage derived T cell trafficking chemokine, in sera from 1,208 glioma cases and 976 controls to assess whether it might provide a biomarker of glioma risk, survival and immune dysfunction.  Cluster models were used to examine the relationship between CCL22 and glioma risk.  Patient survival was assessed using Cox regression models.  We also examd. the relationship between CCL22 levels and CD4 cell counts, as well as allergy history and IgE levels.  CCL22 levels were significantly lower among glioma cases compared with controls (Mean ± SEM: 1.23 ± 0.03 ng/mL in cases vs. 1.60 ± 0.03 ng/mL in controls, p < 0.0001) and this difference remained significant even after controlling for other covariates in the cluster models (highest quartile vs. lowest Odds Ratio = 0.21, p < 0.0001).  CD4 cell counts were pos. correlated with CCL22 in glioma cases (Spearman r2 = 0.51, p < 0.01) and were significantly lower in cases compared with controls.  Higher CCL22 levels were assocd. with longer survival in all cases combined and in GBM cases (hazard ratioallcases = 0.81; 95% CI: 0.72-0.91, p = 0.0003).  CCL22 levels were not assocd. with IgE level or self-reported allergies.  Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histol., grade and IDH mutation status.  CCL22 should be considered a marker of immune status with potential prognostic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7bCfHIddb-LVg90H21EOLACvtfcHk0lgD8yfb3WvLCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVajtb4%253D&md5=8ea50f9c73cca78b7c6f250a302cc7af</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fijc.29441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29441%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DBracci%26aufirst%3DP.%2BM.%26aulast%3DMcCoy%26aufirst%3DL.%2BS.%26aulast%3DHsuang%26aufirst%3DG.%26aulast%3DWiemels%26aufirst%3DJ.%2BL.%26aulast%3DRice%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DKelsey%26aufirst%3DK.%2BT.%26aulast%3DWrensch%26aufirst%3DM.%2BR.%26aulast%3DWiencke%26aufirst%3DJ.%2BK.%26atitle%3DSerum%2520macrophage-derived%2520chemokine%252FCCL22%2520levels%2520are%2520associated%2520with%2520glioma%2520risk%252C%2520CD4%2520T%2520cell%2520lymphopenia%2520and%2520survival%2520time%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D826%26epage%3D836%26doi%3D10.1002%2Fijc.29441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tough, D. F.</span></span> <span> </span><span class="NLM_article-title">Targeting CCR4 as an emerging strategy for cancer therapy and vaccines</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.tips.2014.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=24612600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslOktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=163-165&author=J.+Bayryauthor=E.+Tartourauthor=D.+F.+Tough&title=Targeting+CCR4+as+an+emerging+strategy+for+cancer+therapy+and+vaccines&doi=10.1016%2Fj.tips.2014.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CCR4 as an emerging strategy for cancer therapy and vaccines</span></div><div class="casAuthors">Bayry, Jagadeesh; Tartour, Eric; Tough, David F.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">163-165</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  This paper discusses the CCR4 antagonists are probably preferable for antitumor vaccines and, unlike CCR4 mAbs, this could be independent of the tumor cells expressing CCR4.  The CCR4 blockade clearly represents an original strategy to inhibit both Tregs and tumor cells were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiZt0pWKrl9bVg90H21EOLACvtfcHk0lgD8yfb3WvLCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslOktb8%253D&md5=1399fd3d918a248158a28558e412a733</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DBayry%26aufirst%3DJ.%26aulast%3DTartour%26aufirst%3DE.%26aulast%3DTough%26aufirst%3DD.%2BF.%26atitle%3DTargeting%2520CCR4%2520as%2520an%2520emerging%2520strategy%2520for%2520cancer%2520therapy%2520and%2520vaccines%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D163%26epage%3D165%26doi%3D10.1016%2Fj.tips.2014.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. E.</span></span> <span> </span><span class="NLM_article-title">Targeting chemokine receptors in disease – a case study of CCR4</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>763</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.ejphar.2015.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25981299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=763&publication_year=2015&pages=169-177&author=R.+Solariauthor=J.+E.+Pease&title=Targeting+chemokine+receptors+in+disease+%E2%80%93+a+case+study+of+CCR4&doi=10.1016%2Fj.ejphar.2015.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting chemokine receptors in disease - a case study of CCR4</span></div><div class="casAuthors">Solari, Roberto; Pease, James E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">763</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Since their early 1990s, the chemokine receptor family of G protein-coupled receptors (GPCRs) has been the source of much pharmacol. endeavour.  Best known for their key roles in recruiting leukocytes to sites of infection and inflammation, the receptors present themselves as plausible drug targets for therapeutic intervention.  In this article, we will focus our attention upon CC Chemokine Receptor Four (CCR4) which has been implicated in diseases as diverse as allergic asthma and lymphoma.  We will review the discovery of the receptors and their ligands, their perceived roles in disease and the successful targeting of CCR4 by both small mol. antagonists and monoclonal antibodies.  We will also discuss future directions and strategies for drug discovery in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd4Fw-zabbaLVg90H21EOLACvtfcHk0liS9ruTSsFqdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7bF&md5=79af36fb27d2eb5d501f6929f6378530</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DSolari%26aufirst%3DR.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26atitle%3DTargeting%2520chemokine%2520receptors%2520in%2520disease%2520%25E2%2580%2593%2520a%2520case%2520study%2520of%2520CCR4%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D763%26spage%3D169%26epage%3D177%26doi%3D10.1016%2Fj.ejphar.2015.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span> <span> </span><span class="NLM_article-title">A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15038</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11868-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Fs41598-017-11868-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=29118379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A280%3ADC%252BC1M7pt1ynsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=15038&author=Y.+Zhangauthor=Y.+Wuauthor=H.+Qiauthor=J.+Xiaoauthor=H.+Gongauthor=Y.+Zhangauthor=E.+Xuauthor=S.+Liauthor=D.+Maauthor=Y.+Wangauthor=W.+Liauthor=H.+Shen&title=A+new+antagonist+for+CCR4+attenuates+allergic+lung+inflammation+in+a+mouse+model+of+asthma&doi=10.1038%2Fs41598-017-11868-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma</span></div><div class="casAuthors">Zhang Yang; Qi Hui; Zhang Yan; Xu Enquan; Ma Dalong; Wang Ying; Zhang Yang; Wu Yinfang; Li Wen; Shen Huahao; Qi Hui; Xiao Junhai; Gong Hongwei; Li Song; Gong Hongwei</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15038</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CCR4 is highly expressed on Th2 cells.  CCR4 ligands include CCL22 and CCL17.  Chemokine-like factor 1 can also mediate chemotaxis via CCR4.  We designed and synthetized novel CCR4 antagonists, which were piperazinyl pyridine derivatives, for disrupting the interaction between three ligands and CCR4.  We also determined whether these novel CCR4 antagonists could alleviate allergic asthma in a mouse.  For identifying the potent compounds in vitro, we used chemotaxis inhibition and competition binding assays induced by CCL22, CCL17 and one of CKLF1's C-terminal peptides, C27.  We found compound 8a which showed excellent potency in blocking the interaction of CCR4 and its three ligands.  For studying the specificity of compounds, we chose chemotaxis inhibition assays with different receptors and ligands.  We found compound 8a had excellent receptor specificity and exerted few influence on the interaction of other receptors and their ligands.  In the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, compound 8a had no obvious cytotoxicity till the higher concentration (16 μM).  For determining the potency of compounds in blocking the interaction of CCR4 in vivo, we used the ovalbumin induced allergic asthma model in mice.  Our study demonstrated that CCR4 blockaded by compound 8a effectively attenuated airway hyperresponsiveness, airway eosinophilia and Th2 cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwS9d-cvIEc_csfMJQC1ZdfW6udTcc2ebJQF0o3_F8jbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7pt1ynsw%253D%253D&md5=796db5f0877337b45f4681de2a677666</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11868-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11868-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DH.%26atitle%3DA%2520new%2520antagonist%2520for%2520CCR4%2520attenuates%2520allergic%2520lung%2520inflammation%2520in%2520a%2520mouse%2520model%2520of%2520asthma%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D15038%26doi%3D10.1038%2Fs41598-017-11868-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span>; <span class="NLM_string-name">Ford, A.</span>; <span class="NLM_string-name">Hodgson, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of CCR4 Antagonists</span>. In  <i>New Drugs and Targets for Asthma and COPD</i>; <span class="NLM_publisher-name">Karger Medical and Scientific Publishers</span>, <span class="NLM_year">2010</span>; Vol.  <span class="NLM_volume">39</span>, pp  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">165</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1159%2F000320815" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=161-165&author=D.+Hall&author=A.+Ford&author=S.+Hodgson&title=New+Drugs+and+Targets+for+Asthma+and+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1159%2F000320815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1159%252F000320815%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DD.%26atitle%3DTherapeutic%2520Potential%2520of%2520CCR4%2520Antagonists%26btitle%3DNew%2520Drugs%2520and%2520Targets%2520for%2520Asthma%2520and%2520COPD%26pub%3DKarger%2520Medical%2520and%2520Scientific%2520Publishers%26date%3D2010%26volume%3D39%26spage%3D161%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horuk, R.</span></span> <span> </span><span class="NLM_article-title">Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1517/17460441.2014.897324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1517%2F17460441.2014.897324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=24641500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFClt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=467-483&author=J.+E.+Peaseauthor=R.+Horuk&title=Recent+progress+in+the+development+of+antagonists+to+the+chemokine+receptors+CCR3+and+CCR4&doi=10.1517%2F17460441.2014.897324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4</span></div><div class="casAuthors">Pease, James Edward; Horuk, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">467-483</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The chemokine receptors CCR3 and CCR4 have been shown to be important therapeutic targets for the treatment of a variety of diseases.  Although only two chemokine receptor inhibitors have been approved so far, there are numerous compds. that are in various stages of development.  Areas covered: In this review article, the authors provide an update on the progress made in the identification of antagonists against the chemokine receptors CCR3 and CCR4 from 2009 to the present.  The rationale of writing this review article is to cover the most important approaches to identifying antagonists to these two receptors, which could prove to be useful therapeutics in treating proinflammatory diseases.  Expert opinion: Pharmaceutical companies have expended a considerable amt. of money and effort to identify potent inhibitors of CCR3 and CCR4 for the treatment of asthma and atopic diseases.  Although a variety of compds. have been described and several have progressed into the clinic, none have so far made it as approved drugs.  There are, however, novel approaches such as mogamulizumab, a monoclonal antibody to CCR4 currently is in clin. trials for cancer and ASM8, an antisense nucleotide to CCR3, which is in Phase II clin. trials for asthma that might still prove to be successful new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXmZrBcC5PbLVg90H21EOLACvtfcHk0liS9ruTSsFqdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFClt7o%253D&md5=d77cb820f88320311ed1c09f15f7a800</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.897324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.897324%26sid%3Dliteratum%253Aachs%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DRecent%2520progress%2520in%2520the%2520development%2520of%2520antagonists%2520to%2520the%2520chemokine%2520receptors%2520CCR3%2520and%2520CCR4%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D467%26epage%3D483%26doi%3D10.1517%2F17460441.2014.897324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wreggett, K. A.</span></span> <span> </span><span class="NLM_article-title">An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1124/mol.107.039321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1124%2Fmol.107.039321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=18042736" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=855-867&author=G.+Andrewsauthor=C.+Jonesauthor=K.+A.+Wreggett&title=An+intracellular+allosteric+site+for+a+specific+class+of+antagonists+of+the+CC+chemokine+G+protein-coupled+receptors+CCR4+and+CCR5&doi=10.1124%2Fmol.107.039321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.039321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.039321%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DWreggett%26aufirst%3DK.%2BA.%26atitle%3DAn%2520intracellular%2520allosteric%2520site%2520for%2520a%2520specific%2520class%2520of%2520antagonists%2520of%2520the%2520CC%2520chemokine%2520G%2520protein-coupled%2520receptors%2520CCR4%2520and%2520CCR5%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D855%26epage%3D867%26doi%3D10.1124%2Fmol.107.039321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalesso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span> <span> </span><span class="NLM_article-title">Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e00019</span> <span class="refDoi"> DOI: 10.1002/prp2.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1002%2Fprp2.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25505571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yntr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&author=R.+J.+Slackauthor=L.+J.+Russellauthor=N.+P.+Bartonauthor=C.+Westonauthor=G.+Nalessoauthor=S.-A.+Thompsonauthor=M.+Allenauthor=Y.+H.+Chenauthor=A.+Barnesauthor=S.+T.+Hodgsonauthor=D.+A.+Hall&title=Antagonism+of+human+CC-chemokine+receptor+4+can+be+achieved+through+three+distinct+binding+sites+on+the+receptor&doi=10.1002%2Fprp2.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor</span></div><div class="casAuthors">Slack, Robert J.; Russell, Linda J.; Barton, Nick P.; Weston, Cathryn; Nalesso, Giovanna; Thompson, Sally-Anne; Allen, Morven; Chen, Yu Hua; Barnes, Ashley; Hodgson, Simon T.; Hall, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology Research & Perspectives</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e00019/1-e00019/25</span>CODEN:
                <span class="NLM_cas:coden">PRPHCA</span>;
        ISSN:<span class="NLM_cas:issn">2052-1707</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Chemokine receptor antagonists appear to access two distinct binding sites on different members of this receptor family.  One class of CCR4 antagonists has been suggested to bind to a site accessible from the cytoplasm while a second class did not bind to this site.  In this report, we demonstrate that antagonists representing a variety of structural classes bind to two distinct allosteric sites on CCR4.  The effects of pairs of low-mol. wt. and/or chemokine CCR4 antagonists were evaluated on CCL17- and CCL22-induced responses of human CCR4+ T cells.  This provided an initial grouping of the antagonists into sets which appeared to bind to distinct binding sites.  Binding studies were then performed with radioligands from each set to confirm these groupings.  Some novel receptor theory was developed to allow the interpretation of the effects of the antagonist combinations.  The theory indicates that, generally, the concn.-ratio of a pair of competing allosteric modulators is maximally the sum of their individual effects while that of two modulators acting at different sites is likely to be greater than their sum.  The low-mol. wt. antagonists could be grouped into two sets on the basis of the functional and binding expts.  The antagonistic chemokines formed a third set whose behavior was consistent with that of simple competitive antagonists.  These studies indicate that there are two allosteric regulatory sites on CCR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj9cDmC7ops7Vg90H21EOLACvtfcHk0lhtC6RstKLCVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yntr3O&md5=d3c75616ffba6b6644c8755fcff21e5c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fprp2.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.19%26sid%3Dliteratum%253Aachs%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DRussell%26aufirst%3DL.%2BJ.%26aulast%3DBarton%26aufirst%3DN.%2BP.%26aulast%3DWeston%26aufirst%3DC.%26aulast%3DNalesso%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DS.-A.%26aulast%3DAllen%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DBarnes%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DHall%26aufirst%3DD.%2BA.%26atitle%3DAntagonism%2520of%2520human%2520CC-chemokine%2520receptor%25204%2520can%2520be%2520achieved%2520through%2520three%2520distinct%2520binding%2520sites%2520on%2520the%2520receptor%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2013%26volume%3D1%26doi%3D10.1002%2Fprp2.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ajram, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swieboda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousnier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>729</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.ejphar.2014.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=24534492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1CrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=729&publication_year=2014&pages=75-85&author=L.+Ajramauthor=M.+Beggauthor=R.+Slackauthor=J.+Cryanauthor=D.+Hallauthor=S.+Hodgsonauthor=A.+Fordauthor=A.+Barnesauthor=D.+Swiebodaauthor=A.+Mousnierauthor=R.+Solari&title=Internalization+of+the+chemokine+receptor+CCR4+can+be+evoked+by+orthosteric+and+allosteric+receptor+antagonists&doi=10.1016%2Fj.ejphar.2014.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists</span></div><div class="casAuthors">Ajram, Laura; Begg, Malcolm; Slack, Robert; Cryan, Jenni; Hall, David; Hodgson, Simon; Ford, Alison; Barnes, Ashley; Swieboda, Dawid; Mousnier, Aurelie; Solari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">729</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The chemokine receptor CCR4 has at least two natural agonist ligands, MDC (CCL22) and TARC (CCL17) which bind to the same orthosteric site with a similar affinity.  Both ligands are known to evoke chemotaxis of CCR4-bearing T cells and also elicit CCR4 receptor internalization.  A series of small mol. allosteric antagonists have been described which displace the agonist ligand, and inhibit chemotaxis.  The aim of this study was to det. which cellular coupling pathways are involved in internalization, and if antagonists binding to the CCR4 receptor could themselves evoke receptor internalization.  CCL22 binding coupled CCR4 efficiently to β-arrestin and stimulated GTPγS binding however CCL17 did not couple to β-arrestin and only partially stimulated GTPγS binding.  CCL22 potently induced internalization of almost all cell surface CCR4, while CCL17 showed only weak effects.  We describe four small mol. antagonists that were demonstrated to bind to two distinct allosteric sites on the CCR4 receptor, and while both classes inhibited agonist ligand binding and chemotaxis, one of the allosteric sites also evoked receptor internalization.  Furthermore, we also characterize an N-terminally truncated version of CCL22 which acts as a competitive antagonist at the orthosteric site, and surprisingly also evokes receptor internalization without demonstrating any agonist activity.  Collectively this study demonstrates that orthosteric and allosteric antagonists of the CCR4 receptor are capable of evoking receptor internalization, providing a novel strategy for drug discovery against this class of target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cp_MmkWDlrVg90H21EOLACvtfcHk0lhtC6RstKLCVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1CrsrY%253D&md5=2d48b60057b1a037979e02f0a4fe95b4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DAjram%26aufirst%3DL.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DSlack%26aufirst%3DR.%26aulast%3DCryan%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DFord%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DA.%26aulast%3DSwieboda%26aufirst%3DD.%26aulast%3DMousnier%26aufirst%3DA.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DInternalization%2520of%2520the%2520chemokine%2520receptor%2520CCR4%2520can%2520be%2520evoked%2520by%2520orthosteric%2520and%2520allosteric%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D729%26spage%3D75%26epage%3D85%26doi%3D10.1016%2Fj.ejphar.2014.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heifetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schertler, G. F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourmy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storer, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhonova, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodkin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, R. J.</span></span> <span> </span><span class="NLM_article-title">Biggin, P.C. GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014</span>. <i>Naunyn-Schmiedeberg’s Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1007/s00210-015-1111-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1007%2Fs00210-015-1111-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25772061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksV2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2015&pages=883-903&author=A.+Heifetzauthor=G.+F.+X.+Schertlerauthor=R.+Seifertauthor=C.+G.+Tateauthor=P.+M.+Sextonauthor=V.+V.+Gurevichauthor=D.+Fourmyauthor=V.+Cherezovauthor=F.+H.+Marshallauthor=R.+I.+Storerauthor=I.+Moraesauthor=I.+G.+Tikhonovaauthor=C.+S.+Tautermannauthor=P.+Huntauthor=T.+Ceskaauthor=S.+Hodgsonauthor=M.+J.+Bodkinauthor=S.+Singhauthor=R.+J.+Law&title=Biggin%2C+P.C.+GPCR+structure%2C+function%2C+drug+discovery+and+crystallography%3A+report+from+Academia-Industry+International+Conference+%28UK+Royal+Society%29+Chicheley+Hall%2C+1%E2%80%932+September+2014&doi=10.1007%2Fs00210-015-1111-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014</span></div><div class="casAuthors">Heifetz, Alexander; Schertler, Gebhard F. X.; Seifert, Roland; Tate, Christopher G.; Sexton, Patrick M.; Gurevich, Vsevolod V.; Fourmy, Daniel; Cherezov, Vadim; Marshall, Fiona H.; Storer, R. Ian; Moraes, Isabel; Tikhonova, Irina G.; Tautermann, Christofer S.; Hunt, Peter; Ceska, Tom; Hodgson, Simon; Bodkin, Mike J.; Singh, Shweta; Law, Richard J.; Biggin, Philip C.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  G-protein coupled receptors (GPCRs) are the targets of over half of all prescribed drugs today.  The UniProt database has records for about 800 proteins classified as GPCRs, but drugs have only been developed against 50 of these.  Thus, there is huge potential in terms of the no. of targets for new therapies to be designed.  Several breakthroughs in GPCRs biased pharmacol., structural biol., modeling and scoring have resulted in a resurgence of interest in GPCRs as drug targets.  Therefore, an international conference, sponsored by the Royal Society, with world-renowned researchers from industry and academia was recently held to discuss recent progress and highlight key areas of future research needed to accelerate GPCR drug discovery.  Several key points emerged.  Firstly, structures for all three major classes of GPCRs have now been solved and there is increasing coverage across the GPCR phylogenetic tree.  This is likely to be substantially enhanced with data from x-ray free electron sources as they move beyond proof of concept.  Secondly, the concept of biased signalling or functional selectivity is likely to be prevalent in many GPCRs, and this presents exciting new opportunities for selectivity and the control of side effects, esp. when combined with increasing data regarding allosteric modulation.  Thirdly, there will almost certainly be some GPCRs that will remain difficult targets because they exhibit complex ligand dependencies and have many metastable states rendering them difficult to resolve by crystallog. methods.  Subtle effects within the packing of the transmembrane helixes are likely to mask and contribute to this aspect, which may play a role in species dependent behavior.  This is particularly important because it has ramifications for how we interpret pre-clin. data.  In summary, collaborative efforts between industry and academia have delivered significant progress in terms of structure and understanding of GPCRs and will be essential for resolving problems assocd. with the more difficult targets in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcK1I7affT27Vg90H21EOLACvtfcHk0liMakNpQQX4aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksV2msrk%253D&md5=a2f1ef2996666eec21056ac4fe51d534</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00210-015-1111-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-015-1111-8%26sid%3Dliteratum%253Aachs%26aulast%3DHeifetz%26aufirst%3DA.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26aulast%3DSeifert%26aufirst%3DR.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DFourmy%26aufirst%3DD.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DStorer%26aufirst%3DR.%2BI.%26aulast%3DMoraes%26aufirst%3DI.%26aulast%3DTikhonova%26aufirst%3DI.%2BG.%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DHunt%26aufirst%3DP.%26aulast%3DCeska%26aufirst%3DT.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DBodkin%26aufirst%3DM.%2BJ.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DLaw%26aufirst%3DR.%2BJ.%26atitle%3DBiggin%252C%2520P.C.%2520GPCR%2520structure%252C%2520function%252C%2520drug%2520discovery%2520and%2520crystallography%253A%2520report%2520from%2520Academia-Industry%2520International%2520Conference%2520%2528UK%2520Royal%2520Society%2529%2520Chicheley%2520Hall%252C%25201%25E2%2580%25932%2520September%25202014%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D2015%26volume%3D388%26spage%3D883%26epage%3D903%26doi%3D10.1007%2Fs00210-015-1111-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kontani, T.</span>; <span class="NLM_string-name">Kawano, N.</span>; <span class="NLM_string-name">Masuda, N.</span>; <span class="NLM_string-name">Kato, K.</span>; <span class="NLM_string-name">Nagata, H.</span>; <span class="NLM_string-name">Inami, H.</span>; <span class="NLM_string-name">Terasaka, T.</span>; <span class="NLM_string-name">Kazuhir, Y.</span>; <span class="NLM_string-name">Miyazaki, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Amino(acylaminopiperidinyl)quinazoline Derivatives as CCR4 Inhibitors for Treatment of Inflammation, Allergy, and Autoimmune Disease</span>. <span class="NLM_patent">WO2007111227A</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Kontani&author=N.+Kawano&author=N.+Masuda&author=K.+Kato&author=H.+Nagata&author=H.+Inami&author=T.+Terasaka&author=Y.+Kazuhir&author=T.+Miyazaki&title=Preparation+of+Amino%28acylaminopiperidinyl%29quinazoline+Derivatives+as+CCR4+Inhibitors+for+Treatment+of+Inflammation%2C+Allergy%2C+and+Autoimmune+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKontani%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Amino%2528acylaminopiperidinyl%2529quinazoline%2520Derivatives%2520as%2520CCR4%2520Inhibitors%2520for%2520Treatment%2520of%2520Inflammation%252C%2520Allergy%252C%2520and%2520Autoimmune%2520Disease%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koganemaru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span> <span> </span><span class="NLM_article-title">Potent and orally bioavailable CCR4 atagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.bmc.2008.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=19081254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFamtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=64-73&author=K.+Yokoyamaauthor=N.+Ishikawaauthor=S.+Igarashiauthor=N.+Kawanoauthor=N.+Masudaauthor=W.+Hamaguchiauthor=S.+Yamasakiauthor=Y.+Koganemaruauthor=K.+Hattoriauthor=T.+Miyazakiauthor=S.+Oginoauthor=Y.+Matsumotoauthor=M.+Takeuchiauthor=M.+Ohta&title=Potent+and+orally+bioavailable+CCR4+atagonists%3A+Synthesis+and+structure-activity+relationship+study+of+2-aminoquinazolines&doi=10.1016%2Fj.bmc.2008.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines</span></div><div class="casAuthors">Yokoyama, Kazuhiro; Ishikawa, Noriko; Igarashi, Susumu; Kawano, Noriyuki; Masuda, Naoyuki; Hamaguchi, Wataru; Yamasaki, Shingo; Koganemaru, Yohei; Hattori, Kazuyuki; Miyazaki, Takahiro; Ogino, Shin-ichi; Matsumoto, Yuzo; Takeuchi, Makoto; Ohta, Mitsuaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-73</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting with a series of CC chemokine receptor-4 (CCR4) antagonists developed in a previous study, the potency was improved by replacing the pyrrolidine moiety of N-(4-chlorophenyl)-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine 2 with a 3-(hydroxymethyl)piperidine.  The resulting compd. (1'-{4-[(4-chlorophenyl)amino]-6,7-dimethoxyquinazolin-2-yl}-1,4'-bipiperidin-3-yl)methanol 8ic was a strong inhibitor of human/mouse chemotaxis.  Oral administration of 8ic showed anti-inflammatory activity in a murine model of acute dermatitis (oxazolone-induced contact hypersensitivity test) in a dose-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbBY8f7PEJE7Vg90H21EOLACvtfcHk0liMakNpQQX4aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFamtr3J&md5=181807b8003d07572368f43807ec6ede</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DN.%26aulast%3DIgarashi%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DN.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DHamaguchi%26aufirst%3DW.%26aulast%3DYamasaki%26aufirst%3DS.%26aulast%3DKoganemaru%26aufirst%3DY.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26atitle%3DPotent%2520and%2520orally%2520bioavailable%2520CCR4%2520atagonists%253A%2520Synthesis%2520and%2520structure-activity%2520relationship%2520study%2520of%25202-aminoquinazolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D64%26epage%3D73%26doi%3D10.1016%2Fj.bmc.2008.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerville, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span> <span> </span><span class="NLM_article-title">Core exploration in optimization of chemokine receptor CCR4 antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.10.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.bmcl.2006.10.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=17098428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFaguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=679-682&author=A.+V.+Purandareauthor=H.+Wanauthor=J.+E.+Somervilleauthor=C.+Burkeauthor=W.+Vaccaroauthor=X.+Yangauthor=K.+W.+McIntyreauthor=M.+A.+Poss&title=Core+exploration+in+optimization+of+chemokine+receptor+CCR4+antagonists&doi=10.1016%2Fj.bmcl.2006.10.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Core exploration in optimization of chemokine receptor CCR4 antagonists</span></div><div class="casAuthors">Purandare, Ashok V.; Wan, Honghe; Somerville, John E.; Burke, Christine; Vaccaro, Wayne; Yang, XiaoXia; McIntyre, Kim W.; Poss, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">679-682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design, synthesis, and SAR studies of 'core' variations led to identification of novel, selective, and potent small mol. antagonist (I) of the CC chemokine receptor-4 (CCR4) with improved in vitro activity and liability profile.  Compd. I was efficacious in a murine allergic inflammation model (ED50 ∼ 10 mg/kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCc-Oj8IV7u7Vg90H21EOLACvtfcHk0liMakNpQQX4aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFaguw%253D%253D&md5=604537d7fd88fe913ef078ab1602ea02</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.10.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.10.091%26sid%3Dliteratum%253Aachs%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSomerville%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DC.%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26atitle%3DCore%2520exploration%2520in%2520optimization%2520of%2520chemokine%2520receptor%2520CCR4%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D679%26epage%3D682%26doi%3D10.1016%2Fj.bmcl.2006.10.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuribayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span> <span> </span><span class="NLM_article-title">RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1248/bpb.33.1067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1248%2Fbpb.33.1067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=20522980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslynsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=1067-1069&author=Y.+Nakagamiauthor=Y.+Kawaseauthor=K.+Yonekuboauthor=E.+Nosakaauthor=M.+Etoriauthor=S.+Takahashiauthor=N.+Takagiauthor=T.+Fukudaauthor=T.+Kuribayashiauthor=F.+Naraauthor=M.+Yamashita&title=RS-1748%2C+a+novel+CC+chemokine+receptor+4+antagonist%2C+inhibits+ovalbumin-induced+airway+inflammation+in+guinea+pigs&doi=10.1248%2Fbpb.33.1067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs</span></div><div class="casAuthors">Nakagami, Yasuhiro; Kawase, Yumi; Yonekubo, Kazuki; Nosaka, Emi; Etori, Maki; Takahashi, Sakiko; Takagi, Nana; Fukuda, Takeshi; Kuribayashi, Takeshi; Nara, Futoshi; Yamashita, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1067-1069</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">CC chemokine receptor 4 (CCR4) is generally recognized as a preferential marker for T helper 2 cells, and we have previously reported morpholine-deriv. CCR4 antagonists, RS-1154 and RS-1269.  Here, we investigate the pharmacol. profiles of a novel pyrimidine-deriv. CCR4 antagonist, 2-{4-[2-(diethylamino)-ethoxy]phenyl}-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine (RS-1748), which showed potency to inhibit the bindings of [125I]CCL17 and [35S]GTPγS to human CCR4-expressing Chinese hamster ovary (CHO) cells with IC50 values of 59.9 nM and 18.4 nM, resp.  Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg.  These results indicate that RS-1748 would be a promising lead compd. for developing a therapeutic agent against asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKappxf9t5rVg90H21EOLACvtfcHk0lixDg78lktQ8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslynsLY%253D&md5=f859158d9f471329d0235c58c02b844f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1248%2Fbpb.33.1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.33.1067%26sid%3Dliteratum%253Aachs%26aulast%3DNakagami%26aufirst%3DY.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DYonekubo%26aufirst%3DK.%26aulast%3DNosaka%26aufirst%3DE.%26aulast%3DEtori%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DKuribayashi%26aufirst%3DT.%26aulast%3DNara%26aufirst%3DF.%26aulast%3DYamashita%26aufirst%3DM.%26atitle%3DRS-1748%252C%2520a%2520novel%2520CC%2520chemokine%2520receptor%25204%2520antagonist%252C%2520inhibits%2520ovalbumin-induced%2520airway%2520inflammation%2520in%2520guinea%2520pigs%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2010%26volume%3D33%26spage%3D1067%26epage%3D1069%26doi%3D10.1248%2Fbpb.33.1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuberson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teobald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=981-986&author=N.+Kindonauthor=G.+Andrewsauthor=A.+Baxterauthor=D.+Cheshireauthor=P.+Hemsleyauthor=T.+Johnsonauthor=Y.+Z.+Liuauthor=D.+McGinnityauthor=M.+McHaleauthor=A.+Meteauthor=J.+Reubersonauthor=B.+Robertsauthor=J.+Steeleauthor=B.+Teobaldauthor=J.+Unittauthor=D.+Vaughanauthor=I.+Waltersauthor=M.+Stocks&title=Discovery+of+AZD-2098+and+AZD-1678%2C+two+potent+and+bioavailable+CCR4+receptor+antagonists&doi=10.1021%2Facsmedchemlett.7b00315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists</span></div><div class="casAuthors">Kindon, Nicholas; Andrews, Glen; Baxter, Andrew; Cheshire, David; Hemsley, Paul; Johnson, Timothy; Liu, Yu-Zhen; McGinnity, Dermot; McHale, Mark; Mete, Antonio; Reuberson, James; Roberts, Bryan; Steele, John; Teobald, Barry; Unitt, John; Vaughan, Deborah; Walters, Iain; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">981-986</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 receptor antagonist high-throughput screen (HTS) of a subset of the AstraZeneca compd. bank.  As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antagonist candidate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolEsVkipAX2LVg90H21EOLACvtfcHk0lixDg78lktQ8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7vI&md5=8ede7ef766e88de9191b0df8ec7938a4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00315%26sid%3Dliteratum%253Aachs%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DBaxter%26aufirst%3DA.%26aulast%3DCheshire%26aufirst%3DD.%26aulast%3DHemsley%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%2BZ.%26aulast%3DMcGinnity%26aufirst%3DD.%26aulast%3DMcHale%26aufirst%3DM.%26aulast%3DMete%26aufirst%3DA.%26aulast%3DReuberson%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSteele%26aufirst%3DJ.%26aulast%3DTeobald%26aufirst%3DB.%26aulast%3DUnitt%26aufirst%3DJ.%26aulast%3DVaughan%26aufirst%3DD.%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DStocks%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520AZD-2098%2520and%2520AZD-1678%252C%2520two%2520potent%2520and%2520bioavailable%2520CCR4%2520receptor%2520antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D981%26epage%3D986%26doi%3D10.1021%2Facsmedchemlett.7b00315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habashita, H.</span>; <span class="NLM_string-name">Kokubo, M.</span>; <span class="NLM_string-name">Shibayama, S.</span>; <span class="NLM_string-name">Tada, H.</span>; <span class="NLM_string-name">Sagawa, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazine and Quinoxaline Derivatives as Chemokine Receptor CCR4 Antagonists and Medicinal Use Thereof</span>. <span class="NLM_patent">W02004007472</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=H.+Habashita&author=M.+Kokubo&author=S.+Shibayama&author=H.+Tada&author=K.+Sagawa&title=Preparation+of+Pyrazine+and+Quinoxaline+Derivatives+as+Chemokine+Receptor+CCR4+Antagonists+and+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHabashita%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520Pyrazine%2520and%2520Quinoxaline%2520Derivatives%2520as%2520Chemokine%2520Receptor%2520CCR4%2520Antagonists%2520and%2520Medicinal%2520Use%2520Thereof%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Procopiou, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumeaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, Y. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morriss, K. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Needham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sollis, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staton, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of indazole arylsulfonamides as allosteric CC-ahemokine receptor 4 (CCR4) antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1960</span>, <span class="refDoi"> DOI: 10.1021/jm301572h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301572h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisF2js7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1946-1960&author=P.+A.+Procopiouauthor=J.+W.+Barrettauthor=N.+P.+Bartonauthor=M.+Beggauthor=D.+Claphamauthor=R.+C.+B.+Copleyauthor=A.+J.+Fordauthor=R.+H.+Gravesauthor=D.+A.+Hallauthor=A.+P.+Hancockauthor=A.+P.+Hillauthor=H.+Hobbsauthor=S.+T.+Hodgsonauthor=C.+Jumeauxauthor=Y.+M.+L.+Lacroixauthor=A.+H.+Miahauthor=K.+M.+L.+Morrissauthor=D.+Needhamauthor=E.+B.+Sheriffauthor=R.+J.+Slackauthor=C.+E.+Smithauthor=S.+L.+Sollisauthor=H.+Staton&title=Synthesis+and+structure%E2%80%93activity+relationships+of+indazole+arylsulfonamides+as+allosteric+CC-ahemokine+receptor+4+%28CCR4%29+antagonists&doi=10.1021%2Fjm301572h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists</span></div><div class="casAuthors">Procopiou, Panayiotis A.; Barrett, John W.; Barton, Nicholas P.; Begg, Malcolm; Clapham, David; Copley, Royston C. B.; Ford, Alison J.; Graves, Rebecca H.; Hall, David A.; Hancock, Ashley P.; Hill, Alan P.; Hobbs, Heather; Hodgson, Simon T.; Jumeaux, Coline; Lacroix, Yannick M. L.; Miah, Afjal H.; Morriss, Karen M. L.; Needham, Deborah; Sheriff, Emma B.; Slack, Robert J.; Smith, Claire E.; Sollis, Steven L.; Staton, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of indazole arylsulfonamides were synthesized and examd. as human CCR4 antagonists.  Methoxy- or hydroxyl- contg. groups were the more potent indazole C4 substituents.  Only small groups were tolerated at C5, C6, or C7, with the C6 analogs being preferred.  The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide.  N1 meta-substituted benzyl groups possessing an α-amino-3-[(methylamino)acyl]- group were the most potent N1-substituents.  Strongly basic amino groups had low oral absorption in vivo.  Less basic analogs, such as morpholines, had good oral absorption; however, they also had high clearance.  The most potent compd. with high absorption in two species was analog I (GSK2239633A), which was selected for further development.  Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II.  X-ray diffraction studies on two indazole sulfonamide fragments suggested the presence of an important intramol. interaction in the active conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGy9j0UZnY77Vg90H21EOLACvtfcHk0lj_170yll2EqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisF2js7k%253D&md5=db6f996af7b0498c9c0196da94005bc2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm301572h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301572h%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DJ.%2BW.%26aulast%3DBarton%26aufirst%3DN.%2BP.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DClapham%26aufirst%3DD.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGraves%26aufirst%3DR.%2BH.%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DHancock%26aufirst%3DA.%2BP.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DHobbs%26aufirst%3DH.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DJumeaux%26aufirst%3DC.%26aulast%3DLacroix%26aufirst%3DY.%2BM.%2BL.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DMorriss%26aufirst%3DK.%2BM.%2BL.%26aulast%3DNeedham%26aufirst%3DD.%26aulast%3DSheriff%26aufirst%3DE.%2BB.%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26aulast%3DSollis%26aufirst%3DS.%2BL.%26aulast%3DStaton%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520indazole%2520arylsulfonamides%2520as%2520allosteric%2520CC-ahemokine%2520receptor%25204%2520%2528CCR4%2529%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1946%26epage%3D1960%26doi%3D10.1021%2Fjm301572h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerahee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Marle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomized study</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1186/2050-6511-14-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1186%2F2050-6511-14-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23289757" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1-11&author=A.+Cahnauthor=S.+Hodgsonauthor=R.+Wilsonauthor=J.+Robertsonauthor=J.+Watsonauthor=M.+Beeraheeauthor=S.+C.+Hughesauthor=G.+Youngauthor=R.+Gravesauthor=D.+Hallauthor=S.+van+Marleauthor=R.+Solari&title=Safety%2C+tolerability%2C+pharmacokinetics+and+pharmacodynamics+of+GSK2239633%2C+a+CC-chemokine+receptor+4+antagonist%2C+in+healthy+male+subjects%3A+results+from+an+open-label+and+from+a+randomized+study&doi=10.1186%2F2050-6511-14-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2F2050-6511-14-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2050-6511-14-14%26sid%3Dliteratum%253Aachs%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DJ.%26aulast%3DBeerahee%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DS.%2BC.%26aulast%3DYoung%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DD.%26aulast%3Dvan%2BMarle%26aufirst%3DS.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DSafety%252C%2520tolerability%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520GSK2239633%252C%2520a%2520CC-chemokine%2520receptor%25204%2520antagonist%252C%2520in%2520healthy%2520male%2520subjects%253A%2520results%2520from%2520an%2520open-label%2520and%2520from%2520a%2520randomized%2520study%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D14%26spage%3D1%26epage%3D11%26doi%3D10.1186%2F2050-6511-14-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P.</span></span> <span> </span><span class="NLM_article-title">Small molecule immuno-oncology therapeutic agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.12.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.bmcl.2017.12.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=29326017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlKltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=319-329&author=P.+Toogood&title=Small+molecule+immuno-oncology+therapeutic+agents&doi=10.1016%2Fj.bmcl.2017.12.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule immuno-oncology therapeutic agents</span></div><div class="casAuthors">Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Treatment of cancer by activation of an antitumor immune response is now a widely practiced and well-accepted approach to therapy.  However, despite dramatic responses in some patients, the high proportion of unresponsive patients points to a considerable unmet medical need.  Although antibody therapies have led the way, small mol. immuno-oncol. agents are close behind.  This perspective provides an overview of some of the many small mol. approaches being explored.  It encompasses small mol. modulators of validated targets such as programed cell death 1 (PD-1) as well as novel approaches still to be proven clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqabNsLZRrBPbVg90H21EOLACvtfcHk0lj_170yll2EqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlKltQ%253D%253D&md5=2457f116552bf50e7134fea28d914524</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.12.044%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%26atitle%3DSmall%2520molecule%2520immuno-oncology%2520therapeutic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D319%26epage%3D329%26doi%3D10.1016%2Fj.bmcl.2017.12.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span> </span><span class="NLM_article-title">FDA approves treatment for two rare types of non-Hodgkin
lymphoma</span>; <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm</a> (accessed Nov 16, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+approves+treatment+for+two+rare+types+of+non-Hodgkin%0Alymphoma%3B+https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm616176.htm+%28accessed+Nov+16%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520approves%2520treatment%2520for%2520two%2520rare%2520types%2520of%2520non-Hodgkin%250Alymphoma%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1111/cas.12116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1111%2Fcas.12116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23360455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVCjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=647-650&author=T.+Ishidaauthor=A.+Itoauthor=F.+Satoauthor=S.+Kusumotoauthor=S.+Iidaauthor=H.+Inagakiauthor=A.+Moritaauthor=S.+Akinagaauthor=R.+Ueda&title=Stevens-Johnson+Syndrome+associated+with+mogamulizumab+treatment+of+adult+T-cell+leukemia%2Flymphoma&doi=10.1111%2Fcas.12116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma</span></div><div class="casAuthors">Ishida, Takashi; Ito, Asahi; Sato, Fumihiko; Kusumoto, Shigeru; Iida, Shinsuke; Inagaki, Hiroshi; Morita, Akimichi; Akinaga, Shiro; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">647-650</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We report an adult T-cell leukemia/lymphoma patient suffering from Stevens-Johnson Syndrome (SJS) during mogamulizumab (humanized anti-CCR4 monoclonal antibody) treatment.  There was a durable significant redn. of the CD4+CD25highFOXP3+ regulatory T (Treg) cell subset in the patient's PBMC, and the affected inflamed skin almost completely lacked FOXP3-pos. cells.  This implies an assocn. between redn. of the Treg subset by mogamulizimab and occurrence of SJS.  The present case should contribute not only to our understanding of human pathol. resulting from therapeutic depletion of Treg cells, but also alert us to the possibility of immune-related severe adverse events such as SJS when using mogamulizumab.  We are currently conducting a clin. trial of mogamulizumab for CCR4-neg. solid cancers (UMIN000010050), specifically aiming to deplete Treg cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKZ1pzzErzKbVg90H21EOLACvtfcHk0liMKY0BRf1czg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVCjsrs%253D&md5=e2050c18ed4be88401547ddede792606</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fcas.12116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12116%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DF.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DStevens-Johnson%2520Syndrome%2520associated%2520with%2520mogamulizumab%2520treatment%2520of%2520adult%2520T-cell%2520leukemia%252Flymphoma%26jtitle%3DCancer%2520Sci.%26date%3D2013%26volume%3D104%26spage%3D647%26epage%3D650%26doi%3D10.1111%2Fcas.12116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyagawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, H.</span></span> <span> </span><span class="NLM_article-title">Predisposition to multi-drug hypersensitivity after administration of magamulizumab</span>. <i>Eur. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=29952299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FislKqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=526-528&author=F.+Miyagawaauthor=S.+Yamamotoauthor=M.+Miyaoauthor=M.+Nishikawaauthor=K.+Ogawaauthor=H.+Asada&title=Predisposition+to+multi-drug+hypersensitivity+after+administration+of+magamulizumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Predisposition to multi-drug hypersensitivity after administration of mogamulizumab</span></div><div class="casAuthors">Miyagawa Fumi; Yamamoto Shoko; Miyao Mariko; Nishikawa Mitsuko; Ogawa Kohei; Asada Hideo</div><div class="citationInfo"><span class="NLM_cas:title">European journal of dermatology : EJD</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">526-528</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8RtSxmMwNmBAiYWy6n3SfW6udTcc2ebuYWP75Hnp9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FislKqsA%253D%253D&md5=dd8145759d05a549b343a25dfc8f4872</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyagawa%26aufirst%3DF.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DMiyao%26aufirst%3DM.%26aulast%3DNishikawa%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DAsada%26aufirst%3DH.%26atitle%3DPredisposition%2520to%2520multi-drug%2520hypersensitivity%2520after%2520administration%2520of%2520magamulizumab%26jtitle%3DEur.%2520J.%2520Dermatol.%26date%3D2018%26volume%3D28%26spage%3D526%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saulite, I.</span>; <span class="NLM_string-name">Guenova, E.</span>; <span class="NLM_string-name">Hoetzenecker, W.</span></span> <span> </span><span class="NLM_article-title">Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximan, Bentuximab Vedotin, Alemtuzumab, and Mogamulizumab</span>. In  <i>Current Problems in Dermatology. Adverse Reactions of Biologics</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, L.</span>, <span class="NLM_string-name">Gulliver, W.</span></span>, Eds.; <span class="NLM_publisher-name">Karger</span>: <span class="NLM_publisher-loc">Basel</span>, <span class="NLM_year">2018</span>: Vol.  <span class="NLM_volume">53</span>, pp  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">81</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1159%2F000478079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=70-81&author=I.+Saulite&author=E.+Guenova&author=W.+Hoetzeneckerauthor=L.+Puig&author=W.+Gulliver&title=Current+Problems+in+Dermatology.+Adverse+Reactions+of+Biologics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1159%2F000478079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1159%252F000478079%26sid%3Dliteratum%253Aachs%26aulast%3DSaulite%26aufirst%3DI.%26atitle%3DAdverse%2520Reactions%2520of%2520Antibody-Therapy%2520for%2520Primary%2520Cutaneous%2520Lymphomas%253A%2520Rituximan%252C%2520Bentuximab%2520Vedotin%252C%2520Alemtuzumab%252C%2520and%2520Mogamulizumab%26btitle%3DCurrent%2520Problems%2520in%2520Dermatology.%2520Adverse%2520Reactions%2520of%2520Biologics%26aulast%3DPuig%26aufirst%3DL.%26pub%3DKarger%26date%3D2018%26volume%3D53%26spage%3D70%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span> <span> </span><span class="NLM_article-title">Tools for GPCR drug discovery</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1038/aps.2011.173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Faps.2011.173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=22266728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1elu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=372-384&author=R.+Zhangauthor=X.+Xie&title=Tools+for+GPCR+drug+discovery&doi=10.1038%2Faps.2011.173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Tools for GPCR drug discovery</span></div><div class="casAuthors">Zhang, Ru; Xie, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-384</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) mediate many important physiol. functions and are considered as one of the most successful therapeutic targets for a broad spectrum of diseases.  The design and implementation of high-throughput GPCR assays that allow the cost-effective screening of large compd. libraries to identify novel drug candidates are crit. in early drug discovery.  Early functional GPCR assays depend primarily on the measurement of G-protein-mediated 2nd messenger generation.  Taking advantage of the continuously deepening understanding of GPCR signal transduction, many G-protein-independent pathways are utilized to detect the activity of GPCRs, and may provide addnl. information on functional selectivity of candidate compds.  With the combination of automated imaging systems and label-free detection systems, such assays are now suitable for high-throughput screening (HTS).  In this review, we summarize the most widely used GPCR assays and recent advances in HTS technologies for GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8pC8anrKpWLVg90H21EOLACvtfcHk0liMKY0BRf1czg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1elu7Y%253D&md5=04ca4fed048dbca837d81c02566e6e25</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.173%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DTools%2520for%2520GPCR%2520drug%2520discovery%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D372%26epage%3D384%26doi%3D10.1038%2Faps.2011.173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proudfoot, A. E. I.</span>; <span class="NLM_string-name">Power, C. A.</span>; <span class="NLM_string-name">Church, D. J.</span>; <span class="NLM_string-name">Soler, D.</span>; <span class="NLM_string-name">Mack, M.</span></span> <span> </span><span class="NLM_article-title">Cellular assays of chemokine receptor activation</span>.  <i>Current Protocols in Pharmacology</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ, USA</span>, <span class="NLM_year">2001</span>; Vol.  <span class="NLM_volume">14</span>, pp  <span class="NLM_fpage">12.4.1</span>– <span class="NLM_lpage">12.4.26</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1002%2F0471141755.ph1204s14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=12.4.1-12.4.26&author=A.+E.+I.+Proudfoot&author=C.+A.+Power&author=D.+J.+Church&author=D.+Soler&author=M.+Mack&title=Current+Protocols+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2F0471141755.ph1204s14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471141755.ph1204s14%26sid%3Dliteratum%253Aachs%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%2BI.%26atitle%3DCellular%2520assays%2520of%2520chemokine%2520receptor%2520activation%26btitle%3DCurrent%2520Protocols%2520in%2520Pharmacology%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2001%26volume%3D14%26spage%3D12.4.1%26epage%3D12.4.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.</span>; <span class="NLM_string-name">Bui, M.</span>; <span class="NLM_string-name">Chian, D.</span>; <span class="NLM_string-name">Diokno, R.</span>; <span class="NLM_string-name">Hu, X. D.</span>; <span class="NLM_string-name">Jacobson, S.</span>; <span class="NLM_string-name">Karbarz, E.</span>; <span class="NLM_string-name">Kassner, P. D.</span>; <span class="NLM_string-name">Ketcham, J. M.</span>; <span class="NLM_string-name">Marshall, L.</span>; <span class="NLM_string-name">McKinnell, J.</span>; <span class="NLM_string-name">Meleza, C.</span>; <span class="NLM_string-name">Reilly, M. K.</span>; <span class="NLM_string-name">Robles, O.</span>; <span class="NLM_string-name">Shunatona, H. P.</span>; <span class="NLM_string-name">Talay, O.</span>; <span class="NLM_string-name">Walker, J. R.</span>; <span class="NLM_string-name">Wustrow, D. J.</span>; <span class="NLM_string-name">Zibinsky, M.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Beck%2C+H.%3B+Bui%2C+M.%3B+Chian%2C+D.%3B+Diokno%2C+R.%3B+Hu%2C+X.+D.%3B+Jacobson%2C+S.%3B+Karbarz%2C+E.%3B+Kassner%2C+P.+D.%3B+Ketcham%2C+J.+M.%3B+Marshall%2C+L.%3B+McKinnell%2C+J.%3B+Meleza%2C+C.%3B+Reilly%2C+M.+K.%3B+Robles%2C+O.%3B+Shunatona%2C+H.+P.%3B+Talay%2C+O.%3B+Walker%2C+J.+R.%3B+Wustrow%2C+D.+J.%3B+Zibinsky%2C+M.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DH." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosely, S.
I.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prime, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainson, R. C.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koopmann, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. Y.Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenawalt, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahdesmaki, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coates Ulrichsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohawn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCourt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valge-Archer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovedi, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. W.</span></span> <span> </span><span class="NLM_article-title">Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-16-0114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1158%2F2326-6066.CIR-16-0114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=27923825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=29-41&author=S.%0AI.S.+Moselyauthor=J.+E.+Primeauthor=R.+C.A.+Sainsonauthor=J.-O.+Koopmannauthor=D.+Y.Q.+Wangauthor=D.+M.+Greenawaltauthor=M.+J.+Ahdesmakiauthor=R.+Leylandauthor=S.+Mullinsauthor=L.+Pacelliauthor=D.+Marcusauthor=J.+Andertonauthor=A.+Watkinsauthor=J.+Coates+Ulrichsenauthor=P.+Brohawnauthor=B.+W.+Higgsauthor=M.+McCourtauthor=H.+Jonesauthor=J.+A.+Harperauthor=M.+Morrowauthor=V.+Valge-Archerauthor=R.+Stewartauthor=S.+J.+Dovediauthor=R.+W.+Wilkinson&title=Rational+selection+of+syngeneic+preclinical+tumor+models+for+immunotherapeutic+drug+discovery&doi=10.1158%2F2326-6066.CIR-16-0114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery</span></div><div class="casAuthors">Mosely, Suzanne I. S.; Prime, John E.; Sainson, Richard C. A.; Koopmann, Jens-Oliver; Wang, Dennis Y. Q.; Greenawalt, Danielle M.; Ahdesmaki, Miika J.; Leyland, Rebecca; Mullins, Stefanie; Pacelli, Luciano; Marcus, Danielle; Anderton, Judith; Watkins, Amanda; Coates Ulrichsen, Jane; Brohawn, Philip; Higgs, Brandon W.; McCourt, Matthew; Jones, Hazel; Harper, James A.; Morrow, Michelle; Valge-Archer, Viia; Stewart, Ross; Dovedi, Simon J.; Wilkinson, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-41</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Murine syngeneic tumor models are crit. to novel immuno-based therapy development, but the mol. and immunol. features of these models are still not clearly defined.  The translational relevance of differences between the models is not fully understood, impeding appropriate preclin. model selection for target validation, and ultimately hindering drug development.  Across a panel of commonly used murine syngeneic tumor models, we showed variable responsiveness to immunotherapies.  We used array comparative genomic hybridization, whole-exome sequencing, exon microarray anal., and flow cytometry to extensively characterize these models, which revealed striking differences that may underlie these contrasting response profiles.  We identified strong differential gene expression in immune-related pathways and changes in immune cell-specific genes that suggested differences in tumor immune infiltrates between models.  Further investigation using flow cytometry showed differences in both the compn. and magnitude of the tumor immune infiltrates, identifying models that harbor "inflamed" and "non-inflamed" tumor immune infiltrate phenotypes.  We also found that immunosuppressive cell types predominated in syngeneic mouse tumor models that did not respond to immune-checkpoint blockade, whereas cytotoxic effector immune cells were enriched in responsive models.  A cytotoxic cell-rich tumor immune infiltrate has been correlated with increased efficacy of immunotherapies in the clinic, and these differences could underlie the varying response profiles to immunotherapy between the syngeneic models.  This characterization highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of immunotherapies as well as combinations with targeted therapies in vivo.  Cancer Immunol Res; 5(1); 29-41. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdDtr1ROaQt7Vg90H21EOLACvtfcHk0lhm-5rcDaZ2Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WltA%253D%253D&md5=96ed6203e7f7275ffd5bd3dc58009c0c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-16-0114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-16-0114%26sid%3Dliteratum%253Aachs%26aulast%3DMosely%26aufirst%3DS.%2BI.S.%26aulast%3DPrime%26aufirst%3DJ.%2BE.%26aulast%3DSainson%26aufirst%3DR.%2BC.A.%26aulast%3DKoopmann%26aufirst%3DJ.-O.%26aulast%3DWang%26aufirst%3DD.%2BY.Q.%26aulast%3DGreenawalt%26aufirst%3DD.%2BM.%26aulast%3DAhdesmaki%26aufirst%3DM.%2BJ.%26aulast%3DLeyland%26aufirst%3DR.%26aulast%3DMullins%26aufirst%3DS.%26aulast%3DPacelli%26aufirst%3DL.%26aulast%3DMarcus%26aufirst%3DD.%26aulast%3DAnderton%26aufirst%3DJ.%26aulast%3DWatkins%26aufirst%3DA.%26aulast%3DCoates%2BUlrichsen%26aufirst%3DJ.%26aulast%3DBrohawn%26aufirst%3DP.%26aulast%3DHiggs%26aufirst%3DB.%2BW.%26aulast%3DMcCourt%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DHarper%26aufirst%3DJ.%2BA.%26aulast%3DMorrow%26aufirst%3DM.%26aulast%3DValge-Archer%26aufirst%3DV.%26aulast%3DStewart%26aufirst%3DR.%26aulast%3DDovedi%26aufirst%3DS.%2BJ.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26atitle%3DRational%2520selection%2520of%2520syngeneic%2520preclinical%2520tumor%2520models%2520for%2520immunotherapeutic%2520drug%2520discovery%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2017%26volume%3D5%26spage%3D29%26epage%3D41%26doi%3D10.1158%2F2326-6066.CIR-16-0114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominitzki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neurath, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span> <span> </span><span class="NLM_article-title">In vitro generation of CD4+CD25+ regulatory cells from murin naive T cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1794</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Fnprot.2007.258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=17641646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1789-1794&author=M.+C.+Fantiniauthor=S.+Dominitzkiauthor=A.+Rizzoauthor=M.+F.+Neurathauthor=C.+Becker&title=In+vitro+generation+of+CD4%2BCD25%2B+regulatory+cells+from+murin+naive+T+cells&doi=10.1038%2Fnprot.2007.258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro generation of CD4+CD25+ regulatory cells from murine naive T cells</span></div><div class="casAuthors">Fantini, Massimo C.; Dominitzki, Sabine; Rizzo, Angelo; Neurath, Markus F.; Becker, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1789-1794</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CD4+CD25+ regulatory T cells (Tregs) are crucial for the maintenance of immunol. tolerance.  Recent data indicate that Tregs not only develop in the thymus during ontogeny but can also differentiate from naive T cells in the periphery.  The following protocol describes a method by which Tregs are generated in vitro by stimulation of naive T cells in the presence of transforming growth factor β (Ti-Tregs).  In vitro-induced regulatory T cells express markers of conventional Treg such as CD25 and the genetic program committing transcription factor FoxP3.  Functionally the in vitro-generated Ti-Tregs suppress T-cell activation and proliferation while in vivo these cells have been proven to control inflammation in different animal models, suggesting a potential use of these cells for immunotherapy.  The protocol can be completed within 5 days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3F3KjV9Klt7Vg90H21EOLACvtfcHk0lhm-5rcDaZ2Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahur7F&md5=98e484cedf0f4ee16dddf269040c2550</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.258%26sid%3Dliteratum%253Aachs%26aulast%3DFantini%26aufirst%3DM.%2BC.%26aulast%3DDominitzki%26aufirst%3DS.%26aulast%3DRizzo%26aufirst%3DA.%26aulast%3DNeurath%26aufirst%3DM.%2BF.%26aulast%3DBecker%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520generation%2520of%2520CD4%252BCD25%252B%2520regulatory%2520cells%2520from%2520murin%2520naive%2520T%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D1789%26epage%3D1794%26doi%3D10.1038%2Fnprot.2007.258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. B.</span></span> <span> </span><span class="NLM_article-title">Generation and function of induced regulatory T cells</span>. <i>Front Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2013.00152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.3389%2Ffimmu.2013.00152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23355837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eisLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1-13&author=E.+G.+Schmittauthor=C.+B.+Williams&title=Generation+and+function+of+induced+regulatory+T+cells&doi=10.3389%2Ffimmu.2013.00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and function of induced regulatoryT cells</span></div><div class="casAuthors">Schmitt, Erica G.; Williams, Calvin B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">CD4+ CD25+ Foxp3+ regulatory T (Treg) cells are essential to the balance between proand anti-inflammatory responses.There are two major subsets ofTreg cells, "natural" Treg (nTreg) cells that develop in the thymus, and "induced" Treg (iTreg) cells that arise in the periphery from CD4+ Foxp3- conventional T cells and can be generated in vitro.  Previous work has established that both subsets are required for immunol. tolerance.  Addnl., in vitro-derived iTreg cells can reestablish tolerance in situations where Treg cells are decreased or defective.  This review will focus on iTreg cells, drawing comparisons to nTreg cells when possible.We discuss the mol. mechanisms of iTreg cell induction, both in vivo and in vitro, reviewthe Foxp3-dependent and -independent transcriptional landscape of iTreg cells, and examine the proposed suppressive mechanisms utilized by each Treg cell subset.  We also compare the T cell receptor repertoire of the Treg cell subsets, discuss inflammatory conditions where iTreg cells are generated or have been used for treatment, and address the issue of iTreg cell stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYYLe4jXKCMLVg90H21EOLACvtfcHk0lhm-5rcDaZ2Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eisLrJ&md5=ad1cc139b8da8608b7cf6bd413cace1a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2013.00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2013.00152%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DE.%2BG.%26aulast%3DWilliams%26aufirst%3DC.%2BB.%26atitle%3DGeneration%2520and%2520function%2520of%2520induced%2520regulatory%2520T%2520cells%26jtitle%3DFront%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D1%26epage%3D13%26doi%3D10.3389%2Ffimmu.2013.00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="note"><p class="first last">More detailed studies on the biology of CCR4 antagonism in the context of various immune cells and antitumor activity will be published in another manuscript.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schall, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proudfoot, A. E. I.</span></span> <span> </span><span class="NLM_article-title">Overcoming hurdles in developing successful drugs targeting chemokine receptors</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1038/nri2972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Fnri2972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=21494268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=355-363&author=T.+J.+Schallauthor=A.+E.+I.+Proudfoot&title=Overcoming+hurdles+in+developing+successful+drugs+targeting+chemokine+receptors&doi=10.1038%2Fnri2972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming hurdles in developing successful drugs targeting chemokine receptors</span></div><div class="casAuthors">Schall, Thomas J.; Proudfoot, Amanda E. I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-363</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemokines and their receptors are central to the inflammatory process and are attractive therapeutic targets.  Drugs that inhibit chemokine receptors are approved for the treatment of HIV infection and for stem cell mobilization, but none have been approved yet for the treatment of inflammatory and/or autoimmune diseases.  We analyze the challenges of developing chemokine receptor antagonists, and propose that inappropriate target selection and ineffective dosing, not the 'redundancy' of the chemokine system, are the main barriers to their use as anti-inflammatory therapies.  We highlight evidence suggesting that chemokine receptor inhibition will prove to be an effective therapy in inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJxZhyoAteTLVg90H21EOLACvtfcHk0liZnnz3l8W7Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCmtb0%253D&md5=3173fc889bd22b7d7e19bd138a599897</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnri2972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2972%26sid%3Dliteratum%253Aachs%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%2BI.%26atitle%3DOvercoming%2520hurdles%2520in%2520developing%2520successful%2520drugs%2520targeting%2520chemokine%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2011%26volume%3D11%26spage%3D355%26epage%3D363%26doi%3D10.1038%2Fnri2972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hersperger, R.</span>; <span class="NLM_string-name">Janser, P.</span>; <span class="NLM_string-name">Pfenninger, E.</span>; <span class="NLM_string-name">Wuethrich, H. J.</span>; <span class="NLM_string-name">Miltz, W.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1H-indole-2-carboxylic acid N-(piperidin-4-yl)amides and related derivatives as chemokine receptor, particularly CCR2 and CCR5 antagonists</span>. <span class="NLM_patent">WO2005077932</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=R.+Hersperger&author=P.+Janser&author=E.+Pfenninger&author=H.+J.+Wuethrich&author=W.+Miltz&title=Preparation+of+1H-indole-2-carboxylic+acid+N-%28piperidin-4-yl%29amides+and+related+derivatives+as+chemokine+receptor%2C+particularly+CCR2+and+CCR5+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHersperger%26aufirst%3DR.%26atitle%3DPreparation%2520of%25201H-indole-2-carboxylic%2520acid%2520N-%2528piperidin-4-yl%2529amides%2520and%2520related%2520derivatives%2520as%2520chemokine%2520receptor%252C%2520particularly%2520CCR2%2520and%2520CCR5%2520antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. K.</span></span> <span> </span><span class="NLM_article-title">A radical mediated approach to the stereoselective formal total synthesis of (+)-Sch 642305</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">6925</span>– <span class="NLM_lpage">6931</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2009.06.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.tet.2009.06.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptVGgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=6925-6931&author=T.+K.+Chakrabortyauthor=R.+Samantaauthor=P.+K.+Kumar&title=A+radical+mediated+approach+to+the+stereoselective+formal+total+synthesis+of+%28%2B%29-Sch+642305&doi=10.1016%2Fj.tet.2009.06.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A radical mediated approach to the stereoselective formal total synthesis of (+)-Sch 642305</span></div><div class="casAuthors">Chakraborty, Tushar Kanti; Samanta, Rajarshi; Kumar, Pulukuri Kiran</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">6925-6931</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A formal total synthesis of (+)-Sch-642305 is described.  The synthesis, which commenced from a simple chiral synthon (5S)-5-(hydroxymethyl)dihydrofuran-2(3H)-one, employed, as a key step, a radical mediated opening of a chiral epoxy alc. intermediate (I) with Cp2Ti(III)Cl following an efficient method developed by us earlier.  The resultant intermediate radical was intramolecularly trapped by the electron deficient double bond present in the mol. to give rise to its highly functionalized six-membered carbocyclic ring in stereoselective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUdTnTeQufrVg90H21EOLACvtfcHk0liZnnz3l8W7Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptVGgtr4%253D&md5=516b98b8777990cdb13f3823489e582e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2009.06.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2009.06.059%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DT.%2BK.%26aulast%3DSamanta%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DP.%2BK.%26atitle%3DA%2520radical%2520mediated%2520approach%2520to%2520the%2520stereoselective%2520formal%2520total%2520synthesis%2520of%2520%2528%252B%2529-Sch%2520642305%26jtitle%3DTetrahedron%26date%3D2009%26volume%3D65%26spage%3D6925%26epage%3D6931%26doi%3D10.1016%2Fj.tet.2009.06.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':[],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Omar Robles, Jeffrey J. Jackson, Lisa Marshall, Oezcan Talay, David Chian, Gene Cutler, Raymond Diokno, Dennis X. Hu, Scott Jacobson, Emily Karbarz, Paul D. Kassner, John M. Ketcham, Jenny McKinnell, Cesar Meleza, Maureen K. Reilly, Erin Riegler, Hunter P. Shunatona, Angela Wadsworth, Ashkaan Younai, Dirk G. Brockstedt, David J. Wustrow, <span class="NLM_string-name hlFld-ContribAuthor">Mikhail Zibinsky</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8584-8607. <a href="https://doi.org/10.1021/acs.jmedchem.0c00988" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00988</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00988%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BPiperidinyl-Azetidines%252Bas%252BPotent%252Band%252BSelective%252BCCR4%252BAntagonists%252BElicit%252BAntitumor%252BResponse%252Bas%252Ba%252BSingle%252BAgent%252Band%252Bin%252BCombination%252Bwith%252BCheckpoint%252BInhibitors%26aulast%3DRobles%26aufirst%3DOmar%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09062020%26date%3D28072020%26date%3D15072020%26volume%3D63%26issue%3D15%26spage%3D8584%26epage%3D8607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">Veronika  Molitorová</span>, <span class="hlFld-ContribAuthor ">Eliška  Pilařová</span>, <span class="hlFld-ContribAuthor ">Veronika  Vojáčková</span>, <span class="hlFld-ContribAuthor ">Eva  Řezníčková</span>, <span class="hlFld-ContribAuthor ">Klára  Svobodová</span>, <span class="hlFld-ContribAuthor ">Karel  Pauk</span>, <span class="hlFld-ContribAuthor ">Aleš  Imramovský</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">Pseudopeptides with aldehyde or vinylsulfone warheads: synthesis and antiproteasomal activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>3 </em>, 105228. <a href="https://doi.org/10.1016/j.bioorg.2021.105228" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105228%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPseudopeptides%252Bwith%252Baldehyde%252Bor%252Bvinylsulfone%252Bwarheads%25253A%252Bsynthesis%252Band%252Bantiproteasomal%252Bactivity%26aulast%3DJorda%26aufirst%3DRadek%26date%3D2021%26volume%3D3%26spage%3D105228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justine  Cinier</span>, <span class="hlFld-ContribAuthor ">Margaux  Hubert</span>, <span class="hlFld-ContribAuthor ">Laurie  Besson</span>, <span class="hlFld-ContribAuthor ">Anthony  Di Roio</span>, <span class="hlFld-ContribAuthor ">Céline  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Vincent  Lombardi</span>, <span class="hlFld-ContribAuthor ">Christophe  Caux</span>, <span class="hlFld-ContribAuthor ">Christine  Ménétrier-Caux</span>. </span><span class="cited-content_cbyCitation_article-title">Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (8)
                                     , 1850. <a href="https://doi.org/10.3390/cancers13081850" title="DOI URL">https://doi.org/10.3390/cancers13081850</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13081850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13081850%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DRecruitment%252Band%252BExpansion%252Bof%252BTregs%252BCells%252Bin%252Bthe%252BTumor%252BEnvironment%2525E2%252580%252594How%252Bto%252BTarget%252BThem%25253F%26aulast%3DCinier%26aufirst%3DJustine%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D8%26spage%3D1850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. Alison  Rinderspacher</span>. </span><span class="cited-content_cbyCitation_article-title">Six-membered ring systems: diazines and benzo derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 431-466. <a href="https://doi.org/10.1016/B978-0-323-89812-6.00013-4" title="DOI URL">https://doi.org/10.1016/B978-0-323-89812-6.00013-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-323-89812-6.00013-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-323-89812-6.00013-4%26sid%3Dliteratum%253Aachs%26atitle%3DSix-membered%252Bring%252Bsystems%25253A%252Bdiazines%252Band%252Bbenzo%252Bderivatives%26aulast%3DRinderspacher%26aufirst%3DK.%2BAlison%26date%3D2021%26spage%3D431%26epage%3D466%26pub%3DElsevier%26date%3D2021%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunxiao  Li</span>, <span class="hlFld-ContribAuthor ">Ping  Jiang</span>, <span class="hlFld-ContribAuthor ">Shuhua  Wei</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Xu</span>, <span class="hlFld-ContribAuthor ">Junjie  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2020,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-020-01234-1" title="DOI URL">https://doi.org/10.1186/s12943-020-01234-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-020-01234-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-020-01234-1%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DRegulatory%252BT%252Bcells%252Bin%252Btumor%252Bmicroenvironment%25253A%252Bnew%252Bmechanisms%25252C%252Bpotential%252Btherapeutic%252Bstrategies%252Band%252Bfuture%252Bprospects%26aulast%3DLi%26aufirst%3DChunxiao%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan  Korbecki</span>, <span class="hlFld-ContribAuthor ">Klaudyna  Kojder</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Barczak</span>, <span class="hlFld-ContribAuthor ">Donata  Simińska</span>, <span class="hlFld-ContribAuthor ">Izabela  Gutowska</span>, <span class="hlFld-ContribAuthor ">Dariusz  Chlubek</span>, <span class="hlFld-ContribAuthor ">Irena  Baranowska-Bosiacka</span>. </span><span class="cited-content_cbyCitation_article-title">Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor–A Literature Review. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (16)
                                     , 5647. <a href="https://doi.org/10.3390/ijms21165647" title="DOI URL">https://doi.org/10.3390/ijms21165647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21165647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21165647%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DHypoxia%252BAlters%252Bthe%252BExpression%252Bof%252BCC%252BChemokines%252Band%252BCC%252BChemokine%252BReceptors%252Bin%252Ba%252BTumor%2525E2%252580%252593A%252BLiterature%252BReview%26aulast%3DKorbecki%26aufirst%3DJan%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D16%26spage%3D5647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natascha  Röhrle</span>, <span class="hlFld-ContribAuthor ">Max M. L.  Knott</span>, <span class="hlFld-ContribAuthor ">David  Anz</span>. </span><span class="cited-content_cbyCitation_article-title">CCL22 Signaling in the Tumor Environment. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 79-96. <a href="https://doi.org/10.1007/978-3-030-36667-4_8" title="DOI URL">https://doi.org/10.1007/978-3-030-36667-4_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-36667-4_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-36667-4_8%26sid%3Dliteratum%253Aachs%26atitle%3DCCL22%252BSignaling%252Bin%252Bthe%252BTumor%252BEnvironment%26aulast%3DR%25C3%25B6hrle%26aufirst%3DNatascha%26date%3D2020%26date%3D2020%26spage%3D79%26epage%3D96%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DTumor%252BMicroenvironment%26aulast%3DBirbrair%26aufirst%3DAlexander%26date%3D2020%26volume%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongxin  Han</span>, <span class="hlFld-ContribAuthor ">Li  Zhu</span>, <span class="hlFld-ContribAuthor ">Wei  Wu</span>, <span class="hlFld-ContribAuthor ">Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Hu</span>, <span class="hlFld-ContribAuthor ">Liguang  Dai</span>, <span class="hlFld-ContribAuthor ">Yanqing  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecular Immune Modulators as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 547-618. <a href="https://doi.org/10.1007/978-981-15-3266-5_22" title="DOI URL">https://doi.org/10.1007/978-981-15-3266-5_22</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-15-3266-5_22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-15-3266-5_22%26sid%3Dliteratum%253Aachs%26atitle%3DSmall%252BMolecular%252BImmune%252BModulators%252Bas%252BAnticancer%252BAgents%26aulast%3DHan%26aufirst%3DYongxin%26date%3D2020%26date%3D2020%26spage%3D547%26epage%3D618%26pub%3DSpringer%2520Singapore%26atitle%3DRegulation%252Bof%252BCancer%252BImmune%252BCheckpoints%26aulast%3DXu%26aufirst%3DJie%26date%3D2020%26volume%3D1248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative CCR4 Antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pharmacophore map of Class I CCR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Discovery of a pyrazolopyrazine core and 3′-methyl-1,4′-bipiperidine side chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stereochemical analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Treatment with compound <b>31</b> selectively reduces T<sub>reg</sub> trafficking into the tumor. (A) Schematic outline of treatment and tumor model that is used in this study. (B) Number of GFP<sup>+</sup> T<sub>reg</sub> in tumor (left) and spleen (right). Plasma concentration of compound <b>31</b> is measured 24 h after last treatment (bottom). For statistical analysis,  one-way ANOVA was used.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Compounds <b>8</b> and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate, 1 M Na<sub>2</sub>CO<sub>3</sub> (aq.), Pd(dppf)Cl<sub>2</sub>, THF, 80–100 °C; (b) 4 N HCl (in dioxane), MeOH, rt; (c) HATU, DIPEA, DMF, rt; (d) 4 N HCl (in dioxane), MeOH, rt.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0007.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) THF, 80 °C; (b) NaH, THF, 0 °C to rt, 50% yield over two steps; (c) NH<sub>4</sub>OH (29% in water), dioxane, rt, 95% yield; (d) Burgess reagent, CH<sub>2</sub>Cl<sub>2</sub>, rt, 88%; (e) Na(OAc)<sub>3</sub>BH, AcOH, 1,2-DCE, rt; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40% over two steps (g) DIPEA, DMF, 100 °C, 10%.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0008.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Cyclohexenyl CCR4 Antagonist <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MeLi, CuCN, TMSCl, Et<sub>2</sub>O:THF, −40 °C; (b) LDA, then PhNTf<sub>2</sub>, THF, −78 °C, 53% over two steps; (c) Bpin<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>, KOAc, KBr, dioxane, 95 °C; (d) Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, THF:H<sub>2</sub>O, 90 °C; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) NaBH<sub>3</sub>CN, AcOH, 1,2-DCE, rt.</p></p></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/medium/jm-2019-00506m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0009.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Second-Generation Synthesis of Cyclohexenyl CCR4 Antagonist <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00506/20190705/images/large/jm-2019-00506m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00506&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzene, 95 °C, quant. yield; (b) NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>:AcOH (10:1), rt, 65%; (c) Pd(OH)<sub>2</sub>, H<sub>2</sub>, MeOH, rt, 97%; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 98%; (e) TsOH, THF:H<sub>2</sub>O, rt, 70%; (f) LiHMDS, PhNTf<sub>2</sub>, THF, −78 °C, 97%; (g) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene:EtOH:H<sub>2</sub>O, 90 °C, 76%; (h) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, rt, quant. yield; (i) DIPEA, MeCN, rt, 75%; (j) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, rt, 82%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i90">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26073" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26073" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">CCR4 as a novel molecular target for immunotherapy of cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2006.00307.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1111%2Fj.1349-7006.2006.00307.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=16952304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFemtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=1139-1146&author=T.+Ishidaauthor=R.+Ueda&title=CCR4+as+a+novel+molecular+target+for+immunotherapy+of+cancer&doi=10.1111%2Fj.1349-7006.2006.00307.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">CCR4 as a novel molecular target for immunotherapy of cancer</span></div><div class="casAuthors">Ishida, Takashi; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1139-1146</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukocyte trafficking, which is critically regulated by chemokines and their receptors, shares many of the characteristics of tumor cell infiltration and metastasis.  Expression of CC chemokine receptor 4 (CCR4) by tumor cells is assocd. with skin involvement, but CCR4 also has an important role in normal and tumor immunity.  In a subset of patients with CCR4+ T-cell leukemia/lymphoma, the tumor cells themselves function as regulatory T (Treg) cells, contributing to tumor survival in the face of host antitumor immune responses.  In other types of cancers, the chemokines TARC/CCL17 and MDC/CCL22, specific ligands for CCR4 that are produced by tumor cells and the tumor microenvironment, attract CCR4+ Treg cells to the tumor, where they create a favorable environment for tumor escape from host immune responses.  A novel humanized anti-CCR4 monoclonal antibody (mAb) has been developed, the Fc region of which is defucosylated to enhance antibody-dependent cellular cytotoxicity by increasing its binding affinity to Fc receptor on effector cells.  We are now conducting a phase I clin. trial of this anti-CCR4 mAb in patients with CCR4+ T-cell leukemia/lymphoma in Japan (clin. trials gov. identifier: NCT00355472).  Anti-CCR4 mAb could be an ideal treatment modality for many different cancers, not only to directly kill the CCR4+ tumor cells, but also to overcome the suppressive effect of CCR4+ Treg cells on the host immune response to tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSaM9sSn_TJbVg90H21EOLACvtfcHk0ljkgL-sGczDBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFemtbjJ&md5=1ae7461548ceb9b10873b891551e4d9e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2006.00307.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2006.00307.x%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DCCR4%2520as%2520a%2520novel%2520molecular%2520target%2520for%2520immunotherapy%2520of%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2006%26volume%3D97%26spage%3D1139%26epage%3D1146%26doi%3D10.1111%2Fj.1349-7006.2006.00307.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanemura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, S.</span></span> <span> </span><span class="NLM_article-title">Anti-CCR4 mAb selectively depletes effector-type FoxP3<sup>+</sup>CD4<sup>+</sup> regulatory T cells, evoking antitumor immune responses in humans</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">17945</span>– <span class="NLM_lpage">17950</span>, <span class="refDoi"> DOI: 10.1073/pnas.1316796110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1073%2Fpnas.1316796110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=24127572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=17945-17950&author=D.+Sugiyamaauthor=H.+Nishikawaauthor=Y.+Maedaauthor=M.+Nishiokaauthor=A.+Tanemuraauthor=I.+Katayamaauthor=S.+Ezoeauthor=Y.+Kanakuraauthor=E.+Satoauthor=Y.+Fukumoriauthor=J.+Karbachauthor=E.+J%C3%A4gerauthor=S.+Sakaguchi&title=Anti-CCR4+mAb+selectively+depletes+effector-type+FoxP3%2BCD4%2B+regulatory+T+cells%2C+evoking+antitumor+immune+responses+in+humans&doi=10.1073%2Fpnas.1316796110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans</span></div><div class="casAuthors">Sugiyama, Daisuke; Nishikawa, Hiroyoshi; Maeda, Yuka; Nishioka, Megumi; Tanemura, Atsushi; Katayama, Ichiro; Ezoe, Sachiko; Kanakura, Yuzuru; Sato, Eiichi; Fukumori, Yasuo; Karbach, Julia; Jager, Elke; Sakaguchi, Shimon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17945-17950,S17945/1-S17945/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">CD4+ Treg cells expressing the transcription factor FOXP3 (forkhead box P3) are abundant in tumor tissues and appear to hinder the induction of effective antitumor immunity.  A substantial no. of T cells, including Treg cells, in tumor tissues and peripheral blood express C-C chemokine receptor 4 (CCR4).  Here we show that CCR4 was specifically expressed by a subset of terminally differentiated and most suppressive CD45RA-FOXP3hiCD4+ Treg cells [designated effector Treg (eTreg) cells], but not by CD45RA+FOXP3loCD4+ naive Treg cells, in peripheral blood of healthy individuals and cancer patients.  In melanoma tissues, CCR4+ eTreg cells were predominant among tumor-infiltrating FOXP3+ T cells and much higher in frequency compared with those in peripheral blood.  With peripheral blood lymphocytes from healthy individuals and melanoma patients, ex vivo depletion of CCR4+ T cells and subsequent in vitro stimulation of the depleted cell population with the cancer/testis antigen NY-ESO-1 efficiently induced NY-ESO-1-specific CD4+ T cells.  Nondepletion failed in the induction.  The magnitude of the responses was comparable with total removal of FOXP3+ Treg cells by CD25+ T-cell depletion.  CCR4+ T-cell depletion also augmented in vitro induction of NY-ESO-1-specific CD8+ T cells in melanoma patients.  Furthermore, in vivo administration of anti-CCR4 mAb markedly reduced the eTreg-cell fraction and augmented NY-ESO-1-specific CD8+ T-cell responses in an adult T-cell leukemia-lymphoma patient whose leukemic cells expressed NY-ESO-1.  Collectively, these findings indicate that anti-CCR4 mAb treatment is instrumental for evoking and augmenting antitumor immunity in cancer patients by selectively depleting eTreg cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDgtUeFW0g-7Vg90H21EOLACvtfcHk0lgaKcxoMkBUsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurzL&md5=86531370de010a65e3cf8742b7e88d56</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1316796110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1316796110%26sid%3Dliteratum%253Aachs%26aulast%3DSugiyama%26aufirst%3DD.%26aulast%3DNishikawa%26aufirst%3DH.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DNishioka%26aufirst%3DM.%26aulast%3DTanemura%26aufirst%3DA.%26aulast%3DKatayama%26aufirst%3DI.%26aulast%3DEzoe%26aufirst%3DS.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DE.%26aulast%3DFukumori%26aufirst%3DY.%26aulast%3DKarbach%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DE.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DAnti-CCR4%2520mAb%2520selectively%2520depletes%2520effector-type%2520FoxP3%252BCD4%252B%2520regulatory%2520T%2520cells%252C%2520evoking%2520antitumor%2520immune%2520responses%2520in%2520humans%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D17945%26epage%3D17950%26doi%3D10.1073%2Fpnas.1316796110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinenaite, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munir Ahmad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Met, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westergaard, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klausen, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svane, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. H.</span></span> <span> </span><span class="NLM_article-title">CCL22-specific T cells: Modulating the immunosuppressive tumor microenvironment</span>. <i>Oncoimmunlogy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1238541</span> <span class="refDoi"> DOI: 10.1080/2162402X.2016.1238541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1080%2F2162402X.2016.1238541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=27999757" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=E.+Martinenaiteauthor=S.+Munir+Ahmadauthor=M.+Hansenauthor=O.+Metauthor=M.+W.+Westergaardauthor=S.+K.+Larsenauthor=T.+W.+Klausenauthor=M.+Doniaauthor=I.+M.+Svaneauthor=M.+H.+Andersen&title=CCL22-specific+T+cells%3A+Modulating+the+immunosuppressive+tumor+microenvironment&doi=10.1080%2F2162402X.2016.1238541"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1238541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1238541%26sid%3Dliteratum%253Aachs%26aulast%3DMartinenaite%26aufirst%3DE.%26aulast%3DMunir%2BAhmad%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DMet%26aufirst%3DO.%26aulast%3DWestergaard%26aufirst%3DM.%2BW.%26aulast%3DLarsen%26aufirst%3DS.%2BK.%26aulast%3DKlausen%26aufirst%3DT.%2BW.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DSvane%26aufirst%3DI.%2BM.%26aulast%3DAndersen%26aufirst%3DM.%2BH.%26atitle%3DCCL22-specific%2520T%2520cells%253A%2520Modulating%2520the%2520immunosuppressive%2520tumor%2520microenvironment%26jtitle%3DOncoimmunlogy%26date%3D2016%26volume%3D5%26doi%3D10.1080%2F2162402X.2016.1238541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurowska-Stolarska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolarski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kewin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrigan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirchandani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooijen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSharry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liew, F. Y.</span></span> <span> </span><span class="NLM_article-title">IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">6469</span>– <span class="NLM_lpage">6477</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.4049%2Fjimmunol.0901575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=19841166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKhsbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=6469-6477&author=M.+Kurowska-Stolarskaauthor=B.+Stolarskiauthor=P.+Kewinauthor=G.+Murphyauthor=C.+J.+Corriganauthor=S.+Yingauthor=N.+Pitmanauthor=A.+Mirchandaniauthor=B.+Ranaauthor=N.+van+Rooijenauthor=M.+Shepherdauthor=C.+McSharryauthor=I.+B.+McInnesauthor=D.+Xuauthor=F.+Y.+Liew&title=IL-33+amplifies+the+polarization+of+alternatively+activated+macrophages+that+contribute+to+airway+inflammation&doi=10.4049%2Fjimmunol.0901575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation</span></div><div class="casAuthors">Kurowska-Stolarska, Mariola; Stolarski, Bartosz; Kewin, Peter; Murphy, Grace; Corrigan, Christopher J.; Ying, Sun; Pitman, Nick; Mirchandani, Ananda; Rana, Batika; van Rooijen, Nico; Shepherd, Malcolm; McSharry, Charlie; McInnes, Iain B.; Xu, Damo; Liew, Foo Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6469-6477</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Alternatively activated macrophages (AAM) play a crucial role in type 2 immunity.  Mice deficient in ST2, a receptor for the latest member of the IL-1 family, IL-33, have impaired type 2 immune responses.  We therefore reasoned that IL-33/ST2 signaling may be involved in the differentiation and activation of AAM during airway inflammation.  We report here that IL-33 changed the quiescent phenotype of alveolar macrophages toward an AAM phenotype that expressed mannose receptor, IL-4Rα, and produced high levels of CCL24 and CCL17 in an IL-13-dependent manner during IL-33-induced airway inflammation.  Neutralization of AAM-derived CCL24 led to an amelioration of IL-33-induced eosinophilia in the lungs.  Moreover, depletion of alveolar macrophages reduced IL-33-induced airway inflammation.  Addnl., the attenuated OVA-induced airway inflammation in ST2-/- mice was assocd. with a decrease in AAM differentiation.  In vitro, IL-33 amplified IL-13-induced polarization of alveolar- and bone marrow-derived macrophage toward an AAM phenotype by increasing the expression of arginase I, Ym1, as well as the prodn. of CCL24 and CCL17.  IL-13/IL-4Rα signaling was crucial for IL-33-driven AAM amplification by inducing the expression of ST2L.  Finally, we showed that IL-33 was more abundantly expressed in the lung epithelial cells of asthma patients than those from healthy controls, suggesting that IL-33 may be involved in lung macrophage activation in clin. asthma.  Taken together, we demonstrate here that IL-33/ST2 plays a significant role in the amplification of AAM polarization and chemokine prodn. which contribute to innate and Ag-induced airway inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriG7WXOe7oWbVg90H21EOLACvtfcHk0lgaKcxoMkBUsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKhsbfE&md5=5aef6ccb0faecb16830a499cf2bdbee8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901575%26sid%3Dliteratum%253Aachs%26aulast%3DKurowska-Stolarska%26aufirst%3DM.%26aulast%3DStolarski%26aufirst%3DB.%26aulast%3DKewin%26aufirst%3DP.%26aulast%3DMurphy%26aufirst%3DG.%26aulast%3DCorrigan%26aufirst%3DC.%2BJ.%26aulast%3DYing%26aufirst%3DS.%26aulast%3DPitman%26aufirst%3DN.%26aulast%3DMirchandani%26aufirst%3DA.%26aulast%3DRana%26aufirst%3DB.%26aulast%3Dvan%2BRooijen%26aufirst%3DN.%26aulast%3DShepherd%26aufirst%3DM.%26aulast%3DMcSharry%26aufirst%3DC.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DLiew%26aufirst%3DF.%2BY.%26atitle%3DIL-33%2520amplifies%2520the%2520polarization%2520of%2520alternatively%2520activated%2520macrophages%2520that%2520contribute%2520to%2520airway%2520inflammation%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D6469%26epage%3D6477%26doi%3D10.4049%2Fjimmunol.0901575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdemon-Hogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conejo-Garcia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryczek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span> <span> </span><span class="NLM_article-title">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1038/nm1093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Fnm1093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=15322536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=942-949&author=T.+J.+Curielauthor=G.+Coukosauthor=L.+Zouauthor=X.+Alvarezauthor=P.+Chengauthor=P.+Mottramauthor=M.+Evdemon-Hoganauthor=J.+R.+Conejo-Garciaauthor=L.+Zhangauthor=M.+Burowauthor=Y.+Zhuauthor=S.+Weiauthor=I.+Kryczekauthor=B.+Danielauthor=A.+Gordonauthor=L.+Myersauthor=A.+Lacknerauthor=M.+L.+Disisauthor=K.+L.+Knutsonauthor=L.+Chenauthor=W.+Zou&title=Specific+recruitment+of+regulatory+T+cells+in+ovarian+carcinoma+fosters+immune+privilege+and+predicts+reduced+survival&doi=10.1038%2Fnm1093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span></div><div class="casAuthors">Curiel, Tyler J.; Coukos, George; Zou, Linhua; Alvarez, Xavier; Cheng, Pui; Mottram, Peter; Evdemon-Hogan, Melina; Conejo-Garcia, Jose R.; Zhang, Lin; Burow, Matthew; Zhu, Yun; Wei, Shuang; Kryczek, Ilona; Daniel, Ben; Gordon, Alan; Myers, Leann; Lackner, Andrew; Disis, Mary L.; Knutson, Keith L.; Chen, Lieping; Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">942-949</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Regulatory T (Treg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells.  Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-assocd. antigen-reactive lymphocytes mediated by Treg cells; however, definitive evidence that Treg cells have an immunopathol. role in human cancer is lacking.  Here the authors show, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor Treg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo.  The authors also show that tumor Treg cells are assocd. with a high death hazard and reduced survival.  Human Treg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages.  Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of Treg cells to the tumor.  This specific recruitment of Treg cells represents a mechanism by which tumors may foster immune privilege.  Thus, blocking Treg cell migration or function may help to defeat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUuPjm7zZim7Vg90H21EOLACvtfcHk0ljfqV7p_NOaCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D&md5=eaf598e6096d6e92381c1b26f4b2fe91</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm1093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1093%26sid%3Dliteratum%253Aachs%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DAlvarez%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DP.%26aulast%3DMottram%26aufirst%3DP.%26aulast%3DEvdemon-Hogan%26aufirst%3DM.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBurow%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DKryczek%26aufirst%3DI.%26aulast%3DDaniel%26aufirst%3DB.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DMyers%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DA.%26aulast%3DDisis%26aufirst%3DM.%2BL.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DW.%26atitle%3DSpecific%2520recruitment%2520of%2520regulatory%2520T%2520cells%2520in%2520ovarian%2520carcinoma%2520fosters%2520immune%2520privilege%2520and%2520predicts%2520reduced%2520survival%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D942%26epage%3D949%26doi%3D10.1038%2Fnm1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hadrup, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straten, P.</span></span> <span> </span><span class="NLM_article-title">Effector CD4 and CD8 T cells and their role in the tumor microenvironment</span>. <i>Cancer Microenviron.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1007/s12307-012-0127-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1007%2Fs12307-012-0127-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23242673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOlur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=123-133&author=S.+Hadrupauthor=M.+Doniaauthor=P.+Straten&title=Effector+CD4+and+CD8+T+cells+and+their+role+in+the+tumor+microenvironment&doi=10.1007%2Fs12307-012-0127-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment</span></div><div class="casAuthors">Hadrup, Sine; Donia, Marco; thor Straten, Per</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Microenvironment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-133</span>CODEN:
                <span class="NLM_cas:coden">CMAICW</span>;
        ISSN:<span class="NLM_cas:issn">1875-2284</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  T cells in tumors-the so-called tumor infiltrating lymphocytes (TIL) have been studied intensively over the past years.  Compelling evidence point to a clin. relevance for high nos. of T cells at the tumor site with CD8 memory T cells as a key denominator for overall survival (OS) in patients with colo-rectal cancer (CRC), and also for others solid cancers.  These data goes hand in hand with studies of clonality of TIL showing the T cells among TIL are expanded clonally, and also that tumor specific T cells of CD4 as well as CD8 type are enriched at the tumor site.  The tumor microenvironment is hostile to T cell function e.g., due to expression of enzymes that depletes the amino acids tryptophan and arginine, high concn. of tumor secreted lactate, and presence innate cells or regulatory T cells both with suppressive activity.  Analyses of the specificity of TILs in melanoma demonstrate that quite few known antigens are in fact recognized by these cultures underscoring patient unique and/or mutated antigens may represent important target for recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO_PUIt1Wyz7Vg90H21EOLACvtfcHk0ljfqV7p_NOaCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOlur%252FL&md5=eab48cec4355dedc34341179927989d4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs12307-012-0127-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12307-012-0127-6%26sid%3Dliteratum%253Aachs%26aulast%3DHadrup%26aufirst%3DS.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DStraten%26aufirst%3DP.%26atitle%3DEffector%2520CD4%2520and%2520CD8%2520T%2520cells%2520and%2520their%2520role%2520in%2520the%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Microenviron.%26date%3D2013%26volume%3D6%26spage%3D123%26epage%3D133%26doi%3D10.1007%2Fs12307-012-0127-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krausz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y. X.</span></span> <span> </span><span class="NLM_article-title">Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.1084/jem.20041684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1084%2Fjem.20041684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=15753211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitl2rt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2005&pages=779-791&author=P.+Yuauthor=Y.+Leeauthor=W.+Liuauthor=T.+Krauszauthor=A.+Chongauthor=H.+Schreiberauthor=Y.+X.+Fu&title=Intratumor+depletion+of+CD4%2B+cells+unmasks+tumor+immunogenicity+leading+to+the+rejection+of+late-stage+tumors&doi=10.1084%2Fjem.20041684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors</span></div><div class="casAuthors">Yu, Ping; Lee, Youjin; Liu, Wenhua; Krausz, Thomas; Chong, Anita; Schreiber, Hans; Fu, Yang-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">779-791</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Tumor environment can be crit. for preventing the immunol. destruction of antigenic tumors.  We have obsd. a selective accumulation of CD4+CD25+ T cells inside tumors.  In a murine fibrosarcoma Ld-expressing Ag104, these cells made up the majority of tumor-infiltrating lymphocytes at the late stage of tumor progression, and their depletion during the effector phase, rather than priming phase, successfully enhanced antitumor immunity.  We show here that CD4+CD25+ T cells suppressed the proliferation and interferon-γ prodn. of CD8+ T cells in vivo at the local tumor site.  Blockade of the effects of IL-10 and TGF-β partially reversed the suppression imposed by the CD4+ cells.  Furthermore, local depletion of CD4+ cells inside the tumor resulted in a change of cytokine milieu and led to the eradication of well-established highly aggressive tumors and the development of long-term antitumor memory.  Therefore, CD4+CD25+ T cells maintained an environment in the tumor that concealed the immunogenicity of tumor cells to permit progressive growth of antigenic tumors.  Our study illustrates that the suppression of antitumor immunity by regulatory T cells occurs predominantly at the tumor site, and that local reversal of suppression, even at a late stage of tumor development, can be an effective treatment for well-established cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ldyYnwbG37Vg90H21EOLACvtfcHk0ljfqV7p_NOaCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitl2rt7s%253D&md5=63be9bb9913bf4025b1397133c9172f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1084%2Fjem.20041684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20041684%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DChong%26aufirst%3DA.%26aulast%3DSchreiber%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DY.%2BX.%26atitle%3DIntratumor%2520depletion%2520of%2520CD4%252B%2520cells%2520unmasks%2520tumor%2520immunogenicity%2520leading%2520to%2520the%2520rejection%2520of%2520late-stage%2520tumors%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2005%26volume%3D201%26spage%3D779%26epage%3D791%26doi%3D10.1084%2Fjem.20041684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Met, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frosig, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klausen, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svane, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. H.</span></span> <span> </span><span class="NLM_article-title">HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1764</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1158%2F0008-5472.CAN-12-3507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23328583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVGisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1764-1776&author=S.+Munirauthor=G.+H.+Andersenauthor=O.+Metauthor=M.+Doniaauthor=T.+M.+Frosigauthor=S.+K.+Larsenauthor=T.+W.+Klausenauthor=I.+M.+Svaneauthor=M.+H.+Andersen&title=HLA-restricted+cytotoxic+T+cells+that+are+specific+for+the+immune+checkpoint+ligand+PD-L1+occur+with+high+frequency+in+cancer+patients&doi=10.1158%2F0008-5472.CAN-12-3507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients</span></div><div class="casAuthors">Munir, Shamaila; Andersen, Gitte Holmen; Met, Oezcan; Donia, Marco; Frosig, Thomas Morch; Larsen, Stine Kiaer; Klausen, Tobias Wirenfeldt; Svane, Inge Marie; Andersen, Mads Hald</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1764-1776</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PD-L1 (CD274) contributes to functional exhaustion of T cells and limits immune responses in patients with cancer.  In this study, we report the identification of an human leukocyte antigen (HLA)-A2-restricted epitope from PD-L1, and we describe natural, cytolytic T-cell reactivity against PD-L1 in the peripheral blood of patients with cancer and healthy individuals.  Notably, PD-L1-specific T cells were able not only to recognize and kill tumor cells but also PD-L1-expressing dendritic cells in a PD-L1-dependent manner, insofar as PD-L1 ablation rescued dendritic cells from killing.  Furthermore, by incubating nonprofessional antigen-presenting cells with long peptides from PD-L1, we found that PD-L1 was rapidly internalized, processed, and cross-presented by HLA-A2 on the cell surface.  Apparently, this cross-presentation was TAP-independent, as it was conducted not only by B cells but in addn. by TAP-deficient T2-cells.  This is intriguing, as sol. PD-L1 has been detected in the sera from patients with cancer.  PD-L1-specific CTL may boost immunity by the killing of immunosuppressive tumor cells as well as regulatory cells.  However, PD-L1-specific CTLs may as well suppress immunity by the elimination of normal immune cells esp. PD-L1 expressing mature dendritic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGresMlYTnMTSbVg90H21EOLACvtfcHk0lgDST7jzACabQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVGisrs%253D&md5=72959c46650c347dbe87c7ce53cc36ef</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3507%26sid%3Dliteratum%253Aachs%26aulast%3DMunir%26aufirst%3DS.%26aulast%3DAndersen%26aufirst%3DG.%2BH.%26aulast%3DMet%26aufirst%3DO.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DFrosig%26aufirst%3DT.%2BM.%26aulast%3DLarsen%26aufirst%3DS.%2BK.%26aulast%3DKlausen%26aufirst%3DT.%2BW.%26aulast%3DSvane%26aufirst%3DI.%2BM.%26aulast%3DAndersen%26aufirst%3DM.%2BH.%26atitle%3DHLA-restricted%2520cytotoxic%2520T%2520cells%2520that%2520are%2520specific%2520for%2520the%2520immune%2520checkpoint%2520ligand%2520PD-L1%2520occur%2520with%2520high%2520frequency%2520in%2520cancer%2520patients%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D1764%26epage%3D1776%26doi%3D10.1158%2F0008-5472.CAN-12-3507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treilleux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendriss-Vermare, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard-Leon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arfi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biota, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffin, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqual, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray-Coquard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puisieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J. Y.</span></span> <span> </span><span class="NLM_article-title">Menetrier-Caux, C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1158%2F0008-5472.CAN-08-2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=19244125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFSrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2000-2009&author=M.+Gobertauthor=I.+Treilleuxauthor=N.+Bendriss-Vermareauthor=T.+Bachelotauthor=S.+Goddard-Leonauthor=V.+Arfiauthor=C.+Biotaauthor=A.+C.+Doffinauthor=I.+Durandauthor=D.+Oliveauthor=S.+Perezauthor=M.+Pasqualauthor=C.+Faureauthor=I.+Ray-Coquardauthor=A.+Puisieuxauthor=C.+Cauxauthor=J.+Y.+Blay&title=Menetrier-Caux%2C+C.+Regulatory+T+cells+recruited+through+CCL22%2FCCR4+are+selectively+activated+in+lymphoid+infiltrates+surrounding+primary+breast+tumors+and+lead+to+an+adverse+clinical+outcome&doi=10.1158%2F0008-5472.CAN-08-2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome</span></div><div class="casAuthors">Gobert, Michael; Treilleux, Isabelle; Bendriss-Vermare, Nathalie; Bachelot, Thomas; Goddard-Leon, Sophie; Arfi, Vanessa; Biota, Cathy; Doffin, Anne Claire; Durand, Isabelle; Olive, Daniel; Perez, Solene; Pasqual, Nicolas; Faure, Christelle; Ray-Coquard, Isabelle; Puisieux, Alain; Caux, Christophe; Blay, Jean-Yves; Menetrier-Caux, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immunohistochem. anal. of FOXP3 in primary breast tumors showed that a high no. of tumor-infiltrating regulatory T cells (Ti-Treg) within lymphoid infiltrates surrounding the tumor was predictive of relapse and death, in contrast to those present within the tumor bed.  Ex vivo anal. showed that these tumor-infiltrating FOXP3+ T cells are typical Treg based on their CD4+CD25highCD127lowFOXP3+ phenotype, their anergic state on in vitro stimulation, and their suppressive functions.  These Ti-Treg could be selectively recruited through CCR4 as illustrated by (a) selective blood Treg CCR4 expression and migration to CCR4 ligands, (b) CCR4 down-regulation on Ti-Treg, and (c) correlation between Ti-Treg in lymphoid infiltrates and intratumoral CCL22 expression.  Importantly, in contrast to other T cells, Ti-Treg are selectively activated locally and proliferate in situ, showing T-cell receptor engagement and suggesting specific recognition of tumor-assocd. antigens (TAA).  Immunohistochem. stainings for ICOS, Ki67, and DC-LAMP show that Ti-Treg were close to mature DC-LAMP+ dendritic cells (DC) in lymphoid infiltrates but not in tumor bed and were activated and proliferating.  Furthermore, proximity between Ti-Treg, CD3+, and CD8+ T cells was documented within lymphoid infiltrates.  Altogether, these results show that Treg are selectively recruited within lymphoid infiltrates and activated by mature DC likely through TAA presentation, resulting in the prevention of effector T-cell activation, immune escape, and ultimately tumor progression.  This study sheds new light on Treg physiol. and validates CCR4/CCL22 and ICOS as therapeutic targets in breast tumors, which represent a major health problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqhKbsz9ynO7Vg90H21EOLACvtfcHk0lhwZgAhfJJxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFSrtbg%253D&md5=452bc4cee9c3cba90cfce6cf6dd4994d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2360%26sid%3Dliteratum%253Aachs%26aulast%3DGobert%26aufirst%3DM.%26aulast%3DTreilleux%26aufirst%3DI.%26aulast%3DBendriss-Vermare%26aufirst%3DN.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DGoddard-Leon%26aufirst%3DS.%26aulast%3DArfi%26aufirst%3DV.%26aulast%3DBiota%26aufirst%3DC.%26aulast%3DDoffin%26aufirst%3DA.%2BC.%26aulast%3DDurand%26aufirst%3DI.%26aulast%3DOlive%26aufirst%3DD.%26aulast%3DPerez%26aufirst%3DS.%26aulast%3DPasqual%26aufirst%3DM.%26aulast%3DFaure%26aufirst%3DC.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26atitle%3DMenetrier-Caux%252C%2520C.%2520Regulatory%2520T%2520cells%2520recruited%2520through%2520CCL22%252FCCR4%2520are%2520selectively%2520activated%2520in%2520lymphoid%2520infiltrates%2520surrounding%2520primary%2520breast%2520tumors%2520and%2520lead%2520to%2520an%2520adverse%2520clinical%2520outcome%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D2000%26epage%3D2009%26doi%3D10.1158%2F0008-5472.CAN-08-2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komabayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishibe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkuri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harabuchi, Y.</span></span> <span> </span><span class="NLM_article-title">CCL17 and CCL22/CCR4 signaling is a strong candidate for novel target therapy against nasal natural killer/T-cell lymphoma</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1007/s00262-015-1675-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1007%2Fs00262-015-1675-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25754123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1Omsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=697-705&author=T.+Kumaiauthor=T.+Nagatoauthor=H.+Kobayashiauthor=Y.+Komabayashiauthor=S.+Uedaauthor=K.+Kishibeauthor=T.+Ohkuriauthor=M.+Takaharaauthor=E.+Celisauthor=Y.+Harabuchi&title=CCL17+and+CCL22%2FCCR4+signaling+is+a+strong+candidate+for+novel+target+therapy+against+nasal+natural+killer%2FT-cell+lymphoma&doi=10.1007%2Fs00262-015-1675-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma</span></div><div class="casAuthors">Kumai, Takumi; Nagato, Toshihiro; Kobayashi, Hiroya; Komabayashi, Yuki; Ueda, Seigo; Kishibe, Kan; Ohkuri, Takayuki; Takahara, Miki; Celis, Esteban; Harabuchi, Yasuaki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">697-705</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Nasal natural killer/T-cell lymphoma (NNKTL) is assocd. with Epstein-Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination.  Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematol. malignancies.  The aim of the present study was to det. whether specific chemokines are produced by NNKTL.  We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA.  Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines.  In addn., CCL17 and CCL22 were readily obsd. in the sera of NNKTL patients.  The levels of these chemokines were significantly higher in patients than in healthy controls.  Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients.  Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines.  Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg0g-aCyoytLVg90H21EOLACvtfcHk0lhwZgAhfJJxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1Omsrk%253D&md5=8d437143dd821e1f2785236b556c1bdd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00262-015-1675-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-015-1675-7%26sid%3Dliteratum%253Aachs%26aulast%3DKumai%26aufirst%3DT.%26aulast%3DNagato%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DKomabayashi%26aufirst%3DY.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DKishibe%26aufirst%3DK.%26aulast%3DOhkuri%26aufirst%3DT.%26aulast%3DTakahara%26aufirst%3DM.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DHarabuchi%26aufirst%3DY.%26atitle%3DCCL17%2520and%2520CCL22%252FCCR4%2520signaling%2520is%2520a%2520strong%2520candidate%2520for%2520novel%2520target%2520therapy%2520against%2520nasal%2520natural%2520killer%252FT-cell%2520lymphoma%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2015%26volume%3D64%26spage%3D697%26epage%3D705%26doi%3D10.1007%2Fs00262-015-1675-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracci, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsuang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemels, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrensch, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiencke, J. K.</span></span> <span> </span><span class="NLM_article-title">Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">826</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1002/ijc.29441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1002%2Fijc.29441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25604093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVajtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=826-836&author=M.+Zhouauthor=P.+M.+Bracciauthor=L.+S.+McCoyauthor=G.+Hsuangauthor=J.+L.+Wiemelsauthor=T.+Riceauthor=S.+Zhengauthor=K.+T.+Kelseyauthor=M.+R.+Wrenschauthor=J.+K.+Wiencke&title=Serum+macrophage-derived+chemokine%2FCCL22+levels+are+associated+with+glioma+risk%2C+CD4+T+cell+lymphopenia+and+survival+time&doi=10.1002%2Fijc.29441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time</span></div><div class="casAuthors">Zhou, Mi; Bracci, Paige M.; McCoy, Lucie S.; Hsuang, George; Wiemels, Joseph L.; Rice, Terri; Zheng, Shichun; Kelsey, Karl T.; Wrensch, Margaret R.; Wiencke, John K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">826-836</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Defects in antigen presenting cell function have been implicated in glioma immunosuppression.  We measured peripheral CCL22, a dendritic cell/macrophage derived T cell trafficking chemokine, in sera from 1,208 glioma cases and 976 controls to assess whether it might provide a biomarker of glioma risk, survival and immune dysfunction.  Cluster models were used to examine the relationship between CCL22 and glioma risk.  Patient survival was assessed using Cox regression models.  We also examd. the relationship between CCL22 levels and CD4 cell counts, as well as allergy history and IgE levels.  CCL22 levels were significantly lower among glioma cases compared with controls (Mean ± SEM: 1.23 ± 0.03 ng/mL in cases vs. 1.60 ± 0.03 ng/mL in controls, p < 0.0001) and this difference remained significant even after controlling for other covariates in the cluster models (highest quartile vs. lowest Odds Ratio = 0.21, p < 0.0001).  CD4 cell counts were pos. correlated with CCL22 in glioma cases (Spearman r2 = 0.51, p < 0.01) and were significantly lower in cases compared with controls.  Higher CCL22 levels were assocd. with longer survival in all cases combined and in GBM cases (hazard ratioallcases = 0.81; 95% CI: 0.72-0.91, p = 0.0003).  CCL22 levels were not assocd. with IgE level or self-reported allergies.  Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histol., grade and IDH mutation status.  CCL22 should be considered a marker of immune status with potential prognostic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7bCfHIddb-LVg90H21EOLACvtfcHk0lhwZgAhfJJxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVajtb4%253D&md5=8ea50f9c73cca78b7c6f250a302cc7af</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fijc.29441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29441%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DBracci%26aufirst%3DP.%2BM.%26aulast%3DMcCoy%26aufirst%3DL.%2BS.%26aulast%3DHsuang%26aufirst%3DG.%26aulast%3DWiemels%26aufirst%3DJ.%2BL.%26aulast%3DRice%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DKelsey%26aufirst%3DK.%2BT.%26aulast%3DWrensch%26aufirst%3DM.%2BR.%26aulast%3DWiencke%26aufirst%3DJ.%2BK.%26atitle%3DSerum%2520macrophage-derived%2520chemokine%252FCCL22%2520levels%2520are%2520associated%2520with%2520glioma%2520risk%252C%2520CD4%2520T%2520cell%2520lymphopenia%2520and%2520survival%2520time%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D826%26epage%3D836%26doi%3D10.1002%2Fijc.29441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tough, D. F.</span></span> <span> </span><span class="NLM_article-title">Targeting CCR4 as an emerging strategy for cancer therapy and vaccines</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.tips.2014.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=24612600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslOktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=163-165&author=J.+Bayryauthor=E.+Tartourauthor=D.+F.+Tough&title=Targeting+CCR4+as+an+emerging+strategy+for+cancer+therapy+and+vaccines&doi=10.1016%2Fj.tips.2014.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CCR4 as an emerging strategy for cancer therapy and vaccines</span></div><div class="casAuthors">Bayry, Jagadeesh; Tartour, Eric; Tough, David F.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">163-165</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  This paper discusses the CCR4 antagonists are probably preferable for antitumor vaccines and, unlike CCR4 mAbs, this could be independent of the tumor cells expressing CCR4.  The CCR4 blockade clearly represents an original strategy to inhibit both Tregs and tumor cells were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiZt0pWKrl9bVg90H21EOLACvtfcHk0liXeIElqhasgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslOktb8%253D&md5=1399fd3d918a248158a28558e412a733</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DBayry%26aufirst%3DJ.%26aulast%3DTartour%26aufirst%3DE.%26aulast%3DTough%26aufirst%3DD.%2BF.%26atitle%3DTargeting%2520CCR4%2520as%2520an%2520emerging%2520strategy%2520for%2520cancer%2520therapy%2520and%2520vaccines%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D163%26epage%3D165%26doi%3D10.1016%2Fj.tips.2014.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. E.</span></span> <span> </span><span class="NLM_article-title">Targeting chemokine receptors in disease – a case study of CCR4</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>763</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.ejphar.2015.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25981299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=763&publication_year=2015&pages=169-177&author=R.+Solariauthor=J.+E.+Pease&title=Targeting+chemokine+receptors+in+disease+%E2%80%93+a+case+study+of+CCR4&doi=10.1016%2Fj.ejphar.2015.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting chemokine receptors in disease - a case study of CCR4</span></div><div class="casAuthors">Solari, Roberto; Pease, James E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">763</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Since their early 1990s, the chemokine receptor family of G protein-coupled receptors (GPCRs) has been the source of much pharmacol. endeavour.  Best known for their key roles in recruiting leukocytes to sites of infection and inflammation, the receptors present themselves as plausible drug targets for therapeutic intervention.  In this article, we will focus our attention upon CC Chemokine Receptor Four (CCR4) which has been implicated in diseases as diverse as allergic asthma and lymphoma.  We will review the discovery of the receptors and their ligands, their perceived roles in disease and the successful targeting of CCR4 by both small mol. antagonists and monoclonal antibodies.  We will also discuss future directions and strategies for drug discovery in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd4Fw-zabbaLVg90H21EOLACvtfcHk0liXeIElqhasgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7bF&md5=79af36fb27d2eb5d501f6929f6378530</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DSolari%26aufirst%3DR.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26atitle%3DTargeting%2520chemokine%2520receptors%2520in%2520disease%2520%25E2%2580%2593%2520a%2520case%2520study%2520of%2520CCR4%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D763%26spage%3D169%26epage%3D177%26doi%3D10.1016%2Fj.ejphar.2015.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span> <span> </span><span class="NLM_article-title">A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15038</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11868-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Fs41598-017-11868-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=29118379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A280%3ADC%252BC1M7pt1ynsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=15038&author=Y.+Zhangauthor=Y.+Wuauthor=H.+Qiauthor=J.+Xiaoauthor=H.+Gongauthor=Y.+Zhangauthor=E.+Xuauthor=S.+Liauthor=D.+Maauthor=Y.+Wangauthor=W.+Liauthor=H.+Shen&title=A+new+antagonist+for+CCR4+attenuates+allergic+lung+inflammation+in+a+mouse+model+of+asthma&doi=10.1038%2Fs41598-017-11868-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma</span></div><div class="casAuthors">Zhang Yang; Qi Hui; Zhang Yan; Xu Enquan; Ma Dalong; Wang Ying; Zhang Yang; Wu Yinfang; Li Wen; Shen Huahao; Qi Hui; Xiao Junhai; Gong Hongwei; Li Song; Gong Hongwei</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15038</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CCR4 is highly expressed on Th2 cells.  CCR4 ligands include CCL22 and CCL17.  Chemokine-like factor 1 can also mediate chemotaxis via CCR4.  We designed and synthetized novel CCR4 antagonists, which were piperazinyl pyridine derivatives, for disrupting the interaction between three ligands and CCR4.  We also determined whether these novel CCR4 antagonists could alleviate allergic asthma in a mouse.  For identifying the potent compounds in vitro, we used chemotaxis inhibition and competition binding assays induced by CCL22, CCL17 and one of CKLF1's C-terminal peptides, C27.  We found compound 8a which showed excellent potency in blocking the interaction of CCR4 and its three ligands.  For studying the specificity of compounds, we chose chemotaxis inhibition assays with different receptors and ligands.  We found compound 8a had excellent receptor specificity and exerted few influence on the interaction of other receptors and their ligands.  In the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, compound 8a had no obvious cytotoxicity till the higher concentration (16 μM).  For determining the potency of compounds in blocking the interaction of CCR4 in vivo, we used the ovalbumin induced allergic asthma model in mice.  Our study demonstrated that CCR4 blockaded by compound 8a effectively attenuated airway hyperresponsiveness, airway eosinophilia and Th2 cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwS9d-cvIEc_csfMJQC1ZdfW6udTcc2eZqWSHx-qqW6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7pt1ynsw%253D%253D&md5=796db5f0877337b45f4681de2a677666</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11868-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11868-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DH.%26atitle%3DA%2520new%2520antagonist%2520for%2520CCR4%2520attenuates%2520allergic%2520lung%2520inflammation%2520in%2520a%2520mouse%2520model%2520of%2520asthma%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D15038%26doi%3D10.1038%2Fs41598-017-11868-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span>; <span class="NLM_string-name">Ford, A.</span>; <span class="NLM_string-name">Hodgson, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of CCR4 Antagonists</span>. In  <i>New Drugs and Targets for Asthma and COPD</i>; <span class="NLM_publisher-name">Karger Medical and Scientific Publishers</span>, <span class="NLM_year">2010</span>; Vol.  <span class="NLM_volume">39</span>, pp  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">165</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1159%2F000320815" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=161-165&author=D.+Hall&author=A.+Ford&author=S.+Hodgson&title=New+Drugs+and+Targets+for+Asthma+and+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1159%2F000320815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1159%252F000320815%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DD.%26atitle%3DTherapeutic%2520Potential%2520of%2520CCR4%2520Antagonists%26btitle%3DNew%2520Drugs%2520and%2520Targets%2520for%2520Asthma%2520and%2520COPD%26pub%3DKarger%2520Medical%2520and%2520Scientific%2520Publishers%26date%3D2010%26volume%3D39%26spage%3D161%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horuk, R.</span></span> <span> </span><span class="NLM_article-title">Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1517/17460441.2014.897324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1517%2F17460441.2014.897324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=24641500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFClt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=467-483&author=J.+E.+Peaseauthor=R.+Horuk&title=Recent+progress+in+the+development+of+antagonists+to+the+chemokine+receptors+CCR3+and+CCR4&doi=10.1517%2F17460441.2014.897324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4</span></div><div class="casAuthors">Pease, James Edward; Horuk, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">467-483</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The chemokine receptors CCR3 and CCR4 have been shown to be important therapeutic targets for the treatment of a variety of diseases.  Although only two chemokine receptor inhibitors have been approved so far, there are numerous compds. that are in various stages of development.  Areas covered: In this review article, the authors provide an update on the progress made in the identification of antagonists against the chemokine receptors CCR3 and CCR4 from 2009 to the present.  The rationale of writing this review article is to cover the most important approaches to identifying antagonists to these two receptors, which could prove to be useful therapeutics in treating proinflammatory diseases.  Expert opinion: Pharmaceutical companies have expended a considerable amt. of money and effort to identify potent inhibitors of CCR3 and CCR4 for the treatment of asthma and atopic diseases.  Although a variety of compds. have been described and several have progressed into the clinic, none have so far made it as approved drugs.  There are, however, novel approaches such as mogamulizumab, a monoclonal antibody to CCR4 currently is in clin. trials for cancer and ASM8, an antisense nucleotide to CCR3, which is in Phase II clin. trials for asthma that might still prove to be successful new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXmZrBcC5PbLVg90H21EOLACvtfcHk0liHQKzqXn11Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFClt7o%253D&md5=d77cb820f88320311ed1c09f15f7a800</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.897324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.897324%26sid%3Dliteratum%253Aachs%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DRecent%2520progress%2520in%2520the%2520development%2520of%2520antagonists%2520to%2520the%2520chemokine%2520receptors%2520CCR3%2520and%2520CCR4%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D467%26epage%3D483%26doi%3D10.1517%2F17460441.2014.897324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wreggett, K. A.</span></span> <span> </span><span class="NLM_article-title">An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1124/mol.107.039321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1124%2Fmol.107.039321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=18042736" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=855-867&author=G.+Andrewsauthor=C.+Jonesauthor=K.+A.+Wreggett&title=An+intracellular+allosteric+site+for+a+specific+class+of+antagonists+of+the+CC+chemokine+G+protein-coupled+receptors+CCR4+and+CCR5&doi=10.1124%2Fmol.107.039321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.039321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.039321%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DWreggett%26aufirst%3DK.%2BA.%26atitle%3DAn%2520intracellular%2520allosteric%2520site%2520for%2520a%2520specific%2520class%2520of%2520antagonists%2520of%2520the%2520CC%2520chemokine%2520G%2520protein-coupled%2520receptors%2520CCR4%2520and%2520CCR5%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D855%26epage%3D867%26doi%3D10.1124%2Fmol.107.039321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalesso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span> <span> </span><span class="NLM_article-title">Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e00019</span> <span class="refDoi"> DOI: 10.1002/prp2.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1002%2Fprp2.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25505571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yntr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&author=R.+J.+Slackauthor=L.+J.+Russellauthor=N.+P.+Bartonauthor=C.+Westonauthor=G.+Nalessoauthor=S.-A.+Thompsonauthor=M.+Allenauthor=Y.+H.+Chenauthor=A.+Barnesauthor=S.+T.+Hodgsonauthor=D.+A.+Hall&title=Antagonism+of+human+CC-chemokine+receptor+4+can+be+achieved+through+three+distinct+binding+sites+on+the+receptor&doi=10.1002%2Fprp2.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor</span></div><div class="casAuthors">Slack, Robert J.; Russell, Linda J.; Barton, Nick P.; Weston, Cathryn; Nalesso, Giovanna; Thompson, Sally-Anne; Allen, Morven; Chen, Yu Hua; Barnes, Ashley; Hodgson, Simon T.; Hall, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology Research & Perspectives</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e00019/1-e00019/25</span>CODEN:
                <span class="NLM_cas:coden">PRPHCA</span>;
        ISSN:<span class="NLM_cas:issn">2052-1707</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Chemokine receptor antagonists appear to access two distinct binding sites on different members of this receptor family.  One class of CCR4 antagonists has been suggested to bind to a site accessible from the cytoplasm while a second class did not bind to this site.  In this report, we demonstrate that antagonists representing a variety of structural classes bind to two distinct allosteric sites on CCR4.  The effects of pairs of low-mol. wt. and/or chemokine CCR4 antagonists were evaluated on CCL17- and CCL22-induced responses of human CCR4+ T cells.  This provided an initial grouping of the antagonists into sets which appeared to bind to distinct binding sites.  Binding studies were then performed with radioligands from each set to confirm these groupings.  Some novel receptor theory was developed to allow the interpretation of the effects of the antagonist combinations.  The theory indicates that, generally, the concn.-ratio of a pair of competing allosteric modulators is maximally the sum of their individual effects while that of two modulators acting at different sites is likely to be greater than their sum.  The low-mol. wt. antagonists could be grouped into two sets on the basis of the functional and binding expts.  The antagonistic chemokines formed a third set whose behavior was consistent with that of simple competitive antagonists.  These studies indicate that there are two allosteric regulatory sites on CCR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj9cDmC7ops7Vg90H21EOLACvtfcHk0liHQKzqXn11Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yntr3O&md5=d3c75616ffba6b6644c8755fcff21e5c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fprp2.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.19%26sid%3Dliteratum%253Aachs%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DRussell%26aufirst%3DL.%2BJ.%26aulast%3DBarton%26aufirst%3DN.%2BP.%26aulast%3DWeston%26aufirst%3DC.%26aulast%3DNalesso%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DS.-A.%26aulast%3DAllen%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DBarnes%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DHall%26aufirst%3DD.%2BA.%26atitle%3DAntagonism%2520of%2520human%2520CC-chemokine%2520receptor%25204%2520can%2520be%2520achieved%2520through%2520three%2520distinct%2520binding%2520sites%2520on%2520the%2520receptor%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2013%26volume%3D1%26doi%3D10.1002%2Fprp2.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ajram, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swieboda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousnier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>729</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.ejphar.2014.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=24534492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1CrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=729&publication_year=2014&pages=75-85&author=L.+Ajramauthor=M.+Beggauthor=R.+Slackauthor=J.+Cryanauthor=D.+Hallauthor=S.+Hodgsonauthor=A.+Fordauthor=A.+Barnesauthor=D.+Swiebodaauthor=A.+Mousnierauthor=R.+Solari&title=Internalization+of+the+chemokine+receptor+CCR4+can+be+evoked+by+orthosteric+and+allosteric+receptor+antagonists&doi=10.1016%2Fj.ejphar.2014.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists</span></div><div class="casAuthors">Ajram, Laura; Begg, Malcolm; Slack, Robert; Cryan, Jenni; Hall, David; Hodgson, Simon; Ford, Alison; Barnes, Ashley; Swieboda, Dawid; Mousnier, Aurelie; Solari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">729</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The chemokine receptor CCR4 has at least two natural agonist ligands, MDC (CCL22) and TARC (CCL17) which bind to the same orthosteric site with a similar affinity.  Both ligands are known to evoke chemotaxis of CCR4-bearing T cells and also elicit CCR4 receptor internalization.  A series of small mol. allosteric antagonists have been described which displace the agonist ligand, and inhibit chemotaxis.  The aim of this study was to det. which cellular coupling pathways are involved in internalization, and if antagonists binding to the CCR4 receptor could themselves evoke receptor internalization.  CCL22 binding coupled CCR4 efficiently to β-arrestin and stimulated GTPγS binding however CCL17 did not couple to β-arrestin and only partially stimulated GTPγS binding.  CCL22 potently induced internalization of almost all cell surface CCR4, while CCL17 showed only weak effects.  We describe four small mol. antagonists that were demonstrated to bind to two distinct allosteric sites on the CCR4 receptor, and while both classes inhibited agonist ligand binding and chemotaxis, one of the allosteric sites also evoked receptor internalization.  Furthermore, we also characterize an N-terminally truncated version of CCL22 which acts as a competitive antagonist at the orthosteric site, and surprisingly also evokes receptor internalization without demonstrating any agonist activity.  Collectively this study demonstrates that orthosteric and allosteric antagonists of the CCR4 receptor are capable of evoking receptor internalization, providing a novel strategy for drug discovery against this class of target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cp_MmkWDlrVg90H21EOLACvtfcHk0liHQKzqXn11Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1CrsrY%253D&md5=2d48b60057b1a037979e02f0a4fe95b4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DAjram%26aufirst%3DL.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DSlack%26aufirst%3DR.%26aulast%3DCryan%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DFord%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DA.%26aulast%3DSwieboda%26aufirst%3DD.%26aulast%3DMousnier%26aufirst%3DA.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DInternalization%2520of%2520the%2520chemokine%2520receptor%2520CCR4%2520can%2520be%2520evoked%2520by%2520orthosteric%2520and%2520allosteric%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D729%26spage%3D75%26epage%3D85%26doi%3D10.1016%2Fj.ejphar.2014.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heifetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schertler, G. F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourmy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storer, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhonova, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodkin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, R. J.</span></span> <span> </span><span class="NLM_article-title">Biggin, P.C. GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014</span>. <i>Naunyn-Schmiedeberg’s Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1007/s00210-015-1111-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1007%2Fs00210-015-1111-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=25772061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksV2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2015&pages=883-903&author=A.+Heifetzauthor=G.+F.+X.+Schertlerauthor=R.+Seifertauthor=C.+G.+Tateauthor=P.+M.+Sextonauthor=V.+V.+Gurevichauthor=D.+Fourmyauthor=V.+Cherezovauthor=F.+H.+Marshallauthor=R.+I.+Storerauthor=I.+Moraesauthor=I.+G.+Tikhonovaauthor=C.+S.+Tautermannauthor=P.+Huntauthor=T.+Ceskaauthor=S.+Hodgsonauthor=M.+J.+Bodkinauthor=S.+Singhauthor=R.+J.+Law&title=Biggin%2C+P.C.+GPCR+structure%2C+function%2C+drug+discovery+and+crystallography%3A+report+from+Academia-Industry+International+Conference+%28UK+Royal+Society%29+Chicheley+Hall%2C+1%E2%80%932+September+2014&doi=10.1007%2Fs00210-015-1111-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014</span></div><div class="casAuthors">Heifetz, Alexander; Schertler, Gebhard F. X.; Seifert, Roland; Tate, Christopher G.; Sexton, Patrick M.; Gurevich, Vsevolod V.; Fourmy, Daniel; Cherezov, Vadim; Marshall, Fiona H.; Storer, R. Ian; Moraes, Isabel; Tikhonova, Irina G.; Tautermann, Christofer S.; Hunt, Peter; Ceska, Tom; Hodgson, Simon; Bodkin, Mike J.; Singh, Shweta; Law, Richard J.; Biggin, Philip C.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  G-protein coupled receptors (GPCRs) are the targets of over half of all prescribed drugs today.  The UniProt database has records for about 800 proteins classified as GPCRs, but drugs have only been developed against 50 of these.  Thus, there is huge potential in terms of the no. of targets for new therapies to be designed.  Several breakthroughs in GPCRs biased pharmacol., structural biol., modeling and scoring have resulted in a resurgence of interest in GPCRs as drug targets.  Therefore, an international conference, sponsored by the Royal Society, with world-renowned researchers from industry and academia was recently held to discuss recent progress and highlight key areas of future research needed to accelerate GPCR drug discovery.  Several key points emerged.  Firstly, structures for all three major classes of GPCRs have now been solved and there is increasing coverage across the GPCR phylogenetic tree.  This is likely to be substantially enhanced with data from x-ray free electron sources as they move beyond proof of concept.  Secondly, the concept of biased signalling or functional selectivity is likely to be prevalent in many GPCRs, and this presents exciting new opportunities for selectivity and the control of side effects, esp. when combined with increasing data regarding allosteric modulation.  Thirdly, there will almost certainly be some GPCRs that will remain difficult targets because they exhibit complex ligand dependencies and have many metastable states rendering them difficult to resolve by crystallog. methods.  Subtle effects within the packing of the transmembrane helixes are likely to mask and contribute to this aspect, which may play a role in species dependent behavior.  This is particularly important because it has ramifications for how we interpret pre-clin. data.  In summary, collaborative efforts between industry and academia have delivered significant progress in terms of structure and understanding of GPCRs and will be essential for resolving problems assocd. with the more difficult targets in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcK1I7affT27Vg90H21EOLACvtfcHk0ljtZ7sYJ98J0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksV2msrk%253D&md5=a2f1ef2996666eec21056ac4fe51d534</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00210-015-1111-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-015-1111-8%26sid%3Dliteratum%253Aachs%26aulast%3DHeifetz%26aufirst%3DA.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26aulast%3DSeifert%26aufirst%3DR.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DFourmy%26aufirst%3DD.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DStorer%26aufirst%3DR.%2BI.%26aulast%3DMoraes%26aufirst%3DI.%26aulast%3DTikhonova%26aufirst%3DI.%2BG.%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DHunt%26aufirst%3DP.%26aulast%3DCeska%26aufirst%3DT.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DBodkin%26aufirst%3DM.%2BJ.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DLaw%26aufirst%3DR.%2BJ.%26atitle%3DBiggin%252C%2520P.C.%2520GPCR%2520structure%252C%2520function%252C%2520drug%2520discovery%2520and%2520crystallography%253A%2520report%2520from%2520Academia-Industry%2520International%2520Conference%2520%2528UK%2520Royal%2520Society%2529%2520Chicheley%2520Hall%252C%25201%25E2%2580%25932%2520September%25202014%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D2015%26volume%3D388%26spage%3D883%26epage%3D903%26doi%3D10.1007%2Fs00210-015-1111-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kontani, T.</span>; <span class="NLM_string-name">Kawano, N.</span>; <span class="NLM_string-name">Masuda, N.</span>; <span class="NLM_string-name">Kato, K.</span>; <span class="NLM_string-name">Nagata, H.</span>; <span class="NLM_string-name">Inami, H.</span>; <span class="NLM_string-name">Terasaka, T.</span>; <span class="NLM_string-name">Kazuhir, Y.</span>; <span class="NLM_string-name">Miyazaki, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Amino(acylaminopiperidinyl)quinazoline Derivatives as CCR4 Inhibitors for Treatment of Inflammation, Allergy, and Autoimmune Disease</span>. <span class="NLM_patent">WO2007111227A</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Kontani&author=N.+Kawano&author=N.+Masuda&author=K.+Kato&author=H.+Nagata&author=H.+Inami&author=T.+Terasaka&author=Y.+Kazuhir&author=T.+Miyazaki&title=Preparation+of+Amino%28acylaminopiperidinyl%29quinazoline+Derivatives+as+CCR4+Inhibitors+for+Treatment+of+Inflammation%2C+Allergy%2C+and+Autoimmune+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKontani%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Amino%2528acylaminopiperidinyl%2529quinazoline%2520Derivatives%2520as%2520CCR4%2520Inhibitors%2520for%2520Treatment%2520of%2520Inflammation%252C%2520Allergy%252C%2520and%2520Autoimmune%2520Disease%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koganemaru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span> <span> </span><span class="NLM_article-title">Potent and orally bioavailable CCR4 atagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.bmc.2008.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=19081254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFamtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=64-73&author=K.+Yokoyamaauthor=N.+Ishikawaauthor=S.+Igarashiauthor=N.+Kawanoauthor=N.+Masudaauthor=W.+Hamaguchiauthor=S.+Yamasakiauthor=Y.+Koganemaruauthor=K.+Hattoriauthor=T.+Miyazakiauthor=S.+Oginoauthor=Y.+Matsumotoauthor=M.+Takeuchiauthor=M.+Ohta&title=Potent+and+orally+bioavailable+CCR4+atagonists%3A+Synthesis+and+structure-activity+relationship+study+of+2-aminoquinazolines&doi=10.1016%2Fj.bmc.2008.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines</span></div><div class="casAuthors">Yokoyama, Kazuhiro; Ishikawa, Noriko; Igarashi, Susumu; Kawano, Noriyuki; Masuda, Naoyuki; Hamaguchi, Wataru; Yamasaki, Shingo; Koganemaru, Yohei; Hattori, Kazuyuki; Miyazaki, Takahiro; Ogino, Shin-ichi; Matsumoto, Yuzo; Takeuchi, Makoto; Ohta, Mitsuaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-73</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting with a series of CC chemokine receptor-4 (CCR4) antagonists developed in a previous study, the potency was improved by replacing the pyrrolidine moiety of N-(4-chlorophenyl)-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine 2 with a 3-(hydroxymethyl)piperidine.  The resulting compd. (1'-{4-[(4-chlorophenyl)amino]-6,7-dimethoxyquinazolin-2-yl}-1,4'-bipiperidin-3-yl)methanol 8ic was a strong inhibitor of human/mouse chemotaxis.  Oral administration of 8ic showed anti-inflammatory activity in a murine model of acute dermatitis (oxazolone-induced contact hypersensitivity test) in a dose-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbBY8f7PEJE7Vg90H21EOLACvtfcHk0ljtZ7sYJ98J0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFamtr3J&md5=181807b8003d07572368f43807ec6ede</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DN.%26aulast%3DIgarashi%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DN.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DHamaguchi%26aufirst%3DW.%26aulast%3DYamasaki%26aufirst%3DS.%26aulast%3DKoganemaru%26aufirst%3DY.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26atitle%3DPotent%2520and%2520orally%2520bioavailable%2520CCR4%2520atagonists%253A%2520Synthesis%2520and%2520structure-activity%2520relationship%2520study%2520of%25202-aminoquinazolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D64%26epage%3D73%26doi%3D10.1016%2Fj.bmc.2008.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerville, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span> <span> </span><span class="NLM_article-title">Core exploration in optimization of chemokine receptor CCR4 antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.10.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.bmcl.2006.10.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=17098428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFaguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=679-682&author=A.+V.+Purandareauthor=H.+Wanauthor=J.+E.+Somervilleauthor=C.+Burkeauthor=W.+Vaccaroauthor=X.+Yangauthor=K.+W.+McIntyreauthor=M.+A.+Poss&title=Core+exploration+in+optimization+of+chemokine+receptor+CCR4+antagonists&doi=10.1016%2Fj.bmcl.2006.10.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Core exploration in optimization of chemokine receptor CCR4 antagonists</span></div><div class="casAuthors">Purandare, Ashok V.; Wan, Honghe; Somerville, John E.; Burke, Christine; Vaccaro, Wayne; Yang, XiaoXia; McIntyre, Kim W.; Poss, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">679-682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design, synthesis, and SAR studies of 'core' variations led to identification of novel, selective, and potent small mol. antagonist (I) of the CC chemokine receptor-4 (CCR4) with improved in vitro activity and liability profile.  Compd. I was efficacious in a murine allergic inflammation model (ED50 ∼ 10 mg/kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCc-Oj8IV7u7Vg90H21EOLACvtfcHk0ljtZ7sYJ98J0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFaguw%253D%253D&md5=604537d7fd88fe913ef078ab1602ea02</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.10.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.10.091%26sid%3Dliteratum%253Aachs%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSomerville%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DC.%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26atitle%3DCore%2520exploration%2520in%2520optimization%2520of%2520chemokine%2520receptor%2520CCR4%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D679%26epage%3D682%26doi%3D10.1016%2Fj.bmcl.2006.10.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuribayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span> <span> </span><span class="NLM_article-title">RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1248/bpb.33.1067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1248%2Fbpb.33.1067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=20522980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslynsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=1067-1069&author=Y.+Nakagamiauthor=Y.+Kawaseauthor=K.+Yonekuboauthor=E.+Nosakaauthor=M.+Etoriauthor=S.+Takahashiauthor=N.+Takagiauthor=T.+Fukudaauthor=T.+Kuribayashiauthor=F.+Naraauthor=M.+Yamashita&title=RS-1748%2C+a+novel+CC+chemokine+receptor+4+antagonist%2C+inhibits+ovalbumin-induced+airway+inflammation+in+guinea+pigs&doi=10.1248%2Fbpb.33.1067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs</span></div><div class="casAuthors">Nakagami, Yasuhiro; Kawase, Yumi; Yonekubo, Kazuki; Nosaka, Emi; Etori, Maki; Takahashi, Sakiko; Takagi, Nana; Fukuda, Takeshi; Kuribayashi, Takeshi; Nara, Futoshi; Yamashita, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1067-1069</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">CC chemokine receptor 4 (CCR4) is generally recognized as a preferential marker for T helper 2 cells, and we have previously reported morpholine-deriv. CCR4 antagonists, RS-1154 and RS-1269.  Here, we investigate the pharmacol. profiles of a novel pyrimidine-deriv. CCR4 antagonist, 2-{4-[2-(diethylamino)-ethoxy]phenyl}-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine (RS-1748), which showed potency to inhibit the bindings of [125I]CCL17 and [35S]GTPγS to human CCR4-expressing Chinese hamster ovary (CHO) cells with IC50 values of 59.9 nM and 18.4 nM, resp.  Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg.  These results indicate that RS-1748 would be a promising lead compd. for developing a therapeutic agent against asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKappxf9t5rVg90H21EOLACvtfcHk0lgetGM03gaIVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslynsLY%253D&md5=f859158d9f471329d0235c58c02b844f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1248%2Fbpb.33.1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.33.1067%26sid%3Dliteratum%253Aachs%26aulast%3DNakagami%26aufirst%3DY.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DYonekubo%26aufirst%3DK.%26aulast%3DNosaka%26aufirst%3DE.%26aulast%3DEtori%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DKuribayashi%26aufirst%3DT.%26aulast%3DNara%26aufirst%3DF.%26aulast%3DYamashita%26aufirst%3DM.%26atitle%3DRS-1748%252C%2520a%2520novel%2520CC%2520chemokine%2520receptor%25204%2520antagonist%252C%2520inhibits%2520ovalbumin-induced%2520airway%2520inflammation%2520in%2520guinea%2520pigs%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2010%26volume%3D33%26spage%3D1067%26epage%3D1069%26doi%3D10.1248%2Fbpb.33.1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuberson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teobald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=981-986&author=N.+Kindonauthor=G.+Andrewsauthor=A.+Baxterauthor=D.+Cheshireauthor=P.+Hemsleyauthor=T.+Johnsonauthor=Y.+Z.+Liuauthor=D.+McGinnityauthor=M.+McHaleauthor=A.+Meteauthor=J.+Reubersonauthor=B.+Robertsauthor=J.+Steeleauthor=B.+Teobaldauthor=J.+Unittauthor=D.+Vaughanauthor=I.+Waltersauthor=M.+Stocks&title=Discovery+of+AZD-2098+and+AZD-1678%2C+two+potent+and+bioavailable+CCR4+receptor+antagonists&doi=10.1021%2Facsmedchemlett.7b00315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists</span></div><div class="casAuthors">Kindon, Nicholas; Andrews, Glen; Baxter, Andrew; Cheshire, David; Hemsley, Paul; Johnson, Timothy; Liu, Yu-Zhen; McGinnity, Dermot; McHale, Mark; Mete, Antonio; Reuberson, James; Roberts, Bryan; Steele, John; Teobald, Barry; Unitt, John; Vaughan, Deborah; Walters, Iain; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">981-986</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 receptor antagonist high-throughput screen (HTS) of a subset of the AstraZeneca compd. bank.  As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antagonist candidate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolEsVkipAX2LVg90H21EOLACvtfcHk0lgetGM03gaIVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7vI&md5=8ede7ef766e88de9191b0df8ec7938a4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00315%26sid%3Dliteratum%253Aachs%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DBaxter%26aufirst%3DA.%26aulast%3DCheshire%26aufirst%3DD.%26aulast%3DHemsley%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%2BZ.%26aulast%3DMcGinnity%26aufirst%3DD.%26aulast%3DMcHale%26aufirst%3DM.%26aulast%3DMete%26aufirst%3DA.%26aulast%3DReuberson%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSteele%26aufirst%3DJ.%26aulast%3DTeobald%26aufirst%3DB.%26aulast%3DUnitt%26aufirst%3DJ.%26aulast%3DVaughan%26aufirst%3DD.%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DStocks%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520AZD-2098%2520and%2520AZD-1678%252C%2520two%2520potent%2520and%2520bioavailable%2520CCR4%2520receptor%2520antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D981%26epage%3D986%26doi%3D10.1021%2Facsmedchemlett.7b00315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habashita, H.</span>; <span class="NLM_string-name">Kokubo, M.</span>; <span class="NLM_string-name">Shibayama, S.</span>; <span class="NLM_string-name">Tada, H.</span>; <span class="NLM_string-name">Sagawa, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazine and Quinoxaline Derivatives as Chemokine Receptor CCR4 Antagonists and Medicinal Use Thereof</span>. <span class="NLM_patent">W02004007472</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=H.+Habashita&author=M.+Kokubo&author=S.+Shibayama&author=H.+Tada&author=K.+Sagawa&title=Preparation+of+Pyrazine+and+Quinoxaline+Derivatives+as+Chemokine+Receptor+CCR4+Antagonists+and+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHabashita%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520Pyrazine%2520and%2520Quinoxaline%2520Derivatives%2520as%2520Chemokine%2520Receptor%2520CCR4%2520Antagonists%2520and%2520Medicinal%2520Use%2520Thereof%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Procopiou, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumeaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, Y. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morriss, K. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Needham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sollis, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staton, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of indazole arylsulfonamides as allosteric CC-ahemokine receptor 4 (CCR4) antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1960</span>, <span class="refDoi"> DOI: 10.1021/jm301572h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301572h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisF2js7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1946-1960&author=P.+A.+Procopiouauthor=J.+W.+Barrettauthor=N.+P.+Bartonauthor=M.+Beggauthor=D.+Claphamauthor=R.+C.+B.+Copleyauthor=A.+J.+Fordauthor=R.+H.+Gravesauthor=D.+A.+Hallauthor=A.+P.+Hancockauthor=A.+P.+Hillauthor=H.+Hobbsauthor=S.+T.+Hodgsonauthor=C.+Jumeauxauthor=Y.+M.+L.+Lacroixauthor=A.+H.+Miahauthor=K.+M.+L.+Morrissauthor=D.+Needhamauthor=E.+B.+Sheriffauthor=R.+J.+Slackauthor=C.+E.+Smithauthor=S.+L.+Sollisauthor=H.+Staton&title=Synthesis+and+structure%E2%80%93activity+relationships+of+indazole+arylsulfonamides+as+allosteric+CC-ahemokine+receptor+4+%28CCR4%29+antagonists&doi=10.1021%2Fjm301572h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists</span></div><div class="casAuthors">Procopiou, Panayiotis A.; Barrett, John W.; Barton, Nicholas P.; Begg, Malcolm; Clapham, David; Copley, Royston C. B.; Ford, Alison J.; Graves, Rebecca H.; Hall, David A.; Hancock, Ashley P.; Hill, Alan P.; Hobbs, Heather; Hodgson, Simon T.; Jumeaux, Coline; Lacroix, Yannick M. L.; Miah, Afjal H.; Morriss, Karen M. L.; Needham, Deborah; Sheriff, Emma B.; Slack, Robert J.; Smith, Claire E.; Sollis, Steven L.; Staton, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of indazole arylsulfonamides were synthesized and examd. as human CCR4 antagonists.  Methoxy- or hydroxyl- contg. groups were the more potent indazole C4 substituents.  Only small groups were tolerated at C5, C6, or C7, with the C6 analogs being preferred.  The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide.  N1 meta-substituted benzyl groups possessing an α-amino-3-[(methylamino)acyl]- group were the most potent N1-substituents.  Strongly basic amino groups had low oral absorption in vivo.  Less basic analogs, such as morpholines, had good oral absorption; however, they also had high clearance.  The most potent compd. with high absorption in two species was analog I (GSK2239633A), which was selected for further development.  Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II.  X-ray diffraction studies on two indazole sulfonamide fragments suggested the presence of an important intramol. interaction in the active conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGy9j0UZnY77Vg90H21EOLACvtfcHk0ljgjhRciSTTYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisF2js7k%253D&md5=db6f996af7b0498c9c0196da94005bc2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm301572h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301572h%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DJ.%2BW.%26aulast%3DBarton%26aufirst%3DN.%2BP.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DClapham%26aufirst%3DD.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGraves%26aufirst%3DR.%2BH.%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DHancock%26aufirst%3DA.%2BP.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DHobbs%26aufirst%3DH.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DJumeaux%26aufirst%3DC.%26aulast%3DLacroix%26aufirst%3DY.%2BM.%2BL.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DMorriss%26aufirst%3DK.%2BM.%2BL.%26aulast%3DNeedham%26aufirst%3DD.%26aulast%3DSheriff%26aufirst%3DE.%2BB.%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26aulast%3DSollis%26aufirst%3DS.%2BL.%26aulast%3DStaton%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520indazole%2520arylsulfonamides%2520as%2520allosteric%2520CC-ahemokine%2520receptor%25204%2520%2528CCR4%2529%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1946%26epage%3D1960%26doi%3D10.1021%2Fjm301572h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerahee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Marle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomized study</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1186/2050-6511-14-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1186%2F2050-6511-14-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23289757" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1-11&author=A.+Cahnauthor=S.+Hodgsonauthor=R.+Wilsonauthor=J.+Robertsonauthor=J.+Watsonauthor=M.+Beeraheeauthor=S.+C.+Hughesauthor=G.+Youngauthor=R.+Gravesauthor=D.+Hallauthor=S.+van+Marleauthor=R.+Solari&title=Safety%2C+tolerability%2C+pharmacokinetics+and+pharmacodynamics+of+GSK2239633%2C+a+CC-chemokine+receptor+4+antagonist%2C+in+healthy+male+subjects%3A+results+from+an+open-label+and+from+a+randomized+study&doi=10.1186%2F2050-6511-14-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2F2050-6511-14-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2050-6511-14-14%26sid%3Dliteratum%253Aachs%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DJ.%26aulast%3DBeerahee%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DS.%2BC.%26aulast%3DYoung%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DD.%26aulast%3Dvan%2BMarle%26aufirst%3DS.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DSafety%252C%2520tolerability%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520GSK2239633%252C%2520a%2520CC-chemokine%2520receptor%25204%2520antagonist%252C%2520in%2520healthy%2520male%2520subjects%253A%2520results%2520from%2520an%2520open-label%2520and%2520from%2520a%2520randomized%2520study%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D14%26spage%3D1%26epage%3D11%26doi%3D10.1186%2F2050-6511-14-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P.</span></span> <span> </span><span class="NLM_article-title">Small molecule immuno-oncology therapeutic agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.12.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.bmcl.2017.12.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=29326017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlKltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=319-329&author=P.+Toogood&title=Small+molecule+immuno-oncology+therapeutic+agents&doi=10.1016%2Fj.bmcl.2017.12.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule immuno-oncology therapeutic agents</span></div><div class="casAuthors">Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Treatment of cancer by activation of an antitumor immune response is now a widely practiced and well-accepted approach to therapy.  However, despite dramatic responses in some patients, the high proportion of unresponsive patients points to a considerable unmet medical need.  Although antibody therapies have led the way, small mol. immuno-oncol. agents are close behind.  This perspective provides an overview of some of the many small mol. approaches being explored.  It encompasses small mol. modulators of validated targets such as programed cell death 1 (PD-1) as well as novel approaches still to be proven clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqabNsLZRrBPbVg90H21EOLACvtfcHk0ljgjhRciSTTYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlKltQ%253D%253D&md5=2457f116552bf50e7134fea28d914524</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.12.044%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%26atitle%3DSmall%2520molecule%2520immuno-oncology%2520therapeutic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D319%26epage%3D329%26doi%3D10.1016%2Fj.bmcl.2017.12.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span> </span><span class="NLM_article-title">FDA approves treatment for two rare types of non-Hodgkin
lymphoma</span>; <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm</a> (accessed Nov 16, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+approves+treatment+for+two+rare+types+of+non-Hodgkin%0Alymphoma%3B+https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm616176.htm+%28accessed+Nov+16%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520approves%2520treatment%2520for%2520two%2520rare%2520types%2520of%2520non-Hodgkin%250Alymphoma%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1111/cas.12116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1111%2Fcas.12116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23360455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVCjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=647-650&author=T.+Ishidaauthor=A.+Itoauthor=F.+Satoauthor=S.+Kusumotoauthor=S.+Iidaauthor=H.+Inagakiauthor=A.+Moritaauthor=S.+Akinagaauthor=R.+Ueda&title=Stevens-Johnson+Syndrome+associated+with+mogamulizumab+treatment+of+adult+T-cell+leukemia%2Flymphoma&doi=10.1111%2Fcas.12116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma</span></div><div class="casAuthors">Ishida, Takashi; Ito, Asahi; Sato, Fumihiko; Kusumoto, Shigeru; Iida, Shinsuke; Inagaki, Hiroshi; Morita, Akimichi; Akinaga, Shiro; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">647-650</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We report an adult T-cell leukemia/lymphoma patient suffering from Stevens-Johnson Syndrome (SJS) during mogamulizumab (humanized anti-CCR4 monoclonal antibody) treatment.  There was a durable significant redn. of the CD4+CD25highFOXP3+ regulatory T (Treg) cell subset in the patient's PBMC, and the affected inflamed skin almost completely lacked FOXP3-pos. cells.  This implies an assocn. between redn. of the Treg subset by mogamulizimab and occurrence of SJS.  The present case should contribute not only to our understanding of human pathol. resulting from therapeutic depletion of Treg cells, but also alert us to the possibility of immune-related severe adverse events such as SJS when using mogamulizumab.  We are currently conducting a clin. trial of mogamulizumab for CCR4-neg. solid cancers (UMIN000010050), specifically aiming to deplete Treg cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKZ1pzzErzKbVg90H21EOLACvtfcHk0ljgjhRciSTTYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVCjsrs%253D&md5=e2050c18ed4be88401547ddede792606</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fcas.12116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12116%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DF.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DStevens-Johnson%2520Syndrome%2520associated%2520with%2520mogamulizumab%2520treatment%2520of%2520adult%2520T-cell%2520leukemia%252Flymphoma%26jtitle%3DCancer%2520Sci.%26date%3D2013%26volume%3D104%26spage%3D647%26epage%3D650%26doi%3D10.1111%2Fcas.12116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyagawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, H.</span></span> <span> </span><span class="NLM_article-title">Predisposition to multi-drug hypersensitivity after administration of magamulizumab</span>. <i>Eur. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=29952299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FislKqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=526-528&author=F.+Miyagawaauthor=S.+Yamamotoauthor=M.+Miyaoauthor=M.+Nishikawaauthor=K.+Ogawaauthor=H.+Asada&title=Predisposition+to+multi-drug+hypersensitivity+after+administration+of+magamulizumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Predisposition to multi-drug hypersensitivity after administration of mogamulizumab</span></div><div class="casAuthors">Miyagawa Fumi; Yamamoto Shoko; Miyao Mariko; Nishikawa Mitsuko; Ogawa Kohei; Asada Hideo</div><div class="citationInfo"><span class="NLM_cas:title">European journal of dermatology : EJD</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">526-528</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8RtSxmMwNmBAiYWy6n3SfW6udTcc2eZVpWq-zfhSPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FislKqsA%253D%253D&md5=dd8145759d05a549b343a25dfc8f4872</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyagawa%26aufirst%3DF.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DMiyao%26aufirst%3DM.%26aulast%3DNishikawa%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DAsada%26aufirst%3DH.%26atitle%3DPredisposition%2520to%2520multi-drug%2520hypersensitivity%2520after%2520administration%2520of%2520magamulizumab%26jtitle%3DEur.%2520J.%2520Dermatol.%26date%3D2018%26volume%3D28%26spage%3D526%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saulite, I.</span>; <span class="NLM_string-name">Guenova, E.</span>; <span class="NLM_string-name">Hoetzenecker, W.</span></span> <span> </span><span class="NLM_article-title">Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximan, Bentuximab Vedotin, Alemtuzumab, and Mogamulizumab</span>. In  <i>Current Problems in Dermatology. Adverse Reactions of Biologics</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, L.</span>, <span class="NLM_string-name">Gulliver, W.</span></span>, Eds.; <span class="NLM_publisher-name">Karger</span>: <span class="NLM_publisher-loc">Basel</span>, <span class="NLM_year">2018</span>: Vol.  <span class="NLM_volume">53</span>, pp  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">81</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1159%2F000478079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=70-81&author=I.+Saulite&author=E.+Guenova&author=W.+Hoetzeneckerauthor=L.+Puig&author=W.+Gulliver&title=Current+Problems+in+Dermatology.+Adverse+Reactions+of+Biologics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1159%2F000478079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1159%252F000478079%26sid%3Dliteratum%253Aachs%26aulast%3DSaulite%26aufirst%3DI.%26atitle%3DAdverse%2520Reactions%2520of%2520Antibody-Therapy%2520for%2520Primary%2520Cutaneous%2520Lymphomas%253A%2520Rituximan%252C%2520Bentuximab%2520Vedotin%252C%2520Alemtuzumab%252C%2520and%2520Mogamulizumab%26btitle%3DCurrent%2520Problems%2520in%2520Dermatology.%2520Adverse%2520Reactions%2520of%2520Biologics%26aulast%3DPuig%26aufirst%3DL.%26pub%3DKarger%26date%3D2018%26volume%3D53%26spage%3D70%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span> <span> </span><span class="NLM_article-title">Tools for GPCR drug discovery</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1038/aps.2011.173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Faps.2011.173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=22266728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1elu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=372-384&author=R.+Zhangauthor=X.+Xie&title=Tools+for+GPCR+drug+discovery&doi=10.1038%2Faps.2011.173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Tools for GPCR drug discovery</span></div><div class="casAuthors">Zhang, Ru; Xie, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-384</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) mediate many important physiol. functions and are considered as one of the most successful therapeutic targets for a broad spectrum of diseases.  The design and implementation of high-throughput GPCR assays that allow the cost-effective screening of large compd. libraries to identify novel drug candidates are crit. in early drug discovery.  Early functional GPCR assays depend primarily on the measurement of G-protein-mediated 2nd messenger generation.  Taking advantage of the continuously deepening understanding of GPCR signal transduction, many G-protein-independent pathways are utilized to detect the activity of GPCRs, and may provide addnl. information on functional selectivity of candidate compds.  With the combination of automated imaging systems and label-free detection systems, such assays are now suitable for high-throughput screening (HTS).  In this review, we summarize the most widely used GPCR assays and recent advances in HTS technologies for GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8pC8anrKpWLVg90H21EOLACvtfcHk0lglGCI0k8ZOzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1elu7Y%253D&md5=04ca4fed048dbca837d81c02566e6e25</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.173%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DTools%2520for%2520GPCR%2520drug%2520discovery%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D372%26epage%3D384%26doi%3D10.1038%2Faps.2011.173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proudfoot, A. E. I.</span>; <span class="NLM_string-name">Power, C. A.</span>; <span class="NLM_string-name">Church, D. J.</span>; <span class="NLM_string-name">Soler, D.</span>; <span class="NLM_string-name">Mack, M.</span></span> <span> </span><span class="NLM_article-title">Cellular assays of chemokine receptor activation</span>.  <i>Current Protocols in Pharmacology</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ, USA</span>, <span class="NLM_year">2001</span>; Vol.  <span class="NLM_volume">14</span>, pp  <span class="NLM_fpage">12.4.1</span>– <span class="NLM_lpage">12.4.26</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1002%2F0471141755.ph1204s14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=12.4.1-12.4.26&author=A.+E.+I.+Proudfoot&author=C.+A.+Power&author=D.+J.+Church&author=D.+Soler&author=M.+Mack&title=Current+Protocols+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2F0471141755.ph1204s14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471141755.ph1204s14%26sid%3Dliteratum%253Aachs%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%2BI.%26atitle%3DCellular%2520assays%2520of%2520chemokine%2520receptor%2520activation%26btitle%3DCurrent%2520Protocols%2520in%2520Pharmacology%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2001%26volume%3D14%26spage%3D12.4.1%26epage%3D12.4.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.</span>; <span class="NLM_string-name">Bui, M.</span>; <span class="NLM_string-name">Chian, D.</span>; <span class="NLM_string-name">Diokno, R.</span>; <span class="NLM_string-name">Hu, X. D.</span>; <span class="NLM_string-name">Jacobson, S.</span>; <span class="NLM_string-name">Karbarz, E.</span>; <span class="NLM_string-name">Kassner, P. D.</span>; <span class="NLM_string-name">Ketcham, J. M.</span>; <span class="NLM_string-name">Marshall, L.</span>; <span class="NLM_string-name">McKinnell, J.</span>; <span class="NLM_string-name">Meleza, C.</span>; <span class="NLM_string-name">Reilly, M. K.</span>; <span class="NLM_string-name">Robles, O.</span>; <span class="NLM_string-name">Shunatona, H. P.</span>; <span class="NLM_string-name">Talay, O.</span>; <span class="NLM_string-name">Walker, J. R.</span>; <span class="NLM_string-name">Wustrow, D. J.</span>; <span class="NLM_string-name">Zibinsky, M.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Beck%2C+H.%3B+Bui%2C+M.%3B+Chian%2C+D.%3B+Diokno%2C+R.%3B+Hu%2C+X.+D.%3B+Jacobson%2C+S.%3B+Karbarz%2C+E.%3B+Kassner%2C+P.+D.%3B+Ketcham%2C+J.+M.%3B+Marshall%2C+L.%3B+McKinnell%2C+J.%3B+Meleza%2C+C.%3B+Reilly%2C+M.+K.%3B+Robles%2C+O.%3B+Shunatona%2C+H.+P.%3B+Talay%2C+O.%3B+Walker%2C+J.+R.%3B+Wustrow%2C+D.+J.%3B+Zibinsky%2C+M.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DH." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosely, S.
I.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prime, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainson, R. C.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koopmann, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. Y.Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenawalt, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahdesmaki, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coates Ulrichsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohawn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCourt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valge-Archer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovedi, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. W.</span></span> <span> </span><span class="NLM_article-title">Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-16-0114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1158%2F2326-6066.CIR-16-0114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=27923825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=29-41&author=S.%0AI.S.+Moselyauthor=J.+E.+Primeauthor=R.+C.A.+Sainsonauthor=J.-O.+Koopmannauthor=D.+Y.Q.+Wangauthor=D.+M.+Greenawaltauthor=M.+J.+Ahdesmakiauthor=R.+Leylandauthor=S.+Mullinsauthor=L.+Pacelliauthor=D.+Marcusauthor=J.+Andertonauthor=A.+Watkinsauthor=J.+Coates+Ulrichsenauthor=P.+Brohawnauthor=B.+W.+Higgsauthor=M.+McCourtauthor=H.+Jonesauthor=J.+A.+Harperauthor=M.+Morrowauthor=V.+Valge-Archerauthor=R.+Stewartauthor=S.+J.+Dovediauthor=R.+W.+Wilkinson&title=Rational+selection+of+syngeneic+preclinical+tumor+models+for+immunotherapeutic+drug+discovery&doi=10.1158%2F2326-6066.CIR-16-0114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery</span></div><div class="casAuthors">Mosely, Suzanne I. S.; Prime, John E.; Sainson, Richard C. A.; Koopmann, Jens-Oliver; Wang, Dennis Y. Q.; Greenawalt, Danielle M.; Ahdesmaki, Miika J.; Leyland, Rebecca; Mullins, Stefanie; Pacelli, Luciano; Marcus, Danielle; Anderton, Judith; Watkins, Amanda; Coates Ulrichsen, Jane; Brohawn, Philip; Higgs, Brandon W.; McCourt, Matthew; Jones, Hazel; Harper, James A.; Morrow, Michelle; Valge-Archer, Viia; Stewart, Ross; Dovedi, Simon J.; Wilkinson, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-41</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Murine syngeneic tumor models are crit. to novel immuno-based therapy development, but the mol. and immunol. features of these models are still not clearly defined.  The translational relevance of differences between the models is not fully understood, impeding appropriate preclin. model selection for target validation, and ultimately hindering drug development.  Across a panel of commonly used murine syngeneic tumor models, we showed variable responsiveness to immunotherapies.  We used array comparative genomic hybridization, whole-exome sequencing, exon microarray anal., and flow cytometry to extensively characterize these models, which revealed striking differences that may underlie these contrasting response profiles.  We identified strong differential gene expression in immune-related pathways and changes in immune cell-specific genes that suggested differences in tumor immune infiltrates between models.  Further investigation using flow cytometry showed differences in both the compn. and magnitude of the tumor immune infiltrates, identifying models that harbor "inflamed" and "non-inflamed" tumor immune infiltrate phenotypes.  We also found that immunosuppressive cell types predominated in syngeneic mouse tumor models that did not respond to immune-checkpoint blockade, whereas cytotoxic effector immune cells were enriched in responsive models.  A cytotoxic cell-rich tumor immune infiltrate has been correlated with increased efficacy of immunotherapies in the clinic, and these differences could underlie the varying response profiles to immunotherapy between the syngeneic models.  This characterization highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of immunotherapies as well as combinations with targeted therapies in vivo.  Cancer Immunol Res; 5(1); 29-41. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdDtr1ROaQt7Vg90H21EOLACvtfcHk0lgT0bavDll5pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WltA%253D%253D&md5=96ed6203e7f7275ffd5bd3dc58009c0c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-16-0114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-16-0114%26sid%3Dliteratum%253Aachs%26aulast%3DMosely%26aufirst%3DS.%2BI.S.%26aulast%3DPrime%26aufirst%3DJ.%2BE.%26aulast%3DSainson%26aufirst%3DR.%2BC.A.%26aulast%3DKoopmann%26aufirst%3DJ.-O.%26aulast%3DWang%26aufirst%3DD.%2BY.Q.%26aulast%3DGreenawalt%26aufirst%3DD.%2BM.%26aulast%3DAhdesmaki%26aufirst%3DM.%2BJ.%26aulast%3DLeyland%26aufirst%3DR.%26aulast%3DMullins%26aufirst%3DS.%26aulast%3DPacelli%26aufirst%3DL.%26aulast%3DMarcus%26aufirst%3DD.%26aulast%3DAnderton%26aufirst%3DJ.%26aulast%3DWatkins%26aufirst%3DA.%26aulast%3DCoates%2BUlrichsen%26aufirst%3DJ.%26aulast%3DBrohawn%26aufirst%3DP.%26aulast%3DHiggs%26aufirst%3DB.%2BW.%26aulast%3DMcCourt%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DHarper%26aufirst%3DJ.%2BA.%26aulast%3DMorrow%26aufirst%3DM.%26aulast%3DValge-Archer%26aufirst%3DV.%26aulast%3DStewart%26aufirst%3DR.%26aulast%3DDovedi%26aufirst%3DS.%2BJ.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26atitle%3DRational%2520selection%2520of%2520syngeneic%2520preclinical%2520tumor%2520models%2520for%2520immunotherapeutic%2520drug%2520discovery%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2017%26volume%3D5%26spage%3D29%26epage%3D41%26doi%3D10.1158%2F2326-6066.CIR-16-0114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominitzki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neurath, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span> <span> </span><span class="NLM_article-title">In vitro generation of CD4+CD25+ regulatory cells from murin naive T cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1794</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Fnprot.2007.258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=17641646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1789-1794&author=M.+C.+Fantiniauthor=S.+Dominitzkiauthor=A.+Rizzoauthor=M.+F.+Neurathauthor=C.+Becker&title=In+vitro+generation+of+CD4%2BCD25%2B+regulatory+cells+from+murin+naive+T+cells&doi=10.1038%2Fnprot.2007.258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro generation of CD4+CD25+ regulatory cells from murine naive T cells</span></div><div class="casAuthors">Fantini, Massimo C.; Dominitzki, Sabine; Rizzo, Angelo; Neurath, Markus F.; Becker, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1789-1794</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CD4+CD25+ regulatory T cells (Tregs) are crucial for the maintenance of immunol. tolerance.  Recent data indicate that Tregs not only develop in the thymus during ontogeny but can also differentiate from naive T cells in the periphery.  The following protocol describes a method by which Tregs are generated in vitro by stimulation of naive T cells in the presence of transforming growth factor β (Ti-Tregs).  In vitro-induced regulatory T cells express markers of conventional Treg such as CD25 and the genetic program committing transcription factor FoxP3.  Functionally the in vitro-generated Ti-Tregs suppress T-cell activation and proliferation while in vivo these cells have been proven to control inflammation in different animal models, suggesting a potential use of these cells for immunotherapy.  The protocol can be completed within 5 days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3F3KjV9Klt7Vg90H21EOLACvtfcHk0lgT0bavDll5pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahur7F&md5=98e484cedf0f4ee16dddf269040c2550</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.258%26sid%3Dliteratum%253Aachs%26aulast%3DFantini%26aufirst%3DM.%2BC.%26aulast%3DDominitzki%26aufirst%3DS.%26aulast%3DRizzo%26aufirst%3DA.%26aulast%3DNeurath%26aufirst%3DM.%2BF.%26aulast%3DBecker%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520generation%2520of%2520CD4%252BCD25%252B%2520regulatory%2520cells%2520from%2520murin%2520naive%2520T%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D1789%26epage%3D1794%26doi%3D10.1038%2Fnprot.2007.258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. B.</span></span> <span> </span><span class="NLM_article-title">Generation and function of induced regulatory T cells</span>. <i>Front Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2013.00152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.3389%2Ffimmu.2013.00152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=23355837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eisLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1-13&author=E.+G.+Schmittauthor=C.+B.+Williams&title=Generation+and+function+of+induced+regulatory+T+cells&doi=10.3389%2Ffimmu.2013.00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and function of induced regulatoryT cells</span></div><div class="casAuthors">Schmitt, Erica G.; Williams, Calvin B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">CD4+ CD25+ Foxp3+ regulatory T (Treg) cells are essential to the balance between proand anti-inflammatory responses.There are two major subsets ofTreg cells, "natural" Treg (nTreg) cells that develop in the thymus, and "induced" Treg (iTreg) cells that arise in the periphery from CD4+ Foxp3- conventional T cells and can be generated in vitro.  Previous work has established that both subsets are required for immunol. tolerance.  Addnl., in vitro-derived iTreg cells can reestablish tolerance in situations where Treg cells are decreased or defective.  This review will focus on iTreg cells, drawing comparisons to nTreg cells when possible.We discuss the mol. mechanisms of iTreg cell induction, both in vivo and in vitro, reviewthe Foxp3-dependent and -independent transcriptional landscape of iTreg cells, and examine the proposed suppressive mechanisms utilized by each Treg cell subset.  We also compare the T cell receptor repertoire of the Treg cell subsets, discuss inflammatory conditions where iTreg cells are generated or have been used for treatment, and address the issue of iTreg cell stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYYLe4jXKCMLVg90H21EOLACvtfcHk0lgT0bavDll5pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eisLrJ&md5=ad1cc139b8da8608b7cf6bd413cace1a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2013.00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2013.00152%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DE.%2BG.%26aulast%3DWilliams%26aufirst%3DC.%2BB.%26atitle%3DGeneration%2520and%2520function%2520of%2520induced%2520regulatory%2520T%2520cells%26jtitle%3DFront%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D1%26epage%3D13%26doi%3D10.3389%2Ffimmu.2013.00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="note"><p class="first last">More detailed studies on the biology of CCR4 antagonism in the context of various immune cells and antitumor activity will be published in another manuscript.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schall, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proudfoot, A. E. I.</span></span> <span> </span><span class="NLM_article-title">Overcoming hurdles in developing successful drugs targeting chemokine receptors</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1038/nri2972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1038%2Fnri2972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=21494268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=355-363&author=T.+J.+Schallauthor=A.+E.+I.+Proudfoot&title=Overcoming+hurdles+in+developing+successful+drugs+targeting+chemokine+receptors&doi=10.1038%2Fnri2972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming hurdles in developing successful drugs targeting chemokine receptors</span></div><div class="casAuthors">Schall, Thomas J.; Proudfoot, Amanda E. I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-363</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemokines and their receptors are central to the inflammatory process and are attractive therapeutic targets.  Drugs that inhibit chemokine receptors are approved for the treatment of HIV infection and for stem cell mobilization, but none have been approved yet for the treatment of inflammatory and/or autoimmune diseases.  We analyze the challenges of developing chemokine receptor antagonists, and propose that inappropriate target selection and ineffective dosing, not the 'redundancy' of the chemokine system, are the main barriers to their use as anti-inflammatory therapies.  We highlight evidence suggesting that chemokine receptor inhibition will prove to be an effective therapy in inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJxZhyoAteTLVg90H21EOLACvtfcHk0lhahPiOTpeI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCmtb0%253D&md5=3173fc889bd22b7d7e19bd138a599897</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnri2972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2972%26sid%3Dliteratum%253Aachs%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%2BI.%26atitle%3DOvercoming%2520hurdles%2520in%2520developing%2520successful%2520drugs%2520targeting%2520chemokine%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2011%26volume%3D11%26spage%3D355%26epage%3D363%26doi%3D10.1038%2Fnri2972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hersperger, R.</span>; <span class="NLM_string-name">Janser, P.</span>; <span class="NLM_string-name">Pfenninger, E.</span>; <span class="NLM_string-name">Wuethrich, H. J.</span>; <span class="NLM_string-name">Miltz, W.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1H-indole-2-carboxylic acid N-(piperidin-4-yl)amides and related derivatives as chemokine receptor, particularly CCR2 and CCR5 antagonists</span>. <span class="NLM_patent">WO2005077932</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=R.+Hersperger&author=P.+Janser&author=E.+Pfenninger&author=H.+J.+Wuethrich&author=W.+Miltz&title=Preparation+of+1H-indole-2-carboxylic+acid+N-%28piperidin-4-yl%29amides+and+related+derivatives+as+chemokine+receptor%2C+particularly+CCR2+and+CCR5+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHersperger%26aufirst%3DR.%26atitle%3DPreparation%2520of%25201H-indole-2-carboxylic%2520acid%2520N-%2528piperidin-4-yl%2529amides%2520and%2520related%2520derivatives%2520as%2520chemokine%2520receptor%252C%2520particularly%2520CCR2%2520and%2520CCR5%2520antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. K.</span></span> <span> </span><span class="NLM_article-title">A radical mediated approach to the stereoselective formal total synthesis of (+)-Sch 642305</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">6925</span>– <span class="NLM_lpage">6931</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2009.06.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=10.1016%2Fj.tet.2009.06.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptVGgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=6925-6931&author=T.+K.+Chakrabortyauthor=R.+Samantaauthor=P.+K.+Kumar&title=A+radical+mediated+approach+to+the+stereoselective+formal+total+synthesis+of+%28%2B%29-Sch+642305&doi=10.1016%2Fj.tet.2009.06.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A radical mediated approach to the stereoselective formal total synthesis of (+)-Sch 642305</span></div><div class="casAuthors">Chakraborty, Tushar Kanti; Samanta, Rajarshi; Kumar, Pulukuri Kiran</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">6925-6931</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A formal total synthesis of (+)-Sch-642305 is described.  The synthesis, which commenced from a simple chiral synthon (5S)-5-(hydroxymethyl)dihydrofuran-2(3H)-one, employed, as a key step, a radical mediated opening of a chiral epoxy alc. intermediate (I) with Cp2Ti(III)Cl following an efficient method developed by us earlier.  The resultant intermediate radical was intramolecularly trapped by the electron deficient double bond present in the mol. to give rise to its highly functionalized six-membered carbocyclic ring in stereoselective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUdTnTeQufrVg90H21EOLACvtfcHk0lhahPiOTpeI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptVGgtr4%253D&md5=516b98b8777990cdb13f3823489e582e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2009.06.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2009.06.059%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DT.%2BK.%26aulast%3DSamanta%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DP.%2BK.%26atitle%3DA%2520radical%2520mediated%2520approach%2520to%2520the%2520stereoselective%2520formal%2520total%2520synthesis%2520of%2520%2528%252B%2529-Sch%2520642305%26jtitle%3DTetrahedron%26date%3D2009%26volume%3D65%26spage%3D6925%26epage%3D6931%26doi%3D10.1016%2Fj.tet.2009.06.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00506">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83633"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00506">10.1021/acs.jmedchem.9b00506</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Assay conditions; hepatocyte stability assay; in vitro safety panel; X-ray structures of synthetic intermediates of <b>16</b> and <b>17</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00506/suppl_file/jm9b00506_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular Formula Strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00506/suppl_file/jm9b00506_si_002.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00506/suppl_file/jm9b00506_si_001.pdf">jm9b00506_si_001.pdf (520.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00506/suppl_file/jm9b00506_si_002.xlsx">jm9b00506_si_002.xlsx (10.83 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00506%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00506" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799cd082f48d18f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
